CA1064905A - Terpenoid esters of steroids - Google Patents
Terpenoid esters of steroidsInfo
- Publication number
- CA1064905A CA1064905A CA246,486A CA246486A CA1064905A CA 1064905 A CA1064905 A CA 1064905A CA 246486 A CA246486 A CA 246486A CA 1064905 A CA1064905 A CA 1064905A
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- dione
- retinoate
- trans
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0027—Azides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0092—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0047—Nitrogen only at position 2(3)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
ABSTRACT
The present invention provides a new class of compounds, namely 16.alpha.-, 17.alpha.- and/or 21-retinoates of anti-inflamma-tory steroids of the pregnane series having a hydroxyl group at least one of the 16.alpha.-, 17.alpha.- and 21-positions, processes for their preparation and cosmetic compositions containing them. The novel compounds are useful in the cosmetic treatment of acne.
The present invention provides a new class of compounds, namely 16.alpha.-, 17.alpha.- and/or 21-retinoates of anti-inflamma-tory steroids of the pregnane series having a hydroxyl group at least one of the 16.alpha.-, 17.alpha.- and 21-positions, processes for their preparation and cosmetic compositions containing them. The novel compounds are useful in the cosmetic treatment of acne.
Description
Deccrn~,er :lO~ 197;
~o~6- ~;`TE-JB/la ~ 6 ~9~ ~
l'his inventlon relates to novel terpenoid esters of steroids Or the pregnane series having valuable cosmetic properties9 to processes for their preparation, and to cosmetic compositions containing them.
According to the inventlon, we provide a 16-, 17a- and/
or 21-retinoate of an anti-inflammatory steroid of the pre~nane series having a hydroxyl group at at least one o~ the 16a-1 17a- and 21-positions.
, A steroidal retinoate accordin~ to the present invention can advantageously be used in the treatment and control of acne vulgaris on administration preferably by the topical or intralesional route.
The steroidal retinoate may for example be a 16~, 21- or 17a,21-diretinoate but is preferably a 16~- or 17a- or especially a 21-monoretinoate.
Retinoic acid exists ag several isomers, the most s~able and common isomer being all-trans-retinoic acid (also ; known as all-trans-Vitamin A acid) which is derived ~rom Vitamln A (retinol)~ The steroidal retinoates of this invention are pre~erably derived ~rom all-trans-retinoic acid; howeverJ this invention includes steroi-dal retinoates derived froin the other isomeric forms of retinoic acid such as ll-cis-retlnoic acid, 9-cis~
retinoic acidJ l~-cis~retinoic acid~ 9J l~-di-cis-reti--
~o~6- ~;`TE-JB/la ~ 6 ~9~ ~
l'his inventlon relates to novel terpenoid esters of steroids Or the pregnane series having valuable cosmetic properties9 to processes for their preparation, and to cosmetic compositions containing them.
According to the inventlon, we provide a 16-, 17a- and/
or 21-retinoate of an anti-inflammatory steroid of the pre~nane series having a hydroxyl group at at least one o~ the 16a-1 17a- and 21-positions.
, A steroidal retinoate accordin~ to the present invention can advantageously be used in the treatment and control of acne vulgaris on administration preferably by the topical or intralesional route.
The steroidal retinoate may for example be a 16~, 21- or 17a,21-diretinoate but is preferably a 16~- or 17a- or especially a 21-monoretinoate.
Retinoic acid exists ag several isomers, the most s~able and common isomer being all-trans-retinoic acid (also ; known as all-trans-Vitamin A acid) which is derived ~rom Vitamln A (retinol)~ The steroidal retinoates of this invention are pre~erably derived ~rom all-trans-retinoic acid; howeverJ this invention includes steroi-dal retinoates derived froin the other isomeric forms of retinoic acid such as ll-cis-retlnoic acid, 9-cis~
retinoic acidJ l~-cis~retinoic acid~ 9J l~-di-cis-reti--
- 2 -- "
- December 10, 1975 1064905 20/ -FTE_3 nolc acid and retr-o-retinoic acidO Thus, unles~ other-wise lndicated, the terms "retinoic acid" and "retinoates"
as used in the specification and claims o~ this appli~
cation include all forms of retinoic acid~ in parti-cular the various cls and trans ~orms and mix'cures there-o~ .
The steroidal retinoate of the present invention i5 pre-ferably a 3,20-diketo-4-dehydro-pregnane or a 3--enol ether thereor or 3-desoxy[3,2-c~pyrazole derivaklve thereof that has a hydroxyl group or a hydrolysable derivative thereor at at least one o~ the 17a- and 21-positions when said re-tinoate is a 16a-retinoate, and in partlcular may be a compound o~ the formula fH2Z
Y ~'~
. ~
I X
o~ ~ Y
wherein X is hydrogen or halo~en having an atomic weight of less than 100;
Y ls (Hg ~ OH) or oxygen) or, provided that X is halo-gen, (H,~-halogen);
~, .
~ 3 -December 10, 1975 1~64905 ~B/an is hydrogen, ~methyl, ~ azido, a-~romo, a-chloro, ~-fluoro, ~-fluoro or -fluoromethyl;
B is hydrogen, or, provided that Y is ~H,~-OH), B is also methyl, fluorine, chlorine or bromine;
W is H2, (H, lower alkyl), (H,a-Cl), ~-OH),(~,-re-~inoyloxy), (H,a-ORl) wherein R is an acyl radical of . a hydrocarbon carboxylic acia having up to 12 carbon atoms, or =CHT wherein T is hydrogen, lower alkyl, - fluorine or chIorine;
Q is hydroxy, retinoyloxy, OR wherein R is an acyl radi-cal of a hydrocarbon carboxylic acid having up to 12 carbon atom~, or, provided that W is hydrogen or (H, lower alkyl), Q is also hydrogen or chlorine, or Q taken . t~gether with W is a 16a,17a lower alkylidenedioxy group;
and Z is hydroxy or retinoyloxy, or, provided that Q is hydroxy or retinoyloxy or that Q is OR and W is ratinoyl-oxy, æ i~ also hydrogen, chlorine, ~luorine or OR~ where-ln R i~ an acyl radical of a hydrocarbon carboxylic acid having up to 12 carbon atoms;
or a l-dehydro, 6-dehydro, or 1,6-b -dehydro der.ivative thereofs or~ when B is hydrogen, a 3-desox.y[3,2~c]pyrazole deri-vative thereof or its 6-dehydro derivative;
2~ or, when ~ is hydrogen, a 6,6-difluoro derivative thereof, or its l-dehydro derivative~
~ecember lo, 1975 10649~5 JB/la The 3-desoxy~,2-c]pyrazole derivatives may i~ desired carry a 2'-substi.tuent selected ~rom lower alkyl, cyclo-alkylJ aralkyl, aryl and hydrocarbon carboxylic acyl groups~
The lower alkyl groups in the definikion o~ W and option-ally substituting the 2~-position in the ~-desoxy[~,2-c~
pyrazole derivatives may have up to 6 but preferably have up to 4 carbon atoms, and thus i.nclude methyl, ethyl~
isopropyl, n-propyl, t-butyl, n-butyl, and isobutyl. Other groups optionally substituting the 2'-position in the
- December 10, 1975 1064905 20/ -FTE_3 nolc acid and retr-o-retinoic acidO Thus, unles~ other-wise lndicated, the terms "retinoic acid" and "retinoates"
as used in the specification and claims o~ this appli~
cation include all forms of retinoic acid~ in parti-cular the various cls and trans ~orms and mix'cures there-o~ .
The steroidal retinoate of the present invention i5 pre-ferably a 3,20-diketo-4-dehydro-pregnane or a 3--enol ether thereor or 3-desoxy[3,2-c~pyrazole derivaklve thereof that has a hydroxyl group or a hydrolysable derivative thereor at at least one o~ the 17a- and 21-positions when said re-tinoate is a 16a-retinoate, and in partlcular may be a compound o~ the formula fH2Z
Y ~'~
. ~
I X
o~ ~ Y
wherein X is hydrogen or halo~en having an atomic weight of less than 100;
Y ls (Hg ~ OH) or oxygen) or, provided that X is halo-gen, (H,~-halogen);
~, .
~ 3 -December 10, 1975 1~64905 ~B/an is hydrogen, ~methyl, ~ azido, a-~romo, a-chloro, ~-fluoro, ~-fluoro or -fluoromethyl;
B is hydrogen, or, provided that Y is ~H,~-OH), B is also methyl, fluorine, chlorine or bromine;
W is H2, (H, lower alkyl), (H,a-Cl), ~-OH),(~,-re-~inoyloxy), (H,a-ORl) wherein R is an acyl radical of . a hydrocarbon carboxylic acia having up to 12 carbon atoms, or =CHT wherein T is hydrogen, lower alkyl, - fluorine or chIorine;
Q is hydroxy, retinoyloxy, OR wherein R is an acyl radi-cal of a hydrocarbon carboxylic acid having up to 12 carbon atom~, or, provided that W is hydrogen or (H, lower alkyl), Q is also hydrogen or chlorine, or Q taken . t~gether with W is a 16a,17a lower alkylidenedioxy group;
and Z is hydroxy or retinoyloxy, or, provided that Q is hydroxy or retinoyloxy or that Q is OR and W is ratinoyl-oxy, æ i~ also hydrogen, chlorine, ~luorine or OR~ where-ln R i~ an acyl radical of a hydrocarbon carboxylic acid having up to 12 carbon atoms;
or a l-dehydro, 6-dehydro, or 1,6-b -dehydro der.ivative thereofs or~ when B is hydrogen, a 3-desox.y[3,2~c]pyrazole deri-vative thereof or its 6-dehydro derivative;
2~ or, when ~ is hydrogen, a 6,6-difluoro derivative thereof, or its l-dehydro derivative~
~ecember lo, 1975 10649~5 JB/la The 3-desoxy~,2-c]pyrazole derivatives may i~ desired carry a 2'-substi.tuent selected ~rom lower alkyl, cyclo-alkylJ aralkyl, aryl and hydrocarbon carboxylic acyl groups~
The lower alkyl groups in the definikion o~ W and option-ally substituting the 2~-position in the ~-desoxy[~,2-c~
pyrazole derivatives may have up to 6 but preferably have up to 4 carbon atoms, and thus i.nclude methyl, ethyl~
isopropyl, n-propyl, t-butyl, n-butyl, and isobutyl. Other groups optionally substituting the 2'-position in the
3-desoxy[3J2-c]pyra~ole derivatives include for example cyclopentyl, cyclohexyl, ~-hydroxyethyl, benzyl~ phene-thyl, phenyl including phenyl substituted (especially in the p-position) by halogen (especially ~luorine), tri-M uoromethyl, meth~l~ methoxy or nitro; and 2-, 3- and
4-pyridyl.
The acyl radioals o~ the oompound~ o~ thl~ lnvent:lon de~ined by R, Rl and R2 in Formula I herelnabove and opkionally present at the 2'-position in the ~-desoxy 13,2-c]pyrazole derivati~es include those derived ~rom hydrocarboncarboxylic acids having up to 12 carbon atoms ' which may be saturated~ unsaturated, straight chain or bran¢hed chain, aliphatloJ cyclic, cyclic-aliphatic~
aromatic, araliphatic, or alkyl-aromatic, and may be suhstituted by alkoxy ¢ontaining ~rom 1 to 5 carbon atoms or by hal.ogen such as ~luorineJ chlorine or bromine.
~ 5 -December 10, 1975 2086~FTE- 5 ~)G4905i JB/la Typical acyl radicals of the steroidal retinoates of our invention may thus be derived from alkanoic acids such as lormic, acetic, propionlc, trimethylacetic, butyric, isobutyric~ valeric, isovaleric~ caproic, caprylic, capric, undecylic and laurlc acids; substLtu-ted alkanoic aclds such as phenoxyacetic, trifluoroacetic and ~-chloropropionic acids; adamantane-l- and -2-carbGxylic aclds; aromatic and substituted aromatic acids including benzoic, toluic and p-chlorobenzoic acids; aralkanoic acids suoh as phenylacetic and phenyl-propionic acids; unsaturated acids such as acrylic and sorbic acids; and dibasic acids such as succinic, tartax-ic and phthalic aoids. Such acyl radicals, when present, are preferably those having up to 8, more pre-ferably up to 5, carbon atoms. It ls especially preferred ~or such acyl radicals to be alkanoyl radicals havin~ up to 5 carbon atoms or benzoyl radioals.
~he steroidal 21-retinoates and partiaularl~ the steroldal 21-all-trans-retinoates havln~ the ~ormula CH20CO~
~W
L J--~ II
~~
~ ~ - ~
December 10, 1975 JB/la 1~6q~9~5 wherein A is hydrogen, methyl or fluorLne;
X is h~drogen or fluorine; and W is H2, (H,a-methyl), (H,~-methyl) or (H,a-hydroxy~;
and their 1 dehydro, 6 dehydro and 1~6-bis-dehydro de-rivatives de~ine a pre~erred group of steroidal retinoates particularly use~ul in the treatment and control o~ aone.
0~ the ~ompounds o~ formula IIp esters particularly use~ul in the treatment Or a~ne are those wherein at least one of X and W is hydrogen.
.
Pre~erred compounds of ~ormula II thus include steroldal retin~at,es such as hydrocortisone 21-all-trans-retinoate (i.e. 4-pregne-ne-11~,17a,21-tri~ ,20-dlone 21 all-trans-retinoate), its l-dehydro derivative (i~e. prednisolone 21-all-trans-re~noate), and its 6-dehydro and 1,6-bis-dehydro derlvatives ~i.e., compounds o~ ~ormula II wherein A and X axe hydrogen and W is H2)~
Other useful esters o~ ~ormula II include betamethasone 21-retinoate (i.e. 9~-~luoro-16~-methyl-1,4-pregnadiene-llp,17a,21-triol 3,20-dione 21-all-trans-retinoat.e), betamethasone 17-n-valerate 21-a~l-trans-retinoate, and dexamethasone 21-r~tinoate (l~e. ga-fluoro-l6a-methyl-~pregn~diene-11~17ag21-trlol-~20~dione 21-all-t_ans-ret~noate), and their 6-dehydro, 1(2)-dihydro, and 1(2)-December 10, 1975 2086-FT~-8 ~3L064905 JB/la dihydro-6-dehydro deriv~tives (i.e.J compounds of ~ormula II wherein A is hydro~en, X is rluorine and W is ~HJ me-thyl));
triamcinolone 21-retlnoate (i.e. 9a-fluoro-1,4-pregnadiene-11~, 16aJ 17a,21-tetrol-~,20-dione 21-all-trans-retinoa~e) and lts 6-dehydro, 1(2)-dih~rdro~ and 1(2)-dihydro-6-de-hydro derivatives (i.e. compounds of formula II wherein A is hydrogen, X is ~luorine and W is (H,a-OH));
6a-fluvrohydrocortisone 21-all-trans-retinoate and its l-dehydro, 6-dehydro and 1,6-bis-dehydro derivatives (iOe~ compounds of ~ormula II wherein A ls M uorlne, X is hydrogen, and W is H2); and 6a-methyl-9~ fluoro-4-pregnene_ll~, 17aJ 21- triol-3,20-dione 21-all-trans-retinoate, and its 6-dehydro, l-dehydro and 1,6~bis-dehydro derivatives (i.e. compounds Or ~ormu-la I wherein A is methyl, X is ~luorine and W is H2).
A partioularly pre~erred compound o~' ~ormula II is hydro-cort~sone 21-all-trans-x7etirl0ate.
Other steroidal 21-retlnoates o~ this invention include .17-desoxy compounds Or rormula I such as 6a-~luoro-9~-~hloro-16~-methyl-1,4-pre~nadiene~ J~l-diol-~,20-dione 21-all~tr~ns-retinoate~ 4-pregnene~ J21-diol-~,20-dione . 21-all-trans-retinQate and 17a-chloro-lJ4-pregnadiene-11~,21-diol-~20-dione 21~all-trans-recinoate, and 21-retinoa~es o~ 17,21-diols havlng a hydrolyzable derivakive at C-17 such as ga-rluoro-lG~-methyl-lJ4-pregnadiene-11~
December 10, 1975 2086-~TE-9 ~0649~5 Js/la 17~,21-trLol-3,20~dione 17-n-butyrate 21-all~trans-re-tinoa'ce, ~9a-difluoro-16~J17a-isopropylidenedloxy-1,4-pregnadiene-11~,21-diol-3,20-dione 21-all--trans-~re-~inoate and 2'-phenyl-6,16a-dimethyl-9a-fluoro-11~,17a,21-~rlhydroxy-20~keto-4~6-pregnadieno~3,~-clpyrazole 17-ace-tate 21~all-trans-retinoate.
.
In addition to 21-retinoates~ the compounds o~ this in-vention include, 16a-retinoate~ such as triamcinolone 16-retinoate 21--; 10 acetate (e.g. 9a-fluoro-1,4-pregnadiene-11~,16a,17~,21_ tetrol-3,20 dione 16-all-trans-retlnoate 21-acetate), and the 6-dehydro, 1~2)-dihydro and 1(2)-dihydro-6-de-hydro derivatives thereo~;
16a,21-diretinoat.es such as triamcinolone 15,21-direti-noate (e.g. s~rluoro 1~ pregnadiene 11~,16a~17a~21~
~e~rol-~20-dione 16J 21-di.-all-~rans-retinoate), and the 6-dehydro, l(~)-dlhydro and 1(2)-~ihydro-G-dehydro d~rivatives thereo~s 17~-retinoates of steroids Or ~ormula I such as hydro-~ortisone 17-all-trans-retinoate (4-pre~nene~ ,17~21~
trlol~3,20-dione 17-all-trans-r~tinoate) and its l-dehydro5 6-dehydro and 1J 5-bis-dehydro derivatives; dexamethasone 17-retinoate ancl betam~thasone 17-retinoate ~e.g. 9a-fluoro-16a- and 16~-methyl~ ~pregnadiene~ ,17a,21-triol 2~ ~,20-dione 17~all-trans-ret:lnoate), 9~ -dlchloro~21-.
_ 9 -December 10, 1975 2086~FTE-10 s JB/l~
~luoro-16a-methyl-1,4-pregnadiene-17a-ol-3,20-dione 17-all-trans-retinoate, 2 t -phenyl-6,16a-dimethyl-9a-fluoro-11~,17a-dihydroxy-20-keto~4,6_pregnadieno[3,2-c]pyrazole 17-all-trans-retinoate and 9a,21-difluoro-16a-methyl-1,4-pregnadiene-llp,17a-diol-3,20-dione 17-all-trans-retinoate;
17a,21-diretlnoates Or steroids Or ~ormula I such as hydrocortisone 17,21-diretinoate (e.g. 4-pregnene-11~, 17,21-triol-~,20-dione 17,21-di-all-trans-retinoate) J
9a-rluoro-16a-methyl-1,4-pregnadiene~ ,I7a,21_triol_ 3,20-diorle 17,21-di-all-trans-retinoate, and 9- M uoro-16~-methyl-1,4-pregnadiene-17a,21-diol-3,11,20-trione 17,21-di-all-trans-retinoate;
and steroidal retinoates that lie outside formula I but are retinoates of anti-in~lammatory steroids and may be exemplified by 6,16-dimethyl-1,4,6,15-pregna~e~raene-11~,17aJ21-trlol-3,20-dione 21-all-~rans-retinoate J
16~-methY1-1, 4J 8(9)-pregnatriene-11~, 17~J 21-triO1-~J 20_ dlone 17-proplonate 21-all-trans-retlnoate, 9a-~luoro-11~,21-dihydroxy-3,20-diketo-1,4-pregnadieno~17a,16a-d]oxa~oline 21-all-trans-retinoate and ~ chloroetho~y)-6-~ormyl-9a-~luoro-16a,17a-isopropylidened~oxy-3J5-preg-nadiene-11~21-diol-20-one 21-all-trans-retinoate.
.
December lo, 1~75 208~FTE~ll 10 6 49 0 5 JB,~an The sterQidal retinoates o~ this :invention are usually yello~
crystalline solid~ ~hat are soluble.j.n organic solvents such as alkanols (e.g~ methanol, eth~nol), ethers ~e~g~
diethyl ether, dioxan, tetrahydro~uran) and chl~rinated hydrocarbons (e.g. me~hylene chloride and cllloroform) but insoluhle in water7 Because of the pr~sence of the five con-jugated double ~onds in the reti.noyl radical, the steroidal retinoates o~ this invention are apt to decompose in the presence o light, oxygen or heat~ Thus, to min~nize decom,-position, th~ novel compounds are preferably stor2d in a cool plac~ in the dark and under an atmosphere o~ an iner'~:
gas such as axgon or nitrcgen.
The steroidal ret.inoates of this invention are prepared from the corresponding ~teroidal alcohols by standard pro-cesses ~or the preparation of esters of steroi~s~ However, as retinoic ac~d is apt to decompose in the presence o~
li.ght, oxygen~ h~at ox acid, all the processe~ o this in vention are pre~erably carried out. in the dark undex an inert a~no~pher~ ~u~u~lly nitro~en) and in an essen~i.ally neutral or alkaline medium at or below room temperature.
Whereas the ester~ication can be carried out above room k~mperature and~or in an acidic meclium, hi~her yields o :l purer steroidal retinoates will usually be obtained w~nen the esteriication is carried out ln a ne~tral or alkaline medi~m a~ ~r ~elow room temperature~
December lO, 1975 2086 FTE~12R' 1064905 JB/an ~ccording to ~ fur~lncr Eeatur~ of the invention, t~nere-~ore, we provide a process fox the preparation of a 16~-, 17a- and/or 21~reti.noate of an antl~inflammatory s~.eroid o~ the pregnane series having a hydroxyl group at at least S one o~ the 16~-, 17a- and 21-positions, which compr:ises reactlng an anti-i.nflammatory steroid of the pre~rlane series that has a hydroxyl gxoup at at least one of the 16a-, 17a- and 21~positions with retinoic acid .in the presence o~ a dehydxating or esterifying a~erlt or with a reactive derivatlve of retinoic acid. The anti-in-flamma-; tory steroid used as starting material is preferably a 3,20~diketo-4~dehydro-pregnane or a 3 enol ether th~reof or 3-desoxy[3,~-~clpyrazole derivative thereof, and has a hydroxyl group a~ at leas~ one of the 16a-, 17a- and 21~
positlons, with the proviso that there is present a hydro-xyl group or a hydrolysable derivative thereoE at at least one of the 17a- and 21-positions together with a 16a-11ydroxy group when a 16~-retinoate is required.
The step of estexi.~ication may then if desired be followed by a number of optional steps, as long as these will neither : cau~e undue hydroly~is o~ the .retinoate estex nor cause the somewh~t unstable retinoyl moiety to clecompose e~t.en siY~ely; or example:
(a) Migrat:ion of an e~t~riying xe~ino~l group ~rom one hydroxy substituent in the steroid nucleus to another;
(h) Selective hydrolysis o~ an ester group at the 21-posi-tion in a ].6a- or 17a-~retionate or at the 16a -posi~ on in a 17a-r~3tllloate;
(c) Removal o~ a prote~ting ether ox es~er group rrom an ll~-hydroxy, 16a--hydrox~ and/or 21-hydroxy group;
(d~ Elimi.nation o a 21~hyclroxy-group -thxou~h sulT onation, eXChan~-3 OL the ~u.lfon~te group for i.odide~ and reduc~ion o the iodide;
- 12 _ December 10, 1975 lOÇ;4905 JB/an (e) Trans~ormation of a 21 hydroxy group into a 21-chlo-rine or fluorine atom ~hrough sul~onation and eY.change of the sulfonate group for chloride or fluGride;
(f) Acylation of a free 16a-, 17a- or 21-hydroxy ~roup~
The conditions chosen for the esteri~ication t~7ill depend largely upon the reactivity o' the hydrox~l group (at the : 16a-, 17a- and/or 21-position) to be esterified, and whether there is present in thé steroid molecule a hydroxyl group of greater reactivity that must be protected, e.g., an ll~-hydro~yl group~ when a 17a-retinoate is to be prcpared or a 21-hydroxyl group when a 16a-retinoate group is to be prepared.
The 16a- and 21-hydroxy groups are both readily esterified under mild conditions, so that a 16a- or 21-monoretinoate or a 16a,21-diretinoate can be readily prepared by reaction o the correspon~ing 16a- or 21-ol or 16a,21 ~iol either ~i) with retinoic acid in the pr~senc~ o~ an inert solvent and a carbodiimicle, an a-alk~nylamine, an al~o~yac~tylene or boron trifluoride as dehydrating or esteri~ying agent, or (ii) with a reactive derivative o~ retinoic acid, in parti-cular with re~inoyl chlorid~ in the presence of a base, ~ith N-retinoylLmida~ole in the pres~nce of a bast, or with a retinoate of,~ N-hydro~yimide of a dicarboxylic acid.
December lo, 1975 ~64905 JB/an ., In the flrst o~ these processes, the preferred dehydxating agent is a carbodiimide, especially dicyclohexylcarbodiimide or l-cyclohexyl-3-(2~morpholinoethyl)carbodiimide metho-~-toluenesul~onate, which is conveniently used in equimolar quantit~ to the retinoic acid. Prefera~ly one equivalent each of diimide and of retinoic acid is added to the steroid in an inert organic solvent, and the reaction mixture is le~t to stand, with further addition of equimolar portions of retinoic acid and of carbodiimide until analysis of a sample (e.g. by thin layer chroma~ograph~) indi~ates that most of the steroidal alcohol has been converted into its retinoate ester. This reaction usually requires consi~erable t~ne, e.g~ two days or more. It i9 preerably carried out in the dark under an inert atmosphere (e.g. under nitrogen) and at about room temperature. The inert organic solvent may be for example acetonitrile, a chlorinated hydrocarbon such as methylene chloride, or an ether ~uch as dioxan or ~specially tetrahydrofuran. The steroidal retinoate may be conveniently isolatcd ~ puri~ied by extraction and chromatograph~.
Other dehydrating esterifying agen~s that may be used ; includ~ ethoxyacet~lene in an inex~ solvent such as ethyl acetate, l-phenyl-2-methylanilino-acetylene in an inert ~olvent such as chlorofoxm, or a catalytic quantity of bo~
~on trifluoride etherate in an inert solvent such as ~iethyl ether.
December lOo 1975 2086 FTE--3.5 1(3!64~305 13~an In the second of these processes, ~he preerred reactive derivative is N~retinoylimidazole (prepared e.g. from retinolc acid and ~ carbonyldiimidazole) in approxi-mately equimolar quantities, except that double quanti-ties must be used for 16a,21-diesterification~ This esteri-fication is carried ou~ in the pxesence of a ba~e such as sodium methoxide, sodamide or imidazolyl sodium, and o~ an inert solvent such as an anhydrous ether, especially a dialkyl ether (e~g~ diethyl e~her)~ dioxan or mosL preferab-ly tetrahydro~uran. This ester~ication i~ preferabl~ carriedout in the dar}c undex an inext at~osphere (e.g~ nitro~en) and conveniently at about room temperature. Completion o~
the re~ction, w~ich may be determined by thin layer chroma-tography, usually requires onl~ a short t~me, e.g. 15 to 30 minute~. The steroidal retinoate may then be readily isola-ted and purified in good -yield by conventional methods, usually chromatogxaphy.
.
When retinoyl chloride i~ u~ed as reactive derivative, the ba~ pre~rably ~n or~aniG ~e~ti~ry amine ~hat ~erves a~
~0 æolvent, e.g~ pyridine or triethylamine~ Retinoates o ~-h~droxy~mides that may be used as reactive derivatives of retinoic acid include N-hydroxy~phthalimide retinoate and hydroxy succinimide retinoate, which can be prepared by reaction o retinoic acid with N-hydroxy-phthalimide or ~-hydroxy~uccinimide in the presence of a carbodiimide.
Dec~N!~e~ 10, 1975 2~86~FTE-16 ~64905 JB/~n 16a~monoretinoate of a 16a,2}-diol ma~ if desired he prepared by the steps of 16a,21-diacylation with retino.ic acid or with a reac~ive deriva~ive thereof as descri~ed above, f~llowed by selective hydroly.sis at the 21-position S with mild alkali, e~g~ with sodium bicarbonate n an aque3us inert or~anic solvent. How~ver, when it is desire~ to con~
vert only one hydroxy group of a 16a,21-diol i.nto a retinoyl-oxy group, i~ is usually pre~erable to protect the other hydroxy group and sub~equen~y liberate it.
Thus, the 21-~lydro~ gxoup may be protected by converslon intv the 21-tri1uoroaceta.te by reaction o~ the skeroid 16a,21-diol with one equivalent of trifluoroacetic anhydri-de. The 16a-hydroxy group may then be converted into reti-noyloxy as described abo~e. Finally, the 21-h~droxy sroup lS may be liberated by selective hydrolysis of ~he 16a-r~t.i-noate 21-trifluoroaceta~e by means o~ sodium azide or sodium benzoake, preerably in an ~queous oxganic 501vent such a~ aqueous methanol.
.
The 16~h~droxy group is best protected by the steps or ~o acetylation of the 16a,21-diol with one equivalen~ o ace~
tic anhydride in pyridine at 0C,to y.ield the 21~monoacetate, and int~o~uction o~ an acid~labile, alkali-stable protec~
ting yroup on the 16u-hydroxy grollpO The 21-acetate group may then be hydrol~sed ~y mild alkali, preferably sodium bi-2S carbonate in aqueou~ meth~xlol, and the l'.berated 21-h~droxy Decemher lo, 1975 2086~TE- 17 .~B/an 9~5 group may then ~e esteri.ied with re~inoic acid or with a reactive derivative thereof as described above. The pro-tect.ing group at the 16-position may then be removed ~y mild acid hydro~ysis.
.
The protecting group at the 16~-position is pre~erably a triloweralkyl silyl ether" especially trimethylsilyl ~ther, or a 2-tetrahydropyrallyl ethex groupO The trilower al~cyl~
silyl ether ~roup can be introduced by reaction of tha 16,21-diol 21~monoacetate with the corresponding trilow~r~
alkyl silsrl chloride in pyrid.ine, whereas the 2-t~trahydro-f pyranyl ethe.r group can be introduced by reaction o~ the I 16a,~1~diol 21qmonoacetate with dihydropyran and a cataly-I tic quantity of a stron~ a~id. Under these circumstances, ,1 any ïl~hydroxy gxoup is ~imilarly protectea, but is rcge~e-rated with the 16a-hydroxy group ~hen the pro~cting ether group is removed by h~rdxol~si~ with ~.ilute acid, preferably with dilute h~drochloric acid in met.hanol.
A 17~nonoret.inoate of a 17~,21-diol is best prepared by the ~teps u~ monoe~terlication at the 21 position with reti.-2~ noic acid i~ the presence of a dehydrating or esterifying agen~ or with a xeacti.ve derivativ~ of retinoic acid as - described above, followed by migration of the esteri~ying r~tinoyl group from the 21-hydroxy grcup to the 17a-hydro~y group by treat~ent o~ the resulting 21 re~inoate with a December 10, 1975 ~ S ~/an non-hydrox~ ba~ in an anhy(lrous aprot:ic m~aium and by protonation o~ the product where~by the 17~monoretinoate is *ormedO ~he general conditions for this reaction are set out in U,S. P. ~oO 3,891,631. The non~hydroxy~ic base i~
s pre~erably an alkali metal ~mide base, a phenolate or an alcoholate, or especially an alkali metal carbanionoid ~ase, e.g., a lithium diloweral~yl cuprate, in paxticular lithium dimethyl cuprate. The anhydrous aprotic medium is preera~'y an ether, e.g~ tetr~hydrofuran, 1,2 di~ethoxye~hane, diox~n ox diethyl et~er. The reaction is desirabl~ e~ected at re-duced tem~erature, pre~erably at a~vut -~0C, undex an inert atmosphere (e.y. nitrogen) and in the dar~;. The protonation i~ pre~erahly ef~ecked ~y means o~ an aqueous ammonium ~alt, e.~. ammonium chloride. ~he result.in~ 17a-retinoate i~ con-veniently isolated by extraction of the aqueous reaclionmixture with a ~ater-immisc~e or~anic solvent, e.g. ethyl acetate, and may be puri~ied by chromatoglaphy.
17a-Retinoates nla~ also be prepared direc~l~, by reaction of the 17~-ol with retinoia acid or wi.th a react.ive d~ri~
va~ive thereo~ under cond.itions vigorous enough to acyla~e the ~texically hindered 17a-hydxox~ group. Thus the æteroidal 17a-ol may be acylated with re~inoic acid in ~he presence of trifluoroacetic an}l~dride and a strong acid catalyst, preferably toluene-p~sul~onic acidl or with re~lnoyl chlo-ricle in the presence o~ d.imethy3.aminopylidirle ~nd a ter-tiar~ am.ine, preferably pyriditle. Condi.ti.ons~ vic30rouS e330~lC~h .
.
`
Decembff~r 10, 1~75 2086--I~TE--19 JB/an i49~
to acylate the 17a-hyarox~l group ~,~ill o~ course also ac~-late any ree llff3-f/f 16a- and/or 21~hydroxyl groupsi so, i:E
the~e groups are present, th~y should be protected and the protect.ing groups should then be removed after the 17a-acy-lation (unless it is dfefsired to prepare a 16a,17a- ox 17a~21-diretinuate, wh2n the 16a~ or 21-hydroxyl group may bs left unprotected) .
The protecting group is conveniently a ~ilyl f~ther or 2-tetrahydropyran~1 ether group as descr.ibed above or pro-tection o the 15a-hydroxy group when a 21~nonoretinoatf&f of a 16,21-diol is ~o be prepared. The protecti.ng group may also bef a nitrate ester group, which can be introduced by reaction o~ the steroidal ~lcohol with ace~yl nitratfef, and can be removed by reduction, preferably with zinc and .1 j15 acetic acid. Another protecting group is the trifluoxoacetyl group, which can be introduced by e.~terification o~ the steroicl with triæluoroacetic anh~dride in pyridine, and can be remo-ved by hydrolysi.s under mildly alkaline condi~ions, ff3.fg. wi~h aff~eou~ me~hanolic sf~dium bicarborlateO
Il 20 Any free 21~hydroxyff~rcfllp that is present in the starff~ing ; stexoid 17a-ol will of fcourse be proteff~ted by L~he abo~e-mentionsd groups. However~ since a 17a-xetinoate ff~an ~e readily prepared froln a 21~ ef~inoa~e ky mif~ra~ion of ~he retinoyl grou~ from the 21- to the 17a-position ;as de~cribed .
December 10, 1975 2086-FTE~20 1064905 JB/an above), the process o direcl acylat.ion a~ the 17u -position with retinoic acid or with a reactive derivative thQreof is more conveniently used only for those steroids l~cking a ~l-hydxox~1 group. After introduction of ~he esterifying 17a-retinoyl group, the protecting groups are removed as described above, and the resulting 17a-retinoate i~ then purified by standard methods, e.g. by chromatography.
A 17a,21-diacylate ~herein at least one acyl group is retinoyl can ~e prepared by successive introduction o~ the two acyl groups. Thus the irst acyl group can be introduced onto the ~l~hydroxyl group; then either the seconcl can be intro-duced onko the 17a-~1ydrox~1 group (any 11~- and/or 16a-hydroxy group be~ng protected as described abo~e), or khe first acyl gxoup can be made to migrate to the 17a-hydroxyl group as lS dèscriked above, and then ~e second can be introduced on10 the 21-hydroxyl group. Thi.s lat~x alt~rnativa has khe ad~
vantage that no pro~ccting groups need be u~ed. Either al~er native ma~ be u~ed to introduce two retinoyl ~roups or on~
retinoyl group and one different acyl group~ The di~fer~n~
ac~l group may be introduced under conditions`analogo~ls to ~ho~ de~cribed ~or the xetinoyl g~oup.
A 17,21--dire-tinoa~e can also be prepared by simultaneous acylation at the '7a- and 21~hydroxyl groups. Under these circumstances, of course, any 11~- arld/or l~-hydroxyl group ~5 must be protected as describ~d above.
:- - 20 ~
Decen~er 1~, 1975 2086~FTE~21 Js/an ;49~
17a-Retinoat~ o~ desoxy-17a--ols can be prepared either by direct acylation o khe 21-desoxy--17a~ols as described above ox by 17a-acylation of the corresponclin~ 17a,21-diols (pre-~erably b~ 21-Acylation followed by migration of the reti noyl group from the 21-~ydroxyl group to the 17a-hydroxyl group) with subsequent elimination of the 21-hydroxyl group or transformation thereof into a 21~fluorine or chlorine atomO
~hus ~he 21~hy~roxyl group can be eliminated by conver~ion ~hereof into a 21-~ulfonate ester, pre~erably the 2:L-~nethane-10 - sulfonate, by ac~lation with a sulfonyl chloride, preerably with methanesul~onyl chloride in pyricline, a~d ~onversion of the 21-sul~ona~e .into the 21-iodide and elimination of the iodide by reaction o the 21-sulonate with sodium iocli de and ace-tic acid, pre~erably in dimethylformamide. Alterna~
tively, the 21-hydroxyl group can be converted into a 21~~1uo rine or chlorine atom by conversion ~hereo~ in~o a 21-sul:Fo-nate e~ter, pre~erably the 21~n~thanesul~onate, b~ ac~la~i.on with a sul~onyl chloride, preEerably with metha~e~ul.~on~l chlo~ide in pyridine, and conversion o~ the 21-sulfonate i.nto the 21~chloride or fluori~e by reaction with lithium chloride or ~luoride resp~ctively in dimethyl~orm~mide.
rrhe retinoate esters, especially the 21-retinoate, 17a-re-tinoate, l~a~retinoate, 16a,71~diretinoate and the 17a,21-di.ret.inoate ~sters of anti-infl~natory steroids of the - 21 ~
' .
December lo, 1975 2086--Fl'E--22R ' JBjan 1(~649~5 pregnane series (particularly of anti-inflan~atory steroids having an order o~ anti-inflammatory activity about that exhibited ~y hydrocortisone) are novel compounds wnich have been found to possess anti-acne activity without significant inflammatory acti~ity as evidenced by tests in the rhino va-riant hairless mouse. When applied topically to ~he skin of such mice that have comedo-like lesions, ;the steroidal reti-noates (e.g. the steroidaL all trans-retinoates) of this invention reduce the size and number of comedones, while ad-vantageously causing little or no irritation to the skin suchas is caused by the topical application o retinoic acid per se. Preferred steroid retinoates inc~ude the 21~, 17~-and 16~-monoretinoates and 16~,21- and 17a,21~dir~tinoates o anti-inflammatory steroids, such as steroidal xetinoates defined by formulae I and II hereinabove. 21-All-trans-retinoates are especially preerred.
It i8 indeed surprising and une~pected that the novel steroidal retinoates are efective topicall~ in reducing thc number o~ com~dones while a~vantageously causing no significant in1an~atory response of the skin; since it has been ~urther discovered that, when all-trans-retinoic acid and a steroid having anti~in1ammatory acti~ity (e~g. of a level such as that exhibited by hydrocorti-sone or prednisolone) axe applied together topically to skin affected by acne~ .e lesions (e.g. as ln the rhino Dec~rnber 10, 1975 ~L~6~L9~5 2086-F'rE- 23 JB/an variant hairless mouse) in molecular equivalent ~nounts to a given quantity of the corresponding ste~oidal re~inoate (e.g. hydrocortisone 21-all~trans-retinoate), the com-bined steroid and all-~trans-retinoic acid application causes substantial inflammation which i6 sometimes even greater than that produced by all-trans-retinoic acid alone.
T~Je have also discovered th~t the combined properties of anti-acne a¢tivity with little in~lamma~ory response is :- i not exhibited by other steroidal esters such as steroidal 10 lo~er alkanoates (e.g. hydrocortison~ 21--aceta~e), or steroidal esters OI acids having a l~pophilicity similar ~o tha~ o~ retinoic acid, e.g~ ~sters .such as hydrocorti-sone 21-stearate. Moreov~r, retinoic acid esters o~ non-steroida} alcohols having the same lypophilicity as hydro- i 15 cortisone 21-retinoate (e.g. 2-phenylethyl retinoate) were ineffective when applied topically to skin affected by acne-like lesions.
, ' ~
The anti-acne properties o th~ ateroid~l retinoates o~
this invention are d~monstrat~d by tests in the rhino 20 variant hairles~s mouse, an animal model found useful in sareening drugs ~or comedol~tic properties. In these tests, a solution of a steroidal retinoa-te o~ this in-vention (e.g~ hydrocoxtisone 21-all- _ans-retinoate in an inert solvent (e.g. ace-tone) in concentrations ranging 25 ~rom abou~ o.01 % to about ~.5 %, usually about 0.1 %
conc2ntration, is applied topically to the skin of a rhino variant hairless mouse once a da~ Eor six days.
' .
Decemb2r 10, 1~75 - 2086~FTE-24 1064~5 JB/an The ~rea of the pilaxy canal containing keratin ~comedo), the n~ber of acu~e in~lan~atory cells and the epidenmal thickness a~ measurea befoxe and ater treatment. Areas t~eated with a solutiQn of a steroidal retinoate of this
The acyl radioals o~ the oompound~ o~ thl~ lnvent:lon de~ined by R, Rl and R2 in Formula I herelnabove and opkionally present at the 2'-position in the ~-desoxy 13,2-c]pyrazole derivati~es include those derived ~rom hydrocarboncarboxylic acids having up to 12 carbon atoms ' which may be saturated~ unsaturated, straight chain or bran¢hed chain, aliphatloJ cyclic, cyclic-aliphatic~
aromatic, araliphatic, or alkyl-aromatic, and may be suhstituted by alkoxy ¢ontaining ~rom 1 to 5 carbon atoms or by hal.ogen such as ~luorineJ chlorine or bromine.
~ 5 -December 10, 1975 2086~FTE- 5 ~)G4905i JB/la Typical acyl radicals of the steroidal retinoates of our invention may thus be derived from alkanoic acids such as lormic, acetic, propionlc, trimethylacetic, butyric, isobutyric~ valeric, isovaleric~ caproic, caprylic, capric, undecylic and laurlc acids; substLtu-ted alkanoic aclds such as phenoxyacetic, trifluoroacetic and ~-chloropropionic acids; adamantane-l- and -2-carbGxylic aclds; aromatic and substituted aromatic acids including benzoic, toluic and p-chlorobenzoic acids; aralkanoic acids suoh as phenylacetic and phenyl-propionic acids; unsaturated acids such as acrylic and sorbic acids; and dibasic acids such as succinic, tartax-ic and phthalic aoids. Such acyl radicals, when present, are preferably those having up to 8, more pre-ferably up to 5, carbon atoms. It ls especially preferred ~or such acyl radicals to be alkanoyl radicals havin~ up to 5 carbon atoms or benzoyl radioals.
~he steroidal 21-retinoates and partiaularl~ the steroldal 21-all-trans-retinoates havln~ the ~ormula CH20CO~
~W
L J--~ II
~~
~ ~ - ~
December 10, 1975 JB/la 1~6q~9~5 wherein A is hydrogen, methyl or fluorLne;
X is h~drogen or fluorine; and W is H2, (H,a-methyl), (H,~-methyl) or (H,a-hydroxy~;
and their 1 dehydro, 6 dehydro and 1~6-bis-dehydro de-rivatives de~ine a pre~erred group of steroidal retinoates particularly use~ul in the treatment and control o~ aone.
0~ the ~ompounds o~ formula IIp esters particularly use~ul in the treatment Or a~ne are those wherein at least one of X and W is hydrogen.
.
Pre~erred compounds of ~ormula II thus include steroldal retin~at,es such as hydrocortisone 21-all-trans-retinoate (i.e. 4-pregne-ne-11~,17a,21-tri~ ,20-dlone 21 all-trans-retinoate), its l-dehydro derivative (i~e. prednisolone 21-all-trans-re~noate), and its 6-dehydro and 1,6-bis-dehydro derlvatives ~i.e., compounds o~ ~ormula II wherein A and X axe hydrogen and W is H2)~
Other useful esters o~ ~ormula II include betamethasone 21-retinoate (i.e. 9~-~luoro-16~-methyl-1,4-pregnadiene-llp,17a,21-triol 3,20-dione 21-all-trans-retinoat.e), betamethasone 17-n-valerate 21-a~l-trans-retinoate, and dexamethasone 21-r~tinoate (l~e. ga-fluoro-l6a-methyl-~pregn~diene-11~17ag21-trlol-~20~dione 21-all-t_ans-ret~noate), and their 6-dehydro, 1(2)-dihydro, and 1(2)-December 10, 1975 2086-FT~-8 ~3L064905 JB/la dihydro-6-dehydro deriv~tives (i.e.J compounds of ~ormula II wherein A is hydro~en, X is rluorine and W is ~HJ me-thyl));
triamcinolone 21-retlnoate (i.e. 9a-fluoro-1,4-pregnadiene-11~, 16aJ 17a,21-tetrol-~,20-dione 21-all-trans-retinoa~e) and lts 6-dehydro, 1(2)-dih~rdro~ and 1(2)-dihydro-6-de-hydro derivatives (i.e. compounds of formula II wherein A is hydrogen, X is ~luorine and W is (H,a-OH));
6a-fluvrohydrocortisone 21-all-trans-retinoate and its l-dehydro, 6-dehydro and 1,6-bis-dehydro derivatives (iOe~ compounds of ~ormula II wherein A ls M uorlne, X is hydrogen, and W is H2); and 6a-methyl-9~ fluoro-4-pregnene_ll~, 17aJ 21- triol-3,20-dione 21-all-trans-retinoate, and its 6-dehydro, l-dehydro and 1,6~bis-dehydro derivatives (i.e. compounds Or ~ormu-la I wherein A is methyl, X is ~luorine and W is H2).
A partioularly pre~erred compound o~' ~ormula II is hydro-cort~sone 21-all-trans-x7etirl0ate.
Other steroidal 21-retlnoates o~ this invention include .17-desoxy compounds Or rormula I such as 6a-~luoro-9~-~hloro-16~-methyl-1,4-pre~nadiene~ J~l-diol-~,20-dione 21-all~tr~ns-retinoate~ 4-pregnene~ J21-diol-~,20-dione . 21-all-trans-retinQate and 17a-chloro-lJ4-pregnadiene-11~,21-diol-~20-dione 21~all-trans-recinoate, and 21-retinoa~es o~ 17,21-diols havlng a hydrolyzable derivakive at C-17 such as ga-rluoro-lG~-methyl-lJ4-pregnadiene-11~
December 10, 1975 2086-~TE-9 ~0649~5 Js/la 17~,21-trLol-3,20~dione 17-n-butyrate 21-all~trans-re-tinoa'ce, ~9a-difluoro-16~J17a-isopropylidenedloxy-1,4-pregnadiene-11~,21-diol-3,20-dione 21-all--trans-~re-~inoate and 2'-phenyl-6,16a-dimethyl-9a-fluoro-11~,17a,21-~rlhydroxy-20~keto-4~6-pregnadieno~3,~-clpyrazole 17-ace-tate 21~all-trans-retinoate.
.
In addition to 21-retinoates~ the compounds o~ this in-vention include, 16a-retinoate~ such as triamcinolone 16-retinoate 21--; 10 acetate (e.g. 9a-fluoro-1,4-pregnadiene-11~,16a,17~,21_ tetrol-3,20 dione 16-all-trans-retlnoate 21-acetate), and the 6-dehydro, 1~2)-dihydro and 1(2)-dihydro-6-de-hydro derivatives thereo~;
16a,21-diretinoat.es such as triamcinolone 15,21-direti-noate (e.g. s~rluoro 1~ pregnadiene 11~,16a~17a~21~
~e~rol-~20-dione 16J 21-di.-all-~rans-retinoate), and the 6-dehydro, l(~)-dlhydro and 1(2)-~ihydro-G-dehydro d~rivatives thereo~s 17~-retinoates of steroids Or ~ormula I such as hydro-~ortisone 17-all-trans-retinoate (4-pre~nene~ ,17~21~
trlol~3,20-dione 17-all-trans-r~tinoate) and its l-dehydro5 6-dehydro and 1J 5-bis-dehydro derivatives; dexamethasone 17-retinoate ancl betam~thasone 17-retinoate ~e.g. 9a-fluoro-16a- and 16~-methyl~ ~pregnadiene~ ,17a,21-triol 2~ ~,20-dione 17~all-trans-ret:lnoate), 9~ -dlchloro~21-.
_ 9 -December 10, 1975 2086~FTE-10 s JB/l~
~luoro-16a-methyl-1,4-pregnadiene-17a-ol-3,20-dione 17-all-trans-retinoate, 2 t -phenyl-6,16a-dimethyl-9a-fluoro-11~,17a-dihydroxy-20-keto~4,6_pregnadieno[3,2-c]pyrazole 17-all-trans-retinoate and 9a,21-difluoro-16a-methyl-1,4-pregnadiene-llp,17a-diol-3,20-dione 17-all-trans-retinoate;
17a,21-diretlnoates Or steroids Or ~ormula I such as hydrocortisone 17,21-diretinoate (e.g. 4-pregnene-11~, 17,21-triol-~,20-dione 17,21-di-all-trans-retinoate) J
9a-rluoro-16a-methyl-1,4-pregnadiene~ ,I7a,21_triol_ 3,20-diorle 17,21-di-all-trans-retinoate, and 9- M uoro-16~-methyl-1,4-pregnadiene-17a,21-diol-3,11,20-trione 17,21-di-all-trans-retinoate;
and steroidal retinoates that lie outside formula I but are retinoates of anti-in~lammatory steroids and may be exemplified by 6,16-dimethyl-1,4,6,15-pregna~e~raene-11~,17aJ21-trlol-3,20-dione 21-all-~rans-retinoate J
16~-methY1-1, 4J 8(9)-pregnatriene-11~, 17~J 21-triO1-~J 20_ dlone 17-proplonate 21-all-trans-retlnoate, 9a-~luoro-11~,21-dihydroxy-3,20-diketo-1,4-pregnadieno~17a,16a-d]oxa~oline 21-all-trans-retinoate and ~ chloroetho~y)-6-~ormyl-9a-~luoro-16a,17a-isopropylidened~oxy-3J5-preg-nadiene-11~21-diol-20-one 21-all-trans-retinoate.
.
December lo, 1~75 208~FTE~ll 10 6 49 0 5 JB,~an The sterQidal retinoates o~ this :invention are usually yello~
crystalline solid~ ~hat are soluble.j.n organic solvents such as alkanols (e.g~ methanol, eth~nol), ethers ~e~g~
diethyl ether, dioxan, tetrahydro~uran) and chl~rinated hydrocarbons (e.g. me~hylene chloride and cllloroform) but insoluhle in water7 Because of the pr~sence of the five con-jugated double ~onds in the reti.noyl radical, the steroidal retinoates o~ this invention are apt to decompose in the presence o light, oxygen or heat~ Thus, to min~nize decom,-position, th~ novel compounds are preferably stor2d in a cool plac~ in the dark and under an atmosphere o~ an iner'~:
gas such as axgon or nitrcgen.
The steroidal ret.inoates of this invention are prepared from the corresponding ~teroidal alcohols by standard pro-cesses ~or the preparation of esters of steroi~s~ However, as retinoic ac~d is apt to decompose in the presence o~
li.ght, oxygen~ h~at ox acid, all the processe~ o this in vention are pre~erably carried out. in the dark undex an inert a~no~pher~ ~u~u~lly nitro~en) and in an essen~i.ally neutral or alkaline medium at or below room temperature.
Whereas the ester~ication can be carried out above room k~mperature and~or in an acidic meclium, hi~her yields o :l purer steroidal retinoates will usually be obtained w~nen the esteriication is carried out ln a ne~tral or alkaline medi~m a~ ~r ~elow room temperature~
December lO, 1975 2086 FTE~12R' 1064905 JB/an ~ccording to ~ fur~lncr Eeatur~ of the invention, t~nere-~ore, we provide a process fox the preparation of a 16~-, 17a- and/or 21~reti.noate of an antl~inflammatory s~.eroid o~ the pregnane series having a hydroxyl group at at least S one o~ the 16~-, 17a- and 21-positions, which compr:ises reactlng an anti-i.nflammatory steroid of the pre~rlane series that has a hydroxyl gxoup at at least one of the 16a-, 17a- and 21~positions with retinoic acid .in the presence o~ a dehydxating or esterifying a~erlt or with a reactive derivatlve of retinoic acid. The anti-in-flamma-; tory steroid used as starting material is preferably a 3,20~diketo-4~dehydro-pregnane or a 3 enol ether th~reof or 3-desoxy[3,~-~clpyrazole derivative thereof, and has a hydroxyl group a~ at leas~ one of the 16a-, 17a- and 21~
positlons, with the proviso that there is present a hydro-xyl group or a hydrolysable derivative thereoE at at least one of the 17a- and 21-positions together with a 16a-11ydroxy group when a 16~-retinoate is required.
The step of estexi.~ication may then if desired be followed by a number of optional steps, as long as these will neither : cau~e undue hydroly~is o~ the .retinoate estex nor cause the somewh~t unstable retinoyl moiety to clecompose e~t.en siY~ely; or example:
(a) Migrat:ion of an e~t~riying xe~ino~l group ~rom one hydroxy substituent in the steroid nucleus to another;
(h) Selective hydrolysis o~ an ester group at the 21-posi-tion in a ].6a- or 17a-~retionate or at the 16a -posi~ on in a 17a-r~3tllloate;
(c) Removal o~ a prote~ting ether ox es~er group rrom an ll~-hydroxy, 16a--hydrox~ and/or 21-hydroxy group;
(d~ Elimi.nation o a 21~hyclroxy-group -thxou~h sulT onation, eXChan~-3 OL the ~u.lfon~te group for i.odide~ and reduc~ion o the iodide;
- 12 _ December 10, 1975 lOÇ;4905 JB/an (e) Trans~ormation of a 21 hydroxy group into a 21-chlo-rine or fluorine atom ~hrough sul~onation and eY.change of the sulfonate group for chloride or fluGride;
(f) Acylation of a free 16a-, 17a- or 21-hydroxy ~roup~
The conditions chosen for the esteri~ication t~7ill depend largely upon the reactivity o' the hydrox~l group (at the : 16a-, 17a- and/or 21-position) to be esterified, and whether there is present in thé steroid molecule a hydroxyl group of greater reactivity that must be protected, e.g., an ll~-hydro~yl group~ when a 17a-retinoate is to be prcpared or a 21-hydroxyl group when a 16a-retinoate group is to be prepared.
The 16a- and 21-hydroxy groups are both readily esterified under mild conditions, so that a 16a- or 21-monoretinoate or a 16a,21-diretinoate can be readily prepared by reaction o the correspon~ing 16a- or 21-ol or 16a,21 ~iol either ~i) with retinoic acid in the pr~senc~ o~ an inert solvent and a carbodiimicle, an a-alk~nylamine, an al~o~yac~tylene or boron trifluoride as dehydrating or esteri~ying agent, or (ii) with a reactive derivative o~ retinoic acid, in parti-cular with re~inoyl chlorid~ in the presence of a base, ~ith N-retinoylLmida~ole in the pres~nce of a bast, or with a retinoate of,~ N-hydro~yimide of a dicarboxylic acid.
December lo, 1975 ~64905 JB/an ., In the flrst o~ these processes, the preferred dehydxating agent is a carbodiimide, especially dicyclohexylcarbodiimide or l-cyclohexyl-3-(2~morpholinoethyl)carbodiimide metho-~-toluenesul~onate, which is conveniently used in equimolar quantit~ to the retinoic acid. Prefera~ly one equivalent each of diimide and of retinoic acid is added to the steroid in an inert organic solvent, and the reaction mixture is le~t to stand, with further addition of equimolar portions of retinoic acid and of carbodiimide until analysis of a sample (e.g. by thin layer chroma~ograph~) indi~ates that most of the steroidal alcohol has been converted into its retinoate ester. This reaction usually requires consi~erable t~ne, e.g~ two days or more. It i9 preerably carried out in the dark under an inert atmosphere (e.g. under nitrogen) and at about room temperature. The inert organic solvent may be for example acetonitrile, a chlorinated hydrocarbon such as methylene chloride, or an ether ~uch as dioxan or ~specially tetrahydrofuran. The steroidal retinoate may be conveniently isolatcd ~ puri~ied by extraction and chromatograph~.
Other dehydrating esterifying agen~s that may be used ; includ~ ethoxyacet~lene in an inex~ solvent such as ethyl acetate, l-phenyl-2-methylanilino-acetylene in an inert ~olvent such as chlorofoxm, or a catalytic quantity of bo~
~on trifluoride etherate in an inert solvent such as ~iethyl ether.
December lOo 1975 2086 FTE--3.5 1(3!64~305 13~an In the second of these processes, ~he preerred reactive derivative is N~retinoylimidazole (prepared e.g. from retinolc acid and ~ carbonyldiimidazole) in approxi-mately equimolar quantities, except that double quanti-ties must be used for 16a,21-diesterification~ This esteri-fication is carried ou~ in the pxesence of a ba~e such as sodium methoxide, sodamide or imidazolyl sodium, and o~ an inert solvent such as an anhydrous ether, especially a dialkyl ether (e~g~ diethyl e~her)~ dioxan or mosL preferab-ly tetrahydro~uran. This ester~ication i~ preferabl~ carriedout in the dar}c undex an inext at~osphere (e.g~ nitro~en) and conveniently at about room temperature. Completion o~
the re~ction, w~ich may be determined by thin layer chroma-tography, usually requires onl~ a short t~me, e.g. 15 to 30 minute~. The steroidal retinoate may then be readily isola-ted and purified in good -yield by conventional methods, usually chromatogxaphy.
.
When retinoyl chloride i~ u~ed as reactive derivative, the ba~ pre~rably ~n or~aniG ~e~ti~ry amine ~hat ~erves a~
~0 æolvent, e.g~ pyridine or triethylamine~ Retinoates o ~-h~droxy~mides that may be used as reactive derivatives of retinoic acid include N-hydroxy~phthalimide retinoate and hydroxy succinimide retinoate, which can be prepared by reaction o retinoic acid with N-hydroxy-phthalimide or ~-hydroxy~uccinimide in the presence of a carbodiimide.
Dec~N!~e~ 10, 1975 2~86~FTE-16 ~64905 JB/~n 16a~monoretinoate of a 16a,2}-diol ma~ if desired he prepared by the steps of 16a,21-diacylation with retino.ic acid or with a reac~ive deriva~ive thereof as descri~ed above, f~llowed by selective hydroly.sis at the 21-position S with mild alkali, e~g~ with sodium bicarbonate n an aque3us inert or~anic solvent. How~ver, when it is desire~ to con~
vert only one hydroxy group of a 16a,21-diol i.nto a retinoyl-oxy group, i~ is usually pre~erable to protect the other hydroxy group and sub~equen~y liberate it.
Thus, the 21-~lydro~ gxoup may be protected by converslon intv the 21-tri1uoroaceta.te by reaction o~ the skeroid 16a,21-diol with one equivalent of trifluoroacetic anhydri-de. The 16a-hydroxy group may then be converted into reti-noyloxy as described abo~e. Finally, the 21-h~droxy sroup lS may be liberated by selective hydrolysis of ~he 16a-r~t.i-noate 21-trifluoroaceta~e by means o~ sodium azide or sodium benzoake, preerably in an ~queous oxganic 501vent such a~ aqueous methanol.
.
The 16~h~droxy group is best protected by the steps or ~o acetylation of the 16a,21-diol with one equivalen~ o ace~
tic anhydride in pyridine at 0C,to y.ield the 21~monoacetate, and int~o~uction o~ an acid~labile, alkali-stable protec~
ting yroup on the 16u-hydroxy grollpO The 21-acetate group may then be hydrol~sed ~y mild alkali, preferably sodium bi-2S carbonate in aqueou~ meth~xlol, and the l'.berated 21-h~droxy Decemher lo, 1975 2086~TE- 17 .~B/an 9~5 group may then ~e esteri.ied with re~inoic acid or with a reactive derivative thereof as described above. The pro-tect.ing group at the 16-position may then be removed ~y mild acid hydro~ysis.
.
The protecting group at the 16~-position is pre~erably a triloweralkyl silyl ether" especially trimethylsilyl ~ther, or a 2-tetrahydropyrallyl ethex groupO The trilower al~cyl~
silyl ether ~roup can be introduced by reaction of tha 16,21-diol 21~monoacetate with the corresponding trilow~r~
alkyl silsrl chloride in pyrid.ine, whereas the 2-t~trahydro-f pyranyl ethe.r group can be introduced by reaction o~ the I 16a,~1~diol 21qmonoacetate with dihydropyran and a cataly-I tic quantity of a stron~ a~id. Under these circumstances, ,1 any ïl~hydroxy gxoup is ~imilarly protectea, but is rcge~e-rated with the 16a-hydroxy group ~hen the pro~cting ether group is removed by h~rdxol~si~ with ~.ilute acid, preferably with dilute h~drochloric acid in met.hanol.
A 17~nonoret.inoate of a 17~,21-diol is best prepared by the ~teps u~ monoe~terlication at the 21 position with reti.-2~ noic acid i~ the presence of a dehydrating or esterifying agen~ or with a xeacti.ve derivativ~ of retinoic acid as - described above, followed by migration of the esteri~ying r~tinoyl group from the 21-hydroxy grcup to the 17a-hydro~y group by treat~ent o~ the resulting 21 re~inoate with a December 10, 1975 ~ S ~/an non-hydrox~ ba~ in an anhy(lrous aprot:ic m~aium and by protonation o~ the product where~by the 17~monoretinoate is *ormedO ~he general conditions for this reaction are set out in U,S. P. ~oO 3,891,631. The non~hydroxy~ic base i~
s pre~erably an alkali metal ~mide base, a phenolate or an alcoholate, or especially an alkali metal carbanionoid ~ase, e.g., a lithium diloweral~yl cuprate, in paxticular lithium dimethyl cuprate. The anhydrous aprotic medium is preera~'y an ether, e.g~ tetr~hydrofuran, 1,2 di~ethoxye~hane, diox~n ox diethyl et~er. The reaction is desirabl~ e~ected at re-duced tem~erature, pre~erably at a~vut -~0C, undex an inert atmosphere (e.y. nitrogen) and in the dar~;. The protonation i~ pre~erahly ef~ecked ~y means o~ an aqueous ammonium ~alt, e.~. ammonium chloride. ~he result.in~ 17a-retinoate i~ con-veniently isolated by extraction of the aqueous reaclionmixture with a ~ater-immisc~e or~anic solvent, e.g. ethyl acetate, and may be puri~ied by chromatoglaphy.
17a-Retinoates nla~ also be prepared direc~l~, by reaction of the 17~-ol with retinoia acid or wi.th a react.ive d~ri~
va~ive thereo~ under cond.itions vigorous enough to acyla~e the ~texically hindered 17a-hydxox~ group. Thus the æteroidal 17a-ol may be acylated with re~inoic acid in ~he presence of trifluoroacetic an}l~dride and a strong acid catalyst, preferably toluene-p~sul~onic acidl or with re~lnoyl chlo-ricle in the presence o~ d.imethy3.aminopylidirle ~nd a ter-tiar~ am.ine, preferably pyriditle. Condi.ti.ons~ vic30rouS e330~lC~h .
.
`
Decembff~r 10, 1~75 2086--I~TE--19 JB/an i49~
to acylate the 17a-hyarox~l group ~,~ill o~ course also ac~-late any ree llff3-f/f 16a- and/or 21~hydroxyl groupsi so, i:E
the~e groups are present, th~y should be protected and the protect.ing groups should then be removed after the 17a-acy-lation (unless it is dfefsired to prepare a 16a,17a- ox 17a~21-diretinuate, wh2n the 16a~ or 21-hydroxyl group may bs left unprotected) .
The protecting group is conveniently a ~ilyl f~ther or 2-tetrahydropyran~1 ether group as descr.ibed above or pro-tection o the 15a-hydroxy group when a 21~nonoretinoatf&f of a 16,21-diol is ~o be prepared. The protecti.ng group may also bef a nitrate ester group, which can be introduced by reaction o~ the steroidal ~lcohol with ace~yl nitratfef, and can be removed by reduction, preferably with zinc and .1 j15 acetic acid. Another protecting group is the trifluoxoacetyl group, which can be introduced by e.~terification o~ the steroicl with triæluoroacetic anh~dride in pyridine, and can be remo-ved by hydrolysi.s under mildly alkaline condi~ions, ff3.fg. wi~h aff~eou~ me~hanolic sf~dium bicarborlateO
Il 20 Any free 21~hydroxyff~rcfllp that is present in the starff~ing ; stexoid 17a-ol will of fcourse be proteff~ted by L~he abo~e-mentionsd groups. However~ since a 17a-xetinoate ff~an ~e readily prepared froln a 21~ ef~inoa~e ky mif~ra~ion of ~he retinoyl grou~ from the 21- to the 17a-position ;as de~cribed .
December 10, 1975 2086-FTE~20 1064905 JB/an above), the process o direcl acylat.ion a~ the 17u -position with retinoic acid or with a reactive derivative thQreof is more conveniently used only for those steroids l~cking a ~l-hydxox~1 group. After introduction of ~he esterifying 17a-retinoyl group, the protecting groups are removed as described above, and the resulting 17a-retinoate i~ then purified by standard methods, e.g. by chromatography.
A 17a,21-diacylate ~herein at least one acyl group is retinoyl can ~e prepared by successive introduction o~ the two acyl groups. Thus the irst acyl group can be introduced onto the ~l~hydroxyl group; then either the seconcl can be intro-duced onko the 17a-~1ydrox~1 group (any 11~- and/or 16a-hydroxy group be~ng protected as described abo~e), or khe first acyl gxoup can be made to migrate to the 17a-hydroxyl group as lS dèscriked above, and then ~e second can be introduced on10 the 21-hydroxyl group. Thi.s lat~x alt~rnativa has khe ad~
vantage that no pro~ccting groups need be u~ed. Either al~er native ma~ be u~ed to introduce two retinoyl ~roups or on~
retinoyl group and one different acyl group~ The di~fer~n~
ac~l group may be introduced under conditions`analogo~ls to ~ho~ de~cribed ~or the xetinoyl g~oup.
A 17,21--dire-tinoa~e can also be prepared by simultaneous acylation at the '7a- and 21~hydroxyl groups. Under these circumstances, of course, any 11~- arld/or l~-hydroxyl group ~5 must be protected as describ~d above.
:- - 20 ~
Decen~er 1~, 1975 2086~FTE~21 Js/an ;49~
17a-Retinoat~ o~ desoxy-17a--ols can be prepared either by direct acylation o khe 21-desoxy--17a~ols as described above ox by 17a-acylation of the corresponclin~ 17a,21-diols (pre-~erably b~ 21-Acylation followed by migration of the reti noyl group from the 21-~ydroxyl group to the 17a-hydroxyl group) with subsequent elimination of the 21-hydroxyl group or transformation thereof into a 21~fluorine or chlorine atomO
~hus ~he 21~hy~roxyl group can be eliminated by conver~ion ~hereof into a 21-~ulfonate ester, pre~erably the 2:L-~nethane-10 - sulfonate, by ac~lation with a sulfonyl chloride, preerably with methanesul~onyl chloride in pyricline, a~d ~onversion of the 21-sul~ona~e .into the 21-iodide and elimination of the iodide by reaction o the 21-sulonate with sodium iocli de and ace-tic acid, pre~erably in dimethylformamide. Alterna~
tively, the 21-hydroxyl group can be converted into a 21~~1uo rine or chlorine atom by conversion ~hereo~ in~o a 21-sul:Fo-nate e~ter, pre~erably the 21~n~thanesul~onate, b~ ac~la~i.on with a sul~onyl chloride, preEerably with metha~e~ul.~on~l chlo~ide in pyridine, and conversion o~ the 21-sulfonate i.nto the 21~chloride or fluori~e by reaction with lithium chloride or ~luoride resp~ctively in dimethyl~orm~mide.
rrhe retinoate esters, especially the 21-retinoate, 17a-re-tinoate, l~a~retinoate, 16a,71~diretinoate and the 17a,21-di.ret.inoate ~sters of anti-infl~natory steroids of the - 21 ~
' .
December lo, 1975 2086--Fl'E--22R ' JBjan 1(~649~5 pregnane series (particularly of anti-inflan~atory steroids having an order o~ anti-inflammatory activity about that exhibited ~y hydrocortisone) are novel compounds wnich have been found to possess anti-acne activity without significant inflammatory acti~ity as evidenced by tests in the rhino va-riant hairless mouse. When applied topically to ~he skin of such mice that have comedo-like lesions, ;the steroidal reti-noates (e.g. the steroidaL all trans-retinoates) of this invention reduce the size and number of comedones, while ad-vantageously causing little or no irritation to the skin suchas is caused by the topical application o retinoic acid per se. Preferred steroid retinoates inc~ude the 21~, 17~-and 16~-monoretinoates and 16~,21- and 17a,21~dir~tinoates o anti-inflammatory steroids, such as steroidal xetinoates defined by formulae I and II hereinabove. 21-All-trans-retinoates are especially preerred.
It i8 indeed surprising and une~pected that the novel steroidal retinoates are efective topicall~ in reducing thc number o~ com~dones while a~vantageously causing no significant in1an~atory response of the skin; since it has been ~urther discovered that, when all-trans-retinoic acid and a steroid having anti~in1ammatory acti~ity (e~g. of a level such as that exhibited by hydrocorti-sone or prednisolone) axe applied together topically to skin affected by acne~ .e lesions (e.g. as ln the rhino Dec~rnber 10, 1975 ~L~6~L9~5 2086-F'rE- 23 JB/an variant hairless mouse) in molecular equivalent ~nounts to a given quantity of the corresponding ste~oidal re~inoate (e.g. hydrocortisone 21-all~trans-retinoate), the com-bined steroid and all-~trans-retinoic acid application causes substantial inflammation which i6 sometimes even greater than that produced by all-trans-retinoic acid alone.
T~Je have also discovered th~t the combined properties of anti-acne a¢tivity with little in~lamma~ory response is :- i not exhibited by other steroidal esters such as steroidal 10 lo~er alkanoates (e.g. hydrocortison~ 21--aceta~e), or steroidal esters OI acids having a l~pophilicity similar ~o tha~ o~ retinoic acid, e.g~ ~sters .such as hydrocorti-sone 21-stearate. Moreov~r, retinoic acid esters o~ non-steroida} alcohols having the same lypophilicity as hydro- i 15 cortisone 21-retinoate (e.g. 2-phenylethyl retinoate) were ineffective when applied topically to skin affected by acne-like lesions.
, ' ~
The anti-acne properties o th~ ateroid~l retinoates o~
this invention are d~monstrat~d by tests in the rhino 20 variant hairles~s mouse, an animal model found useful in sareening drugs ~or comedol~tic properties. In these tests, a solution of a steroidal retinoa-te o~ this in-vention (e.g~ hydrocoxtisone 21-all- _ans-retinoate in an inert solvent (e.g. ace-tone) in concentrations ranging 25 ~rom abou~ o.01 % to about ~.5 %, usually about 0.1 %
conc2ntration, is applied topically to the skin of a rhino variant hairless mouse once a da~ Eor six days.
' .
Decemb2r 10, 1~75 - 2086~FTE-24 1064~5 JB/an The ~rea of the pilaxy canal containing keratin ~comedo), the n~ber of acu~e in~lan~atory cells and the epidenmal thickness a~ measurea befoxe and ater treatment. Areas t~eated with a solutiQn of a steroidal retinoate of this
5 invent~on are compared with areas tre~ted with solvent alone, ~7ith areas treated with a solution of all ~rans-retinoic acidO with areas treated with a solution o~ the fxee stersidal alcohol (e.g~ hydrocortisone), and with areas treated with all-trans-xetino c acid together with a steroidal alcohol.
In such tests, the s~e~oidal retinoates o~ ~his invention signi~ican~ly reduced both the area o the pilaxy canal and the amount of keratin contained therein without cau-sing signi~icant in~lammat;.on when compared with areas treated by solvent alone; retinoic acid, either alone or together with the steroldal alcohol precursor of the ~teroidal retinoate under test, reduc~d the siz~ of piLary canal but ~150 cau~ed a ~igni~icant incx~as~ in the in~lam-matory ce].ls present in kh~ treated skin; and txeatment with the steroidal alcohol alone had no sisni~ican~ effect on the pilary canal, u3ually slightly increasing the size ~he~eo.
A preferred compound o~ ~his inven~ion is hydrocortisone 21-all-trans~retinoate, whi.ch, when applied topically in a Ool % soluti.on ox six days, is as e~ective in reducing comedones a~ a 0.0~ % all~rans-re1:inoic ac.id solution D~c~mber lo~ 1975 20~6~F~25 ~ V ~ 490 5 JB/a~
appl.ied o~rc!r ~h~ same p~:riod, without causin~ any signi-ficant inflammator~ si.de eEf~ct~ caused by the retinoic acid solutions.
The invention there~ore pro~.~ides cosmetic compositions 5 for use in the treatment o~ acne and c~mprising as active ingredient a~ least ~ne steroid retinoclte of the present invention toyether with a cosmetically acceptable carrier.
Such con~positions can be prepared by b~inging a steroidal re~inoate of the present invention i.nto a form ~uitable lo ~or cosmetic administration, e~g~ by ~dmixin~ .it wi~h a ~os~netically acceptc~ble carrier~ The invention fllrther prov.id~s a method o~ txeatin~ acne which comprises a~mini-s~ring to an area o skin afec~ed by acne an effective amount of a steroidal retinoate of the present invention~
Thus, a composition comprising a ste~oidal ret.inoate (preerably a ~teroidal all trans-retinoate) usually a~.
co~centxal,ions in ~h~ x~nge o~ xom about 0~01 % to about 0.5 %, preerably ~rom about 0.025 % to abou~
0.1 %, together with a non-to~cic~ cosmetically acc~pt~ble aarrier, i~ applied onae or twice da.ily to skin afec~ed b~r acne vulgari.s usua1.ly by the topical xoute (althou~h intralesional injec~ion~ rnay be macle in cases of ~evere acne) until ~he acne cond.ition has impro~-2d Topi~al application of the st~roidal retinoates n~ay than be CQn tinuecl at less frec~lent inte.rvals (e~gO evexy other day) to conkrol comedo formation in oxder-to prev~nt retuxn of ~ ~S ~
- Decemher 10, 1975 2086~FTE~26 ~0649~5 ~B/~
~evexe acne conditions~
The steroidal reti.noates are conveniently applied in a ~ iquid solven~, pre:~erably in a water-~niscible liquid carrier made up of hydrophylic l:iquids having a high solvating action, e.g. a solution of a ~teroiaal retinoate in ethyl alcohol together with polyeth~leneglycol. In general, the steroidal xetinoates may be applied in any . topical ~or~ in.cluding creams, lotions ? solutions, gels, suspensions, aerosols and ointments, which are prepared ~y combin.in~ the act;.ve ingxedient, e.g~ a steroidal xe~-tinoate as defined by formula ~, with conventional cosmetic diluents and caxriers.
Top.ical compositions comprising steroidal all~trans~-retinoate esters, particularly those de~ined by formula II
hereinabove wherein at least one o~ X and W is hydrogen, are preerred, co~positions compri~ing h~drocortison~
21-all-trans- retinoake being par~icul~rl~ valua~le.
The cosmetic compositions of the invention axe made according to known procedures.
~he followin~ examples illustrate but do not lLmit the . invention. In Exampleæ 1 to 16, the ret;.noic acid used as reagent is al.l~trans-retinQic acid~ and the retlnoic acid esters prepared there~y and named in ~xamples 1 to 16 and ~ ~6 ~cccrnber lO~ 75 20~6~FT~'-27 JB/an 1~6491~)5 in ~o.~nulation Examples I and II ~re ~ trans-retinoatc esters. In the following eY.arnples, by suhstitu-ting for all~-tr~ns-~retinoic acid an i~omeric fo.nn thereo~, e~g.
ll-cis-retinoic acid, 9- _s-retinoic acid, 13-cls-retinoic S acid~ retro-retinoic acid, or ~,13-di~cls-retlnoic a~id, the corresponding isomeric ester, e.g. the 11- _s-ret.i-noate, 9-ris~retinoate~ 13-ci.s-retinoate, retro-re~inoate~
or the 9~13--di cis~retinoate, respectively, ls obtained.
- December ]0, 1975 20~6-FTE-28 1 ~ 6 490 5 JB/la Example 1 9a-Fluoro-11-oxygenated-16-methyi-1,4-pregnadiene=
17~,2l-diol-3,~0-dione 21-retinoa~es A.(I) To a solution of N-retinoylimidazole (~50 mg., l mmole) and 9~-fluoro-16a-methyl-1,4-pregnadiene-11~,17a, 21-triol-3~20-dione (~92 mg~, 1 mmole) in dry tetrahydro--uran (25 ml.j under nitrogen in the dark add sodium metho-xide (28 mg., 0~5 mmole). Stir at room temperature ~or 15 minutes and evaporate the reaction mixture in vacuo.
Chromatograph the resulting residue on a silica gel oolumn, eluting ~irst with petroleum ether and then with petroleum eth~r/ether solvent mixtures containing in~reasing amounts o~ ether, and finally with ether. Combine like fractions (ae determined by thin layer chromatography) and evaporate them to a residue oomprising 9~-~luoro-16a-methyl-1,4 pregnadiene-llBJ17a,21-triol-3,20-dione 21-retinoate.
Puri~y by recrystallizing ~rom ether/petroleum e~her, yield 230 m~.; m~p. 1~0-13~C,; ~al26 ~ 215 (ohloro~orm); mass spec~rum + 67~ ~ me~ha~ol 24~ nm (~ = 20,000), 358 nm ( = 33')-(II) In similar m~nner treat each o~ the ~ollowing with N-retlnoylimida~ole and sodium methoxide in te~rahydro-~uran under nitrogen in the dark:
(1) 9a-fluoro-16~-methyl-1~4-pregnadiene-17a,21-diol-` 25 3,11,20-trione, - Decem~er 10~ 1975 2086-:~?TE~ 29 1069~9(~$ JB/la (2 ) 9~-rluoro-l6~-meth~Jl-l, 4-pregnadiene-ll~, 17cç, 21~triol-3,20-dione, and (3) ga-~luoro-16~-methyl-1,4-pregnadiene-17a~21-diol-3,11,20-trione.
Isolate and purify each o~ the resulting products su.b-stantially as described hereinabove to obtain, respecti-vely~
(1) 9a-fluoro-16a-methyl-1~ pregnadiene-17~,21-diol-~,ll,~0-trione ~l-retinoate, (~) 9a-~luoro-16~-me~hyl-1,4-pr~gnadlene~ ,17 21-triol 3,~0-dione 21-retinoateJ and (3) 9a-~luoro-16~-mekhyl-1,4-pre~nadiene-17a,21--diol-3,11,20-trione 21-retinoate.
B. The ¢ompound o~ E~ample lA (I) may also be pre-pared as ~ollows.
'rO a ~uspensio~ o~ ~a ~'luoro-16a-methyl-1,4-preg-nadiene-11~,1.7a,21-triol-~,20-dlone (~92 mg., 1 mmole) ; in methylene chloride (50 ml.) under nitrogen and in the dark, add retlnoic acid (~00 mg.~ 1 mmole) and l-c~clo--hexyl-~-(2-mo~pholinoethyl)-carbodiimide metho-p-toluene-sul.~onate (4~ll rng., 1 mmole). Stir at room temperature ror 17 hours, then ~dd an addi~ti.onal mmole o~ retinoic acid and an ~dditi.onal mmole o~ the diimide, and continue stirrlng the reaction mixture ~or an additional 24 hours~
-- 29 ~
December 10, 19~5 2086-FTE- ~o ~ ~ ~ 49 0 5 JB/la Exkra¢t the reaction mixture sequenti.ally with 2% hydro~
chloric acid, water, 5~ aqueou.s sodium bicarbonate and again with water, dry ik over sodium sulrate and evaporate it in vacuo. Chromatograph the resulting residue on silica gel GF thick layer plates~ developing with ethyl acetate/
chlororo.rm (1:2). Remove the steroidal retinoate band from the thîc~ layer plate, extract it with ethyl acetate, filter and evaporate in vacuo to a residue comprising 9~-~luoro-16a-mekhyl-1,4-pregnadiene-11~,17a,~1-triol-~J20-dione 21-retinoate. Purify by recrystallization from ether-/petroleum ether; yield 128 mg~ having physical oon-stants identical to those o~ the compound prepar~d in Example lA (I).
Example 2 11-Oxy~enated-~,4-pregnadiene-17a,21-diol-~?-dione ~l-retinoates A. To a suspension or 1,4-pre~nadiene~ ,17~21-trlol-3,20-dlon~ (360 m~., 1 mmole) in dry acetonitrile . (50 ml.) under nitrogen and in the dark, add l-ayclohexyl-~-(2-morphollnoethyl)-carbodiimide metho-~-toluenesulfo-nate (424 mg., 1 mmole) and retinoic acid (300 mg., 1 mmole). Stir the reaction mixture for 5 days during which time add at intervàls three 1 mmole portions eaoh Or rstinoic acid and o~ the diimide. Pour the rea¢tion mix-~5 ture into 2% hydrochloric acid and .riLter O~r and dry the resulting precipi.tate~ Rinse the dried precipi',ate December 10~ 19'75 2086-~`TE_3 1 1~64L9(35 Js/la with a 3mall portion of cold ethyl acetate and chromatograph it on silica gel GF thick l~yer pl.ates, developing with chloroform/ethyl acetate ~1:1). Scrape o~f the steroidal retinoate band and ex~ract it with ethyl acetate. Evaporate the ex~raet in vacuo to a residue comprising 1,4-pregnadiene-11~,17a,~1-triol-~20-dione 21-retinoate. Puri~y by re-c~ystalliza,,ion from ether, yield 138 mg.; m.p. ~16-218C.; ~al26 + 252 (chloro~orm)~ mass spectrum M~ 642, ~ matha~l 242 nm (~ ,600)~ 357 nm ( -~2,000).
B. In similar manner treat 1,4-pregnadiene-17~J~l-diol 3J11,20-trione ln ace~onitrile under nitrogen in the dark with retlnoic acid and l-cyclohexyl-~~(2-morpholino-ethyl)-carbodiimide metho-p-toluenesulfonate to obtain 1J 4-pregnadiene-17a,21-diol-3,11,~0-trione ~1-retinoate.
:
C. Alternativel~J the 21-retinoates of this exampla are prepared ~rom the correspondin~ steroidal ~l-hydroxy oompound~ ~y kreatment with N-retinoyllmida~ole and sodium methoxLde ln tetrahydrofuran ~coording ~o the proce~lure o~ Example lA (I).
Examp]e ~
_-Oxygenated-4-pregnene-l'f~,?l-dlol-~0~
dione 21-reti.noates A. ~I) To a solution o~ pregnene~ J17a,21-triol-3,~0-dione (362 mg~, 1 mmole) in m~kh~lene ~hlorlde (100 ~nl.) December 10, i975 JB/la ~064~5 add retinoic acid (300 mg., 1 mmole) and l-cyclohexyl-~-(2~morpholinoethyl)-carbodiimide metho-p-toluenesul~onate ~42~ mg., 1 mmole). S~ir under an atmosphere o~ nitrogen in the dark at room temperature ~or 15 hours. Add four additional one mmoLe portlons each o~ retinoic acid and the diimide at 24 hour intervals, after which time no starting steroid remains as determined by thin layer chro-matography. Filter the reaction mix~ure, evaporate the ~iltrate in VaCUQJ and chromatograph the resultin~ residue on silica gel GF plates, developing with ethyl acetate/
petroleum ether ~1:1). Remove the steroidal re~inoate band and extract with ethyl acetate, and evaporate the ethyl acetate extracts in vacuo to a residue comprising 4-pregnene~ 17aJ21-triol-~,20-dione ~l-retinoate. Puri-~5 ry by recrystallization ~rom isopropyl ether/petroleum ether, yield 276 mg.; m.p. 218-220C,; [al26 ~ 151.2 (chloro~orm); rnass spectrum M~ = 644; ~mmathanl 2~2 nm (~ =2L,500) and ~57 ( ~ ~,600).
(lI) The compound o~ this example may also be prepared by treating 4-pregnene~ ,17~ triol-~,20-dione wi~h N-retinoylimldazole ~nd sodlum methoxide in tetrahydro-~uran under an atmosphere Or nitro~en in the manner des-cribed in Example lA (I).
B. In a manner similar to that desoribed in ~xample 2A, treat 4-pregneIle-17a,21-diol 3,11,20-trione with reti-noic acid and l-cyclohexyl-~-(2-morpholinoethgl)-carbodi-_ ~2 -Deceinber lO, 1975 ~o86-F'~E~
J: 3~la 106~Q5 imide metho-~-toluenesul~onat~ in methylene chloride in the dark~ Isolate and purify the resulting product in a manner simllar ~o that described to obtain 4-pregnene-17a, 21-diol-~911,~0-trlone 21-retinoate.
` Example 4 9~-F_oro-16-methyl-lJ 4-pre~nadiene-1l,BJ 17a, .
~l-triol-~,20-dione 17-lower alkanoate 21-reti- ~ ~
. _ noates A. ~-Fluoro-16~-methyl-lJJ~-pre~nadiene~ J17aJ
21-trlol~ 0-dione 17-valerate 21-retinoate (I) To a solution o~ 9a-~luoro-16~-methyl-1,4-pregnadi-en~ ,17a,21-triol~ O--dione 17-valerate (1.59 gm.) in methylene chloride (250 ml.) under an atmosphere o~ nitro-gen at room temperature add l-cyclohexyl-~-(2-morpholino-ethyl)-¢arbodiimlde metho-~~toluen~sulronate (1.~ ~m~) and retinoio aoid (1 gm.). Stir the reaction mixture under an ~tmosphere Or nltrogen in the dark ~or 14 hours and then add an additional 1.4 gm. o~ the diimide and 1 gm. of retinoic acid. Stir an additional 24 hours in the dark~
Extraot the reaotion mixture with dilute hydrochloric acid (5%) and with water. Dry the methylene chloride solution over magnesiu!n sul~ateJ evaporate it in vacuo, and chromatograph the resulking residue on silica gel GF
thick layer plates~developing ~lith petroleum ether/ethyl aoetate ~:1). Scrape of~ the steroidal retinoate band , ~cem~er 10 J 197 - 20~6-FTE-34 5 ' and excract it with ethyl acetate, ~,vaporate the comb1ned ethyl acetate extracts in vacuo to ~ residue comprising 9a-fluoro 1~-methyl-1~4-pregnadiene~ 9 17a~21-triol-3,20-dione 17-valerate 21-retinoate, Puri~y it by recrystalli-zation from isoprop~l ether/he~ane to give 1.1 gm. of pu-rified 9~-fluoro-16~-methyl~1~4-pr~gnadiene-11~,17a,21-triol-3,20-dione 17-valarate 21-retinoate; m.p. 118-120C., ~a~D6 ~ 175.1 (chloroform~; mass spectrum M~ 758;
~l 250 n~ ( -24J~oo), ~65 (~ - 29,400).
(II) In a manner slmilar to that described in Example ~A (I) treat 9a-fluoro-16a-meth~1-1,4-pregnadiene-11~17a~
21-triol-3)20-dione-17-valerate with retinoic acid and l-oyclohexyl-~-(2-morphollnoethyl)-carbodiimide metho-~-toluenesul~onat~ in methylene chloride at room temperature in the dark under an atmosphere o~ nitrogen~ Isolate and : puriry th~ resulting product in a manner similar to that descrlbed to obtain 9a-~luoro~ me~hyl-lJ4-pregnadiene-~
11~J 17a,21-triol-~20-dione 17-valerate 21-retinoate~
. B. In a manner ~imilar to that described in Example 4A (I) treat each o~ the ~ollowin~ steroids with retinoic acid and l-¢yolohexyl-3-(2-morpholinoethyl)-car~odlimide metho-p-toluenesul~onate irl me~hylene chlorlde und~r an atmosphere of nitrogen in the dark:
(1) 9a-~luoro-16~-methyl-1 J 4-pr~gnadiene-11~,17 2L-triol-3J20-dione 17-propiona~e, ~,'` ' ' , .. -' December 10, 1975 ~6-FTF.-~5 ~ 6 4905 JB/la (2) 9a-f'luoro-16~-methyl-1,4-pregnadiene~ ,17~, 21-trlol~ 0-dione 17-n-butyrate, (~) 9a-Iluoro-16~-methyl-1~4-pre~nadi~ne~ ,17a~
21-triol-~,20-d~one 17-prop-Lonate) and (4) 9a-~luoro-l~a-me~hyl.-1,4-pregnadiene-11.~,17a, 2~-triol-3,20-di~ne ~7-n-butyrate.
Isolate and pur~fy ~ach Or ~he resulting products in a manner similar ko that desoribed in ~ample 4A to o~tain, respectively, (1) 9a-~luoro-16~-methyl-1,4-pregnad~ene~ ,17a, 21-triol-~J20-dione 17-propionate 21-retlnoateJ
t2) 9~-~luoro-16~-methyl-lJl~-pregnadiene-11~17a, 21-triol-3J20-diorle l~-n-butyrat~ 21-retinoate, ~3) 9-fluoro-16a-methyl 1,4-pr~gnadiene~ ,17~, ~l~triol-3120-dione 17-propion~te 21-retinoateJ and (4) 9-~luoro-16a-methyl-1,1~-pr~nadi&ne-ll~J17a~ ;
21-triol-3, 20-dione 17-n-bu'cyrat;e 21-retinoa~e.
Exampl e 5 O~y~enated-4-pregnene-17a,?1.-dio 17-r~tinoates and derlvatives thereof i A. ~ r33__ r~ _ ~ ol-~,20-dione 17-ret~no~te To a suspension o~ ~.uprou~ lodide (100 m~.) in ; dry tetrahydrofuran (1 ml.) in the dark under an atmos-., Decnmber 10, ~75 ~ 0 6 49 5 ~o8j6~F`T~-36 phere of nitro~en ~t ~C.add ~ethyl l.lthium solutio!l in ether (0.3 ml., 1.8 M). Stir the m1xture ~or 15 minutes, then lower the temperature to -40G and add a solution Or 4-pre~nene~ ,17a721-triol-3920-dione 21-retinoate (3Z mg.~ 0.05 mmole) in dry tetrarydro~uran (1 mld). Stir the reaction mixture ~or 50 minutes in the dark at -40C.
under an atmosphere Or nitrogen~ and then pour it into aqueous ammon1um chloride and shake well. Extract the aqueous phase ~ h ethyl acetate, wash th~ combined e~hyi acetate extracts with water, then dry ther.1 over magnesium sulfate and evaporate them in vacuo to a resiclue cornprislng 1 4-pregnene-11~,17a,21-triol-3,20-dlone 17-retinoate. Purif'y i by chromakography on sllica gel GF preparati-v~ plates, developin~ with chlor-o~orm/ethyl acetate (~:1). Scrape off the most polar steroidal retino~te band and extract it with ethyl acetate to nbtain 22 mg~ of 4--pr~gnene~
17~ triol-~,20~dione 17-retinoate; mass spectrum M~ -644.
B. 4_Pre~ene-17a ~1-diol-3,11,~0-~rione 17-re~inoate ~ . . ~
In a maImer slmilar to that described in Example 5A treak 4-pr~gnene 17~ diol-~11,20-trione 21-retinoate with ouprous iodi~le and methyl llthium in dry tetrahydro-~uran and then isolate and purl~g the resulting product in the manner described to obtaln 4-pregnene-17a,2l~diol-3~11,20-trione 17-retinoate.
_ 36 -' D~cember 10, 1975 20~6-FT~-~7 9 ~64905 ~/la C ~. 9 ~ =~e nad i ~ne ~ 17c~ ?1-triol 3,~0-dione 17-~r~tinoate (I) To a suspension of cuprous ~o~ide (560 mg.3 ln dry tetrahydrofuran (5.6 ml.~ in the dark under an atmos--phere Or nitrogen at 0 C.add methyl lithium solution in ether ~1~7 ml.~ 1.8 M). Stir the mixture at 0C.in the dark under an atmosphere of nltrogen for 15 mimltes, then lower the temperature to -40C.and add a solutlon of 9a-fluoro~l6a-methyl 1,4-pregnadiene-ll~J17~21-~riol-~,20-d~lone 2 -retinoa~e (1.90 mg.) in dry tetrahydro~uran (5~6 ml.)~ Sl;ir the re~ultln~ mi~ture at ~.40C.in the dark under an atmosphere o~ nltrogen ~or 20 mlnu~es, then pour it inko aqueous ammonium chloride and shake well. Extract the aqueous phase with ethyl acetate, wash the combined extra¢ts with water, dry them over ma~nesium ~ul~ate and evaporate them in vacuo to a r~sidue comprising 9~-fluoro~
16~-meth~ pregna~iene~ J17a~21-triol-3,20-diona 17-retinoate~ Purify by chrom~toKx-aphy on silica ~el ~1~
preparative plates, deYeloplng wi~h ohlorororm/ethyl aoetate ~0 (3:1), Remove the most polar steroidal retinoat~ bandJ
~nd extract it with ethyl acetate. Evaporate the ~ombined ~, ~xtraots in vaauo to a residue and reorystallize this ~rom ether/pstroleum ether to obtain 9~-rluoro-16a-methyl-1,4-pr~gnadiene-11~,17a,21-triol-3,20-dione 17 retinoateJ
.j i ~5 yield 37 mg, ., ' .
(II) In a mal1ner similar to that d~scribed in E:Yample 5C (I) treat 9a-~luoro-16~-me~hyl-1~4-pregnadiene-11~917a, December 109 1975 106~05 JB/la 21~triol-~20-dione ~l-reti.noate wlth cuprous iodide and methyl lithium solution at -40 C.under an atmosphere of nitrogen and in the dark. Isolate and puri~y the resulting product in a manner similar to ~hat described to obtain 9~-~luoro-lS~-methyl-1,4-preg~adiene-11~517a,~1-triol-3~20-dlone 17-retinoate.
D. g~-Fluoro--l6-methyl-l~4-p-regnadiene-l7a?2l _ io~-3,11,20-trlone_17-retlnoates In a manner simil~r to that described in Examp}e 5C (I) treat 9a-fluoro-16a-methyl-lJ4-pregnadiene~17aJ21-diol-~J11,20-trlone ~l-retinoate and 9a-~luoro-16~-methyl-1,4-pre~nadiene-17~,~1-diol-~,11,~0-trione 21-retlnoate with cuprous iodide and methyl llthium in tetrahydrofuran in the dark under an atmosphere o~ nitrogen at -40C.
Isolate and puri~y each of the resul.ting products in a manner simil~r to th~t describe~ to obtain 9a-rluo~o-16a.-methyl-1,4-pregnadiene~17~,21-diol-~,11,20-trlone 17-reti-noate and 9~ f'luor-o-16~ me~hyl-1J4-pre~nadiene-17aJ~l~diol~
~,11,20-trione 17-retinoate, respectively.
.
- ~8 -.
Dec~rn~ex 10, 1975 ~o~6-F~
O 6490 5 ~ /~a EXamP1e 6 11-OXY~e-nated-4-P-r-e~n~e-1-7~ d~ J~
17~21-dire~GinOat~ and 1~-OXYgena~,ed-16-meth~1-.,~1-diO1-~2O-diOne ' 5 :' A r ~-Preg~ene-11~17~J~1-triO1-3J2O-diOn~ d1-' retinOate In a manner simiiar to that described 1n Ex~rnple lA (I), to a solution o~ N-retinoyllmidazole (350 m~., 1 mmol~) and 4 pregnene~ll~ ,2].-trlol-~J~0-di.one 17-retinoate (61~4 mg- J 1 mmO1e) in dry tetrahydro~uran ~mder nitrogen in the dark add sodium ~nethoxlde (25 mg " ~.5 mmole)- Stir at room ternperature f'or 15 minutesJ then evapor~te the reaction mixture in Yacuo and chromatograph the resulting residue on a sllioa gel column, eluting ~lrst with petroleum ~ther and then w:lth petrol~um ether/
ether solven~ mixtur~s ¢ontaining increasin~ arnounts o.
ether, and rinal~y with e~her, ~o~bine llke rractions (as deterrnined ~y thin layer chl~omatography) and evaporate to a residue comprising 4-pr~gnene~ ,17~ triol-~,20-dlone-17~1-diretinoate, yield 550 mg, Puri~y by recry-stalliæ~tion ~rom ether/petroleum ether.
.
B. 1~=
retlnoate ._ _ In a m~nner similar to th~t described in E~ample 6A treat 4-pregnene-17a~21-diol~ 20-tr~one 17-retlnoate ;~
Decel-nber 10~ 1~75 ~'0 86-FTE-I,o i4905 Js/la with N-re~inoylimidazole and sodium methoxide under an atmosphere of nitrogen in the dark~ Isolate ~nd purify the resulting ~roduct in a manner slmilar to that des~
cribed to obtain 4-pregnene-17a,21-diol-~,11,20-~rion~
17,?1-diret:inoate~
C. 9a-Fluoro-16~-me~hyl-1,4-pregnadiene~ ?17a~21-t o 0- 7,~1-diretinoate To a solution of N-retinoylimidazole (175 mg., ~c5 mmole) and ga-~luoro-l6a-mekhy~ 4-pregnad~ene~
iO 17a,~1-triol-~J20-dione 17-retincate (33'7 mg. J 0. 5 mmole) in dry tetrahydro~uran (25 ml~) under nitrogen in the dark add sodium m~thoxide (14 mg., 0.25 rnmole). Stir at room temperature for 15 minutes, evaporate the reaction mixture in vacuo and chromatograph the resulting residue on a siliea gel column, eluting first with petroleum ether, then wlth petroleum ether/ether solv~nt mixtures containing in¢reasing amounts of ether, and *inally with ether. Com-bin~ Like ~rac~ions (as det~rmlned by ~hln layer chroma-~oKraphy) and evaporate them to a residue comprlsin~ 9a-~luoro~16a methyl-1,4-pregnadlene~ J17~21-triol-3,20-dlone 17,21-diretinoake, yield 251 mg. Puri~y by recry-stallization from ether/pe~roleum ether.
D. In a m~nner simllar to that described in Example ~C tr0at, e~ch of the follo~ing with N-rekinoylimidazole ~o -.
December 10~ 1975 10649(~5 JB/la and sodium rnethoxide ln dry tetrahydrofuran under an a~mos-phere o~ nitrogen and in the dark:
(1) 9a-fluoro~16~-methyl-1,4-pregnadiene~ ,17a, 21-triol-3,20~d~one 17-retinoate, (2~ ga-f'uoro-16~-methyl-1,4-pre~nad~ene--17~21-diol-3,1~,20-trio~e 17-retinoate, and (3) 9a-fluor~-16a-methyl-1,4-pregnadiene-17a,21-diol ~11J 20 trione 17-retinoate.
Isolate and puri~y each Or the resultin~ products in a manner similar to that described to obtain, respectivel~, (1) 9a-rluoro-16~--methyl-lJl~-pregnadierle-llfl,17a,21-triol-~,20-dione 17J 21-diretinoate, 2) ga-fluoro-l6~-!neJ~hy~ 4-pregnadien~
3,11,20 trione 17J~l-diretinoate, and (3) 9a-fllloro-l.6a-methyl-1,4-pregnadiene-17a,21~diol-~i, llJ ~0-t~ione 17J 21-dlret,inoate.
Example 7 The 16-retinoat~-21-acetat _ n _the 16,21 dire-t~noates o~ -f~luoro-l, 4-pregnadie e-ll,B, 16a, ~!~
A~ 9 -F].uoro-1,4-pre~rladiene=11~16~17a ~ -tetrol-~0-dione 16-r~tinoat~ 21~acetate _ To a solution o~ 9a-~luoro-1,l~-pI~e~rladiene~
~; 16a,17a921-tetrol-~,20-dione 21-~cetate (2~.5 mg.g 0.05 December lo, 1975 2086-FTR-~2 ~ 9 ~ S JB/la mmole) and N-retinoylirnidazole (17.5 mg., 0.05 mmole) in dry tetrah~(irofuran (2 ml.) under an atmosphere Or ni-tro~en and in the dark add sodium methoxlde (2.8 mg.~
0.05 mmole). Stir the mixture ln the dark under nitrogen i 5 ~or 2 hours3 remove the solvent in vacuo and chromatograph the resulting residue on silica gel GF preparative pla~es~
developing with chloroform/ethyl ace~ate (3:1). Remove the steroldal retinoate band from the plake and extract it with ethyl acetate, and evaporate the ethyl acetate solutlon in v~cuo to a resi.due comprising 9~fluoro-1,4-pregnadien~ ,16a~17~,21-~tetrol-~/20-dione 16-ret:lnoate 21-acetate. Purify this b~r recrystalli~atlon rrom ether;
17 mg. (47~; M~ 718, ~M~OH 237 nm (~ = 20,500) and ~57 ( = 32,000).
B~ g~- luorc-l 4-pregnadiene~ ,16a,17a,21-tetrol-?O-dione 16,~1-dlretinoate In a manner similar to that describecl in F~mple 7A treat ~ 'Luoro-1,4-pregnadiene-11~,16a,17aJ~l-te~rol-3,20-diorle (~1 m~., 0,1 mmole) and N-retinoyl~.midazole (70 mg., 0~2 mmole) in dry tetrahydrofuran (5 ml.) in the dark under an atmosph~re o~ n~trogen and at room tempera-t,ure wlth sodlum methoxlde (5.6 mg., 0.1 mmole). Stir for 2 hours a~ room temperature in the dark under an atmosphere o~ nitrogen, evaporate the solvent in vacuo and chromato-graph the resulting resldue on silica gel preparative GF
plates, developing with chloro~ormjethyl acetate (3~
December L0, 1975 2086-FT~-43 JB/la ~ ~ 6 ~9 ~ ~
Remove the less polar steroidal dlretinoate band and extract it with ethyl acetate. Evaporate the combined ethyl acetate extract in vacuo to a residue cornprising 9~-~luoro-1~4-pregnadiene-11~,16a,17a,21-tetrol-3,20-dione 16,21-diret~noate.
Example 8 .
9a-Fluoro-~l-chloro-16a-meth~l-lJ4-pregnadiene ~ 7~-diol-~,~0-dione 17-retinoate A. 9a-~luoro-21-chloro-1 thyl-l,~-pre~nadiene_ 11~J 17a-diol-3,20-dione ll-trifluoxoacetate _ To a so]ution o~ 9a-~luoro-21-chloro-16~-methyL-1,4-pregnadlene-].1~,17~-diol-3J20-dione (1 gm.) in pyridine (5 ml.) add trifluoroacetic anhydride (1 ml.) and stir the reaction mixture at -20C.for 30 minutes. Pour the mixture into dilute hydrochloric acid and fllter o~f and dry the resultlng preclpitate oomprising 9~-~luoro-21-chloro-16a-methyl~ pregnadiene-11~,17~-diol-3,~0~dione ll-trirluoro-aoet~te whlch may be us~d without further puri~lcat:lon in E~ample 8B.
B. ~ luoro-~l-chloro-l6~-me~ Jl~-pre~nadiene-11~,17a-diol-~J~0-dione ll-~rifluoroacetate 17-retlnoate ~ool a so]ut-lon o~ 9a-rluoro-21-chloro-16a-methyl-1 J 4-pregnadiene-'1~17a.~iol~3,20-dione ll-trirluoroacet~te (S~ m~., 1 mmole) in ~enzene (~0 ml.) and tri~luoroacetic anhydride (o~6 ml.) to 0C.under an atmosphere Or nitrogen ...... ,.. . , . ., . .. ... _ ~ Decem~r 1 OJ 1r~75 1064~905 JB/l a and ln the darl~, and add retinolc aci~ (300 mg., 1 mmole) and p-toluenesulfonic acid (50 mg.). Skir the reaction mixture while allowing it tG ~arm to room temperatureG
Stir it at room temperature for an additiona]. 1/2 hour, then pour it into water and extract with et,her. Wash the comhined ether extracts several tirQes with aqueous sodium bicarbonate, then with water, dry over magneslum sulrate and evaporate in vacuo to a residue comprising 9~ ~luoro-21-chloro-16~-methyl-1,4-pregnadiene-11~ J 17a-diol-~,20-dione ll-trifluoroacetate 17-retinoate which is purified by chromatography on sillca gel GF thick layer plates.
C. 9a-Fluoro-21-chloro-16a-meth 11~,17a-diol-~,20-dione 17-retinoate . Dissolv~ the 9a-~luoro-21~chloro-16a methyl-1,4-pregnadiene-ll~J17a-diol-3,20-dione ll-tri~luoroacetate 17-retinoate prepared in Example 8B in methanol (25 ml.) J
then add sodium benzoate (~.5 gms~) and stir ~or 1/2 hour at room temperat-lre under an atlno~phe~ o~ nitx-ogen~ Eva-porate the solvent in vacuo and partition the resulting : 20 residue betwe~n ether and water~ Wash the ether layer with watQr, dry it over mQgnesium ~ul~ateJ evaporate the ether in vaouo and ohromatogrAph the re~ulting residue on __ _ silica gel GF thick layer plates, developing with ethyl acetate/chloroform (1:2). Remov~ the skeroidal retinoate band ~rom the thick layer plates, extract it with ethyl aceta~e and evapor~te in v~cuo to ~ res~dlle c~mprisin~
9a_rluoro_21_chloro_16a m~thyl-1,4-pregnadiene~ ,17a-_ 44 ~
Dece~n~er 10, 1.975 :~o~36-FTE- 1~5 10649~5 JB/lE~
d iol-7~ ?O~-di.one 17~ .rloa~
Example 9 Procedur_ ror preparin~l deso~7-retinoate~:
f~om ~l-h~ b Ao 9a-Fluoro~16a-meth~ ,4- re nadiene~ ,17c~
riol-~,20-dione 17-retino~te 21-methanesul~onate Cool a solution Or 9a-rluoro-16a-met;llyl~ -preg-nadiene~ ,17a,21-triol-3J20-dione 17-retinoate (674 mgO, 1 mmole) in pyridlne (10 ml. ), to -20C.uncler ~ atmosphere Or nitrngen and in th~ dark, add methanesulronyl chlori~l~
(redlstllled) (o.6 ml.), and allow the reaction mixture to stand at -20C.overnight. Pour the reaction mixture into dilute hydrochloric acid~ ~ilter orf' the re~ultin~
precipitate, wash i.t wlth water and dry it. Puri~y it b~ recr~stallization .~rom ether to obtaln 9a-rluoro-16a-me~hyl-1~4~pre~nadiene-11~17al21-trlol~ 0-dione 17-r~-tinoate 21-m~tha~ulfonate, B. ~-Fluoro-?1-chloro-16a-me h,yl l.ll ~r ~Aa~ le:~e l~-,7~ O-dione ~-retinoat.e q`o a solution o~ 9a-~luoro-16a-methyl-1,4-preg-nadiene~ ,17a,21-triol ~,20-dione 17-1letlnoate 21-metha nesulforlate (75.~ mg., 0~1 mmole) ln dimeth~l~orrnam:;de (3 ml,) under an atmosphere o~ ni~ro~,en ~nd ln the ~ark add lithium chlo~i.de ~4~ mæ. J 1 mss~ol..e) an~ stir the reaction December 10, i37~
20~6-~TE-45 1064905 JB/la mixture at 5ooc~ror 5 hours~ Pour the reaction mixture into water and extract with ether. Wash the combined ether extracts wi~h water, dr~ them over magnesium sul~`ate and evaporate them in vacuo to a residue comprising 9~-~luoro-~l-ehloro-16a-methyl-1~4-pregnadiene-11~317a-diol-3~20-divne 17-retinoate.
C~ 9a-Fluoro-16~-methyl-1,4- ~ e-ll~, 17~-diol-~,20-dione 17-retinoate -To a solution o~ 9a~rluoro-16a-methyl-174-pre~na-diene-llp,17a,21-trlol-3~0-dione 17~retlrloate 21-m~than~
sul~onate (~00 mg,) ~n dimethylformamide (5 ml.) ~mder an atmosphere o~ nitro~en and in the dark add acetic ac:!d (5 ml.) containlng sodium iodide (300 mg.). Heat the reac~
tion mixture on a water bath for 1/2 hour, then cool and dilute with ether. Wash the ethereal solution sequentially with water, a~ueous sodium bicarbonate and as2in with wat,er~
Evaporat.e the ether solutlon in v~ouo and ohromatograph the resultlng r~sldue on silioa ~el aF thlc,k la~er plat~
~eveloping with ethyl ~c~tat0/ohloroform (1:2~ Remove the steraidal retinoate band from the thick lay~r pl~tes, extract it, wlth ethy~ acetate and evaporate ln vacuo to a residue comprlsln~ 9a-fluoro-16a-methyl-].,~pre~nadiene-11~,17~-dlol~ 0-dione 17~retino~te~
_ 46 -:
December 10~ 197 2086~FT~-47 lV~4905 JB~la Example 10 9a,11~ 21-Trihalo-16~-methy]-1,4-pre~nadiene-_ _ ______ 17a-ol-3,20-dione 17-ret noates A . 2~ _D~ o~l~b~=LlE~r~-l5~-meth-y~ 4-pregna d ~ c~20-dione 17-retinoate Cool a solution of 9a921-dichloro..ll~-fluoro-16a~
ethyl-1~4-pregnadiene-17~-ol-3l20-dione (428 mgO, 1 mmole) in benzene (10 ml.) and trifluoroacetic anh~dride (o.6 ml.
~o 0C.under an atmosphere o~ ni~rogen and in the dark~
and add retinolc acid (300 mg., 1 mmole) and ~-toluenesul-~onic ~cid (50 mg.j. Stir the reaction mixture ~or an additiorlal 1/2 hour while allo~ing it to warm to wa~m tem-perature. Pour ~he reaotion mixture into water, extract with ether, and wash the combined ether extracts several times with aqueous sodium bicarbonat~ and then with water.
Dry the ethereal phase over magne~ium sul~te and evaporate in ~aCU07 and chromatograph the resultlng produat on silica g~l GF thick layer plates, developin~ with ~thyl aoe~ate/
I chloro~orm (1:2). Removc the st~roi~al retlnoa~e band ; 20 from the thick layer plates, e~tract it with ethyl acetate and evaporate ln vacuo to a residue comprising 9~,21-dichloro-~ luoro 16~-methyl-1,4~pr~gnadiene-17a-ol-3,20-dione ~ 17-retinoate.
.
.
Dece~ber 10, 1975 2086-~`TE- ~8 ' 1 ~ 6 49 0 5 J~/la B. 9a,11L Dichloro~21-~1u ro- et.hyl 1~4-pregna-diene-17~-ol-3,20-dione 17-retinoate _ _ To a solution o~ 9a,11~-dichloro-~1-fluoro-16a-m~thyl-1,4-pregnadiene-17a-ol-~20-dione (855 mg., 2 mmoles) in pyridine (10 ~nl.) under an atr.iosphere of` nitrogen and in ths dark add re~inoyl chloride (1.272 gm., 4 mmoles) ~nd 4 dimethylamino-pyridlne (50 mg.). Stir the reaction mix-ture~ ov~rnight at 50 C.under an atmosphere of nitrogen and in the dark, ~hen pour it into dilute hydrochloric acid and extract wlth ether. Wash the combined ether extracts with water, dry them over magneslum sulrate, evaporat~ them in vaouo and chromatograph the resultant residue on a silioa ~el column eluting first wikh petroleum ether~ then wlt.h petroleum ether/ether solv~nt m.i.xtures containin~ incre~sln~
15 amounts o~ ether and finally with ether. Combine like steroidal retinoate ~ractlons (as determ~ned by thin layer ¢hromatography) and evaporate them in vaouo to a residue comprlsing 9a911~-diohloro-21-rluo.ro-16a-methyl l,~-preg-nadi.~lle-17a-ol-~,20-~ione 17-retinoate~
Exa~ple 11 Preparati.on o~ 9aJ11~ ihalo-21-desoxy-1,4 nadiene-17a-ol-3 20-dione 17-retinoates Treat each of the ~ollowing 9a~ ~dihal~
desoxy-1~4 pregnadiene-17~ 1-3,~0-di~nes eitiler with retino'c acid~ trlfluoroacetic. anhydride and p-toluenesul-ronio a~id in benzene substarltia~.ly a~ described in -~ 4~ -December 10, 1975 2036-FTE-I~9 1064905 J3~/la Example lOA or with retinoyl chloride and 4-dimethylamino-py~id~ne in p~ridine substantially ~s described in Example lOB:
(1) 9a~ dichloro-lJ4-pre~nadiene-17a-ol ~,20-dione, (~) 9a-chloro~ -fluoro-1,4--pregnadiene-17~-ol-3,20-dioneg (3) 9u"11~-dichloro-1,4,6-pre~natriene-17a~ol ~,20-dione, (4) 9a chloro-ll~-rluoro-l, 4, 6 pregna~ri~ne-17a-ol-~,20- ~;
dione, (5) 9aJll~-dichloro-21~I`luoro-1,4-pre~nacliene-17a-ol-3, 20-dioneJ
In such tests, the s~e~oidal retinoates o~ ~his invention signi~ican~ly reduced both the area o the pilaxy canal and the amount of keratin contained therein without cau-sing signi~icant in~lammat;.on when compared with areas treated by solvent alone; retinoic acid, either alone or together with the steroldal alcohol precursor of the ~teroidal retinoate under test, reduc~d the siz~ of piLary canal but ~150 cau~ed a ~igni~icant incx~as~ in the in~lam-matory ce].ls present in kh~ treated skin; and txeatment with the steroidal alcohol alone had no sisni~ican~ effect on the pilary canal, u3ually slightly increasing the size ~he~eo.
A preferred compound o~ ~his inven~ion is hydrocortisone 21-all-trans~retinoate, whi.ch, when applied topically in a Ool % soluti.on ox six days, is as e~ective in reducing comedones a~ a 0.0~ % all~rans-re1:inoic ac.id solution D~c~mber lo~ 1975 20~6~F~25 ~ V ~ 490 5 JB/a~
appl.ied o~rc!r ~h~ same p~:riod, without causin~ any signi-ficant inflammator~ si.de eEf~ct~ caused by the retinoic acid solutions.
The invention there~ore pro~.~ides cosmetic compositions 5 for use in the treatment o~ acne and c~mprising as active ingredient a~ least ~ne steroid retinoclte of the present invention toyether with a cosmetically acceptable carrier.
Such con~positions can be prepared by b~inging a steroidal re~inoate of the present invention i.nto a form ~uitable lo ~or cosmetic administration, e~g~ by ~dmixin~ .it wi~h a ~os~netically acceptc~ble carrier~ The invention fllrther prov.id~s a method o~ txeatin~ acne which comprises a~mini-s~ring to an area o skin afec~ed by acne an effective amount of a steroidal retinoate of the present invention~
Thus, a composition comprising a ste~oidal ret.inoate (preerably a ~teroidal all trans-retinoate) usually a~.
co~centxal,ions in ~h~ x~nge o~ xom about 0~01 % to about 0.5 %, preerably ~rom about 0.025 % to abou~
0.1 %, together with a non-to~cic~ cosmetically acc~pt~ble aarrier, i~ applied onae or twice da.ily to skin afec~ed b~r acne vulgari.s usua1.ly by the topical xoute (althou~h intralesional injec~ion~ rnay be macle in cases of ~evere acne) until ~he acne cond.ition has impro~-2d Topi~al application of the st~roidal retinoates n~ay than be CQn tinuecl at less frec~lent inte.rvals (e~gO evexy other day) to conkrol comedo formation in oxder-to prev~nt retuxn of ~ ~S ~
- Decemher 10, 1975 2086~FTE~26 ~0649~5 ~B/~
~evexe acne conditions~
The steroidal reti.noates are conveniently applied in a ~ iquid solven~, pre:~erably in a water-~niscible liquid carrier made up of hydrophylic l:iquids having a high solvating action, e.g. a solution of a ~teroiaal retinoate in ethyl alcohol together with polyeth~leneglycol. In general, the steroidal xetinoates may be applied in any . topical ~or~ in.cluding creams, lotions ? solutions, gels, suspensions, aerosols and ointments, which are prepared ~y combin.in~ the act;.ve ingxedient, e.g~ a steroidal xe~-tinoate as defined by formula ~, with conventional cosmetic diluents and caxriers.
Top.ical compositions comprising steroidal all~trans~-retinoate esters, particularly those de~ined by formula II
hereinabove wherein at least one o~ X and W is hydrogen, are preerred, co~positions compri~ing h~drocortison~
21-all-trans- retinoake being par~icul~rl~ valua~le.
The cosmetic compositions of the invention axe made according to known procedures.
~he followin~ examples illustrate but do not lLmit the . invention. In Exampleæ 1 to 16, the ret;.noic acid used as reagent is al.l~trans-retinQic acid~ and the retlnoic acid esters prepared there~y and named in ~xamples 1 to 16 and ~ ~6 ~cccrnber lO~ 75 20~6~FT~'-27 JB/an 1~6491~)5 in ~o.~nulation Examples I and II ~re ~ trans-retinoatc esters. In the following eY.arnples, by suhstitu-ting for all~-tr~ns-~retinoic acid an i~omeric fo.nn thereo~, e~g.
ll-cis-retinoic acid, 9- _s-retinoic acid, 13-cls-retinoic S acid~ retro-retinoic acid, or ~,13-di~cls-retlnoic a~id, the corresponding isomeric ester, e.g. the 11- _s-ret.i-noate, 9-ris~retinoate~ 13-ci.s-retinoate, retro-re~inoate~
or the 9~13--di cis~retinoate, respectively, ls obtained.
- December ]0, 1975 20~6-FTE-28 1 ~ 6 490 5 JB/la Example 1 9a-Fluoro-11-oxygenated-16-methyi-1,4-pregnadiene=
17~,2l-diol-3,~0-dione 21-retinoa~es A.(I) To a solution of N-retinoylimidazole (~50 mg., l mmole) and 9~-fluoro-16a-methyl-1,4-pregnadiene-11~,17a, 21-triol-3~20-dione (~92 mg~, 1 mmole) in dry tetrahydro--uran (25 ml.j under nitrogen in the dark add sodium metho-xide (28 mg., 0~5 mmole). Stir at room temperature ~or 15 minutes and evaporate the reaction mixture in vacuo.
Chromatograph the resulting residue on a silica gel oolumn, eluting ~irst with petroleum ether and then with petroleum eth~r/ether solvent mixtures containing in~reasing amounts o~ ether, and finally with ether. Combine like fractions (ae determined by thin layer chromatography) and evaporate them to a residue oomprising 9~-~luoro-16a-methyl-1,4 pregnadiene-llBJ17a,21-triol-3,20-dione 21-retinoate.
Puri~y by recrystallizing ~rom ether/petroleum e~her, yield 230 m~.; m~p. 1~0-13~C,; ~al26 ~ 215 (ohloro~orm); mass spec~rum + 67~ ~ me~ha~ol 24~ nm (~ = 20,000), 358 nm ( = 33')-(II) In similar m~nner treat each o~ the ~ollowing with N-retlnoylimida~ole and sodium methoxide in te~rahydro-~uran under nitrogen in the dark:
(1) 9a-fluoro-16~-methyl-1~4-pregnadiene-17a,21-diol-` 25 3,11,20-trione, - Decem~er 10~ 1975 2086-:~?TE~ 29 1069~9(~$ JB/la (2 ) 9~-rluoro-l6~-meth~Jl-l, 4-pregnadiene-ll~, 17cç, 21~triol-3,20-dione, and (3) ga-~luoro-16~-methyl-1,4-pregnadiene-17a~21-diol-3,11,20-trione.
Isolate and purify each o~ the resulting products su.b-stantially as described hereinabove to obtain, respecti-vely~
(1) 9a-fluoro-16a-methyl-1~ pregnadiene-17~,21-diol-~,ll,~0-trione ~l-retinoate, (~) 9a-~luoro-16~-me~hyl-1,4-pr~gnadlene~ ,17 21-triol 3,~0-dione 21-retinoateJ and (3) 9a-~luoro-16~-mekhyl-1,4-pre~nadiene-17a,21--diol-3,11,20-trione 21-retinoate.
B. The ¢ompound o~ E~ample lA (I) may also be pre-pared as ~ollows.
'rO a ~uspensio~ o~ ~a ~'luoro-16a-methyl-1,4-preg-nadiene-11~,1.7a,21-triol-~,20-dlone (~92 mg., 1 mmole) ; in methylene chloride (50 ml.) under nitrogen and in the dark, add retlnoic acid (~00 mg.~ 1 mmole) and l-c~clo--hexyl-~-(2-mo~pholinoethyl)-carbodiimide metho-p-toluene-sul.~onate (4~ll rng., 1 mmole). Stir at room temperature ror 17 hours, then ~dd an addi~ti.onal mmole o~ retinoic acid and an ~dditi.onal mmole o~ the diimide, and continue stirrlng the reaction mixture ~or an additional 24 hours~
-- 29 ~
December 10, 19~5 2086-FTE- ~o ~ ~ ~ 49 0 5 JB/la Exkra¢t the reaction mixture sequenti.ally with 2% hydro~
chloric acid, water, 5~ aqueou.s sodium bicarbonate and again with water, dry ik over sodium sulrate and evaporate it in vacuo. Chromatograph the resulting residue on silica gel GF thick layer plates~ developing with ethyl acetate/
chlororo.rm (1:2). Remove the steroidal retinoate band from the thîc~ layer plate, extract it with ethyl acetate, filter and evaporate in vacuo to a residue comprising 9~-~luoro-16a-mekhyl-1,4-pregnadiene-11~,17a,~1-triol-~J20-dione 21-retinoate. Purify by recrystallization from ether-/petroleum ether; yield 128 mg~ having physical oon-stants identical to those o~ the compound prepar~d in Example lA (I).
Example 2 11-Oxy~enated-~,4-pregnadiene-17a,21-diol-~?-dione ~l-retinoates A. To a suspension or 1,4-pre~nadiene~ ,17~21-trlol-3,20-dlon~ (360 m~., 1 mmole) in dry acetonitrile . (50 ml.) under nitrogen and in the dark, add l-ayclohexyl-~-(2-morphollnoethyl)-carbodiimide metho-~-toluenesulfo-nate (424 mg., 1 mmole) and retinoic acid (300 mg., 1 mmole). Stir the reaction mixture for 5 days during which time add at intervàls three 1 mmole portions eaoh Or rstinoic acid and o~ the diimide. Pour the rea¢tion mix-~5 ture into 2% hydrochloric acid and .riLter O~r and dry the resulting precipi.tate~ Rinse the dried precipi',ate December 10~ 19'75 2086-~`TE_3 1 1~64L9(35 Js/la with a 3mall portion of cold ethyl acetate and chromatograph it on silica gel GF thick l~yer pl.ates, developing with chloroform/ethyl acetate ~1:1). Scrape o~f the steroidal retinoate band and ex~ract it with ethyl acetate. Evaporate the ex~raet in vacuo to a residue comprising 1,4-pregnadiene-11~,17a,~1-triol-~20-dione 21-retinoate. Puri~y by re-c~ystalliza,,ion from ether, yield 138 mg.; m.p. ~16-218C.; ~al26 + 252 (chloro~orm)~ mass spectrum M~ 642, ~ matha~l 242 nm (~ ,600)~ 357 nm ( -~2,000).
B. In similar manner treat 1,4-pregnadiene-17~J~l-diol 3J11,20-trione ln ace~onitrile under nitrogen in the dark with retlnoic acid and l-cyclohexyl-~~(2-morpholino-ethyl)-carbodiimide metho-p-toluenesulfonate to obtain 1J 4-pregnadiene-17a,21-diol-3,11,~0-trione ~1-retinoate.
:
C. Alternativel~J the 21-retinoates of this exampla are prepared ~rom the correspondin~ steroidal ~l-hydroxy oompound~ ~y kreatment with N-retinoyllmida~ole and sodium methoxLde ln tetrahydrofuran ~coording ~o the proce~lure o~ Example lA (I).
Examp]e ~
_-Oxygenated-4-pregnene-l'f~,?l-dlol-~0~
dione 21-reti.noates A. ~I) To a solution o~ pregnene~ J17a,21-triol-3,~0-dione (362 mg~, 1 mmole) in m~kh~lene ~hlorlde (100 ~nl.) December 10, i975 JB/la ~064~5 add retinoic acid (300 mg., 1 mmole) and l-cyclohexyl-~-(2~morpholinoethyl)-carbodiimide metho-p-toluenesul~onate ~42~ mg., 1 mmole). S~ir under an atmosphere o~ nitrogen in the dark at room temperature ~or 15 hours. Add four additional one mmoLe portlons each o~ retinoic acid and the diimide at 24 hour intervals, after which time no starting steroid remains as determined by thin layer chro-matography. Filter the reaction mix~ure, evaporate the ~iltrate in VaCUQJ and chromatograph the resultin~ residue on silica gel GF plates, developing with ethyl acetate/
petroleum ether ~1:1). Remove the steroidal re~inoate band and extract with ethyl acetate, and evaporate the ethyl acetate extracts in vacuo to a residue comprising 4-pregnene~ 17aJ21-triol-~,20-dione ~l-retinoate. Puri-~5 ry by recrystallization ~rom isopropyl ether/petroleum ether, yield 276 mg.; m.p. 218-220C,; [al26 ~ 151.2 (chloro~orm); rnass spectrum M~ = 644; ~mmathanl 2~2 nm (~ =2L,500) and ~57 ( ~ ~,600).
(lI) The compound o~ this example may also be prepared by treating 4-pregnene~ ,17~ triol-~,20-dione wi~h N-retinoylimldazole ~nd sodlum methoxide in tetrahydro-~uran under an atmosphere Or nitro~en in the manner des-cribed in Example lA (I).
B. In a manner similar to that desoribed in ~xample 2A, treat 4-pregneIle-17a,21-diol 3,11,20-trione with reti-noic acid and l-cyclohexyl-~-(2-morpholinoethgl)-carbodi-_ ~2 -Deceinber lO, 1975 ~o86-F'~E~
J: 3~la 106~Q5 imide metho-~-toluenesul~onat~ in methylene chloride in the dark~ Isolate and purify the resulting product in a manner simllar ~o that described to obtain 4-pregnene-17a, 21-diol-~911,~0-trlone 21-retinoate.
` Example 4 9~-F_oro-16-methyl-lJ 4-pre~nadiene-1l,BJ 17a, .
~l-triol-~,20-dione 17-lower alkanoate 21-reti- ~ ~
. _ noates A. ~-Fluoro-16~-methyl-lJJ~-pre~nadiene~ J17aJ
21-trlol~ 0-dione 17-valerate 21-retinoate (I) To a solution o~ 9a-~luoro-16~-methyl-1,4-pregnadi-en~ ,17a,21-triol~ O--dione 17-valerate (1.59 gm.) in methylene chloride (250 ml.) under an atmosphere o~ nitro-gen at room temperature add l-cyclohexyl-~-(2-morpholino-ethyl)-¢arbodiimlde metho-~~toluen~sulronate (1.~ ~m~) and retinoio aoid (1 gm.). Stir the reaction mixture under an ~tmosphere Or nltrogen in the dark ~or 14 hours and then add an additional 1.4 gm. o~ the diimide and 1 gm. of retinoic acid. Stir an additional 24 hours in the dark~
Extraot the reaotion mixture with dilute hydrochloric acid (5%) and with water. Dry the methylene chloride solution over magnesiu!n sul~ateJ evaporate it in vacuo, and chromatograph the resulking residue on silica gel GF
thick layer plates~developing ~lith petroleum ether/ethyl aoetate ~:1). Scrape of~ the steroidal retinoate band , ~cem~er 10 J 197 - 20~6-FTE-34 5 ' and excract it with ethyl acetate, ~,vaporate the comb1ned ethyl acetate extracts in vacuo to ~ residue comprising 9a-fluoro 1~-methyl-1~4-pregnadiene~ 9 17a~21-triol-3,20-dione 17-valerate 21-retinoate, Puri~y it by recrystalli-zation from isoprop~l ether/he~ane to give 1.1 gm. of pu-rified 9~-fluoro-16~-methyl~1~4-pr~gnadiene-11~,17a,21-triol-3,20-dione 17-valarate 21-retinoate; m.p. 118-120C., ~a~D6 ~ 175.1 (chloroform~; mass spectrum M~ 758;
~l 250 n~ ( -24J~oo), ~65 (~ - 29,400).
(II) In a manner slmilar to that described in Example ~A (I) treat 9a-fluoro-16a-meth~1-1,4-pregnadiene-11~17a~
21-triol-3)20-dione-17-valerate with retinoic acid and l-oyclohexyl-~-(2-morphollnoethyl)-carbodiimide metho-~-toluenesul~onat~ in methylene chloride at room temperature in the dark under an atmosphere o~ nitrogen~ Isolate and : puriry th~ resulting product in a manner similar to that descrlbed to obtain 9a-~luoro~ me~hyl-lJ4-pregnadiene-~
11~J 17a,21-triol-~20-dione 17-valerate 21-retinoate~
. B. In a manner ~imilar to that described in Example 4A (I) treat each o~ the ~ollowin~ steroids with retinoic acid and l-¢yolohexyl-3-(2-morpholinoethyl)-car~odlimide metho-p-toluenesul~onate irl me~hylene chlorlde und~r an atmosphere of nitrogen in the dark:
(1) 9a-~luoro-16~-methyl-1 J 4-pr~gnadiene-11~,17 2L-triol-3J20-dione 17-propiona~e, ~,'` ' ' , .. -' December 10, 1975 ~6-FTF.-~5 ~ 6 4905 JB/la (2) 9a-f'luoro-16~-methyl-1,4-pregnadiene~ ,17~, 21-trlol~ 0-dione 17-n-butyrate, (~) 9a-Iluoro-16~-methyl-1~4-pre~nadi~ne~ ,17a~
21-triol-~,20-d~one 17-prop-Lonate) and (4) 9a-~luoro-l~a-me~hyl.-1,4-pregnadiene-11.~,17a, 2~-triol-3,20-di~ne ~7-n-butyrate.
Isolate and pur~fy ~ach Or ~he resulting products in a manner similar ko that desoribed in ~ample 4A to o~tain, respectively, (1) 9a-~luoro-16~-methyl-1,4-pregnad~ene~ ,17a, 21-triol-~J20-dione 17-propionate 21-retlnoateJ
t2) 9~-~luoro-16~-methyl-lJl~-pregnadiene-11~17a, 21-triol-3J20-diorle l~-n-butyrat~ 21-retinoate, ~3) 9-fluoro-16a-methyl 1,4-pr~gnadiene~ ,17~, ~l~triol-3120-dione 17-propion~te 21-retinoateJ and (4) 9-~luoro-16a-methyl-1,1~-pr~nadi&ne-ll~J17a~ ;
21-triol-3, 20-dione 17-n-bu'cyrat;e 21-retinoa~e.
Exampl e 5 O~y~enated-4-pregnene-17a,?1.-dio 17-r~tinoates and derlvatives thereof i A. ~ r33__ r~ _ ~ ol-~,20-dione 17-ret~no~te To a suspension o~ ~.uprou~ lodide (100 m~.) in ; dry tetrahydrofuran (1 ml.) in the dark under an atmos-., Decnmber 10, ~75 ~ 0 6 49 5 ~o8j6~F`T~-36 phere of nitro~en ~t ~C.add ~ethyl l.lthium solutio!l in ether (0.3 ml., 1.8 M). Stir the m1xture ~or 15 minutes, then lower the temperature to -40G and add a solution Or 4-pre~nene~ ,17a721-triol-3920-dione 21-retinoate (3Z mg.~ 0.05 mmole) in dry tetrarydro~uran (1 mld). Stir the reaction mixture ~or 50 minutes in the dark at -40C.
under an atmosphere Or nitrogen~ and then pour it into aqueous ammon1um chloride and shake well. Extract the aqueous phase ~ h ethyl acetate, wash th~ combined e~hyi acetate extracts with water, then dry ther.1 over magnesium sulfate and evaporate them in vacuo to a resiclue cornprislng 1 4-pregnene-11~,17a,21-triol-3,20-dlone 17-retinoate. Purif'y i by chromakography on sllica gel GF preparati-v~ plates, developin~ with chlor-o~orm/ethyl acetate (~:1). Scrape off the most polar steroidal retino~te band and extract it with ethyl acetate to nbtain 22 mg~ of 4--pr~gnene~
17~ triol-~,20~dione 17-retinoate; mass spectrum M~ -644.
B. 4_Pre~ene-17a ~1-diol-3,11,~0-~rione 17-re~inoate ~ . . ~
In a maImer slmilar to that described in Example 5A treak 4-pr~gnene 17~ diol-~11,20-trione 21-retinoate with ouprous iodi~le and methyl llthium in dry tetrahydro-~uran and then isolate and purl~g the resulting product in the manner described to obtaln 4-pregnene-17a,2l~diol-3~11,20-trione 17-retinoate.
_ 36 -' D~cember 10, 1975 20~6-FT~-~7 9 ~64905 ~/la C ~. 9 ~ =~e nad i ~ne ~ 17c~ ?1-triol 3,~0-dione 17-~r~tinoate (I) To a suspension of cuprous ~o~ide (560 mg.3 ln dry tetrahydrofuran (5.6 ml.~ in the dark under an atmos--phere Or nitrogen at 0 C.add methyl lithium solution in ether ~1~7 ml.~ 1.8 M). Stir the mixture at 0C.in the dark under an atmosphere of nltrogen for 15 mimltes, then lower the temperature to -40C.and add a solutlon of 9a-fluoro~l6a-methyl 1,4-pregnadiene-ll~J17~21-~riol-~,20-d~lone 2 -retinoa~e (1.90 mg.) in dry tetrahydro~uran (5~6 ml.)~ Sl;ir the re~ultln~ mi~ture at ~.40C.in the dark under an atmosphere o~ nltrogen ~or 20 mlnu~es, then pour it inko aqueous ammonium chloride and shake well. Extract the aqueous phase with ethyl acetate, wash the combined extra¢ts with water, dry them over ma~nesium ~ul~ate and evaporate them in vacuo to a r~sidue comprising 9~-fluoro~
16~-meth~ pregna~iene~ J17a~21-triol-3,20-diona 17-retinoate~ Purify by chrom~toKx-aphy on silica ~el ~1~
preparative plates, deYeloplng wi~h ohlorororm/ethyl aoetate ~0 (3:1), Remove the most polar steroidal retinoat~ bandJ
~nd extract it with ethyl acetate. Evaporate the ~ombined ~, ~xtraots in vaauo to a residue and reorystallize this ~rom ether/pstroleum ether to obtain 9~-rluoro-16a-methyl-1,4-pr~gnadiene-11~,17a,21-triol-3,20-dione 17 retinoateJ
.j i ~5 yield 37 mg, ., ' .
(II) In a mal1ner similar to that d~scribed in E:Yample 5C (I) treat 9a-~luoro-16~-me~hyl-1~4-pregnadiene-11~917a, December 109 1975 106~05 JB/la 21~triol-~20-dione ~l-reti.noate wlth cuprous iodide and methyl lithium solution at -40 C.under an atmosphere of nitrogen and in the dark. Isolate and puri~y the resulting product in a manner similar to ~hat described to obtain 9~-~luoro-lS~-methyl-1,4-preg~adiene-11~517a,~1-triol-3~20-dlone 17-retinoate.
D. g~-Fluoro--l6-methyl-l~4-p-regnadiene-l7a?2l _ io~-3,11,20-trlone_17-retlnoates In a manner simil~r to that described in Examp}e 5C (I) treat 9a-fluoro-16a-methyl-lJ4-pregnadiene~17aJ21-diol-~J11,20-trlone ~l-retinoate and 9a-~luoro-16~-methyl-1,4-pre~nadiene-17~,~1-diol-~,11,~0-trione 21-retlnoate with cuprous iodide and methyl llthium in tetrahydrofuran in the dark under an atmosphere o~ nitrogen at -40C.
Isolate and puri~y each of the resul.ting products in a manner simil~r to th~t describe~ to obtain 9a-rluo~o-16a.-methyl-1,4-pregnadiene~17~,21-diol-~,11,20-trlone 17-reti-noate and 9~ f'luor-o-16~ me~hyl-1J4-pre~nadiene-17aJ~l~diol~
~,11,20-trione 17-retinoate, respectively.
.
- ~8 -.
Dec~rn~ex 10, 1975 ~o~6-F~
O 6490 5 ~ /~a EXamP1e 6 11-OXY~e-nated-4-P-r-e~n~e-1-7~ d~ J~
17~21-dire~GinOat~ and 1~-OXYgena~,ed-16-meth~1-.,~1-diO1-~2O-diOne ' 5 :' A r ~-Preg~ene-11~17~J~1-triO1-3J2O-diOn~ d1-' retinOate In a manner simiiar to that described 1n Ex~rnple lA (I), to a solution o~ N-retinoyllmidazole (350 m~., 1 mmol~) and 4 pregnene~ll~ ,2].-trlol-~J~0-di.one 17-retinoate (61~4 mg- J 1 mmO1e) in dry tetrahydro~uran ~mder nitrogen in the dark add sodium ~nethoxlde (25 mg " ~.5 mmole)- Stir at room ternperature f'or 15 minutesJ then evapor~te the reaction mixture in Yacuo and chromatograph the resulting residue on a sllioa gel column, eluting ~lrst with petroleum ~ther and then w:lth petrol~um ether/
ether solven~ mixtur~s ¢ontaining increasin~ arnounts o.
ether, and rinal~y with e~her, ~o~bine llke rractions (as deterrnined ~y thin layer chl~omatography) and evaporate to a residue comprising 4-pr~gnene~ ,17~ triol-~,20-dlone-17~1-diretinoate, yield 550 mg, Puri~y by recry-stalliæ~tion ~rom ether/petroleum ether.
.
B. 1~=
retlnoate ._ _ In a m~nner similar to th~t described in E~ample 6A treat 4-pregnene-17a~21-diol~ 20-tr~one 17-retlnoate ;~
Decel-nber 10~ 1~75 ~'0 86-FTE-I,o i4905 Js/la with N-re~inoylimidazole and sodium methoxide under an atmosphere of nitrogen in the dark~ Isolate ~nd purify the resulting ~roduct in a manner slmilar to that des~
cribed to obtain 4-pregnene-17a,21-diol-~,11,20-~rion~
17,?1-diret:inoate~
C. 9a-Fluoro-16~-me~hyl-1,4-pregnadiene~ ?17a~21-t o 0- 7,~1-diretinoate To a solution of N-retinoylimidazole (175 mg., ~c5 mmole) and ga-~luoro-l6a-mekhy~ 4-pregnad~ene~
iO 17a,~1-triol-~J20-dione 17-retincate (33'7 mg. J 0. 5 mmole) in dry tetrahydro~uran (25 ml~) under nitrogen in the dark add sodium m~thoxide (14 mg., 0.25 rnmole). Stir at room temperature for 15 minutes, evaporate the reaction mixture in vacuo and chromatograph the resulting residue on a siliea gel column, eluting first with petroleum ether, then wlth petroleum ether/ether solv~nt mixtures containing in¢reasing amounts of ether, and *inally with ether. Com-bin~ Like ~rac~ions (as det~rmlned by ~hln layer chroma-~oKraphy) and evaporate them to a residue comprlsin~ 9a-~luoro~16a methyl-1,4-pregnadlene~ J17~21-triol-3,20-dlone 17,21-diretinoake, yield 251 mg. Puri~y by recry-stallization from ether/pe~roleum ether.
D. In a m~nner simllar to that described in Example ~C tr0at, e~ch of the follo~ing with N-rekinoylimidazole ~o -.
December 10~ 1975 10649(~5 JB/la and sodium rnethoxide ln dry tetrahydrofuran under an a~mos-phere o~ nitrogen and in the dark:
(1) 9a-fluoro~16~-methyl-1,4-pregnadiene~ ,17a, 21-triol-3,20~d~one 17-retinoate, (2~ ga-f'uoro-16~-methyl-1,4-pre~nad~ene--17~21-diol-3,1~,20-trio~e 17-retinoate, and (3) 9a-fluor~-16a-methyl-1,4-pregnadiene-17a,21-diol ~11J 20 trione 17-retinoate.
Isolate and puri~y each Or the resultin~ products in a manner similar to that described to obtain, respectivel~, (1) 9a-rluoro-16~--methyl-lJl~-pregnadierle-llfl,17a,21-triol-~,20-dione 17J 21-diretinoate, 2) ga-fluoro-l6~-!neJ~hy~ 4-pregnadien~
3,11,20 trione 17J~l-diretinoate, and (3) 9a-fllloro-l.6a-methyl-1,4-pregnadiene-17a,21~diol-~i, llJ ~0-t~ione 17J 21-dlret,inoate.
Example 7 The 16-retinoat~-21-acetat _ n _the 16,21 dire-t~noates o~ -f~luoro-l, 4-pregnadie e-ll,B, 16a, ~!~
A~ 9 -F].uoro-1,4-pre~rladiene=11~16~17a ~ -tetrol-~0-dione 16-r~tinoat~ 21~acetate _ To a solution o~ 9a-~luoro-1,l~-pI~e~rladiene~
~; 16a,17a921-tetrol-~,20-dione 21-~cetate (2~.5 mg.g 0.05 December lo, 1975 2086-FTR-~2 ~ 9 ~ S JB/la mmole) and N-retinoylirnidazole (17.5 mg., 0.05 mmole) in dry tetrah~(irofuran (2 ml.) under an atmosphere Or ni-tro~en and in the dark add sodium methoxlde (2.8 mg.~
0.05 mmole). Stir the mixture ln the dark under nitrogen i 5 ~or 2 hours3 remove the solvent in vacuo and chromatograph the resulting residue on silica gel GF preparative pla~es~
developing with chloroform/ethyl ace~ate (3:1). Remove the steroldal retinoate band from the plake and extract it with ethyl acetate, and evaporate the ethyl acetate solutlon in v~cuo to a resi.due comprising 9~fluoro-1,4-pregnadien~ ,16a~17~,21-~tetrol-~/20-dione 16-ret:lnoate 21-acetate. Purify this b~r recrystalli~atlon rrom ether;
17 mg. (47~; M~ 718, ~M~OH 237 nm (~ = 20,500) and ~57 ( = 32,000).
B~ g~- luorc-l 4-pregnadiene~ ,16a,17a,21-tetrol-?O-dione 16,~1-dlretinoate In a manner similar to that describecl in F~mple 7A treat ~ 'Luoro-1,4-pregnadiene-11~,16a,17aJ~l-te~rol-3,20-diorle (~1 m~., 0,1 mmole) and N-retinoyl~.midazole (70 mg., 0~2 mmole) in dry tetrahydrofuran (5 ml.) in the dark under an atmosph~re o~ n~trogen and at room tempera-t,ure wlth sodlum methoxlde (5.6 mg., 0.1 mmole). Stir for 2 hours a~ room temperature in the dark under an atmosphere o~ nitrogen, evaporate the solvent in vacuo and chromato-graph the resulting resldue on silica gel preparative GF
plates, developing with chloro~ormjethyl acetate (3~
December L0, 1975 2086-FT~-43 JB/la ~ ~ 6 ~9 ~ ~
Remove the less polar steroidal dlretinoate band and extract it with ethyl acetate. Evaporate the combined ethyl acetate extract in vacuo to a residue cornprising 9~-~luoro-1~4-pregnadiene-11~,16a,17a,21-tetrol-3,20-dione 16,21-diret~noate.
Example 8 .
9a-Fluoro-~l-chloro-16a-meth~l-lJ4-pregnadiene ~ 7~-diol-~,~0-dione 17-retinoate A. 9a-~luoro-21-chloro-1 thyl-l,~-pre~nadiene_ 11~J 17a-diol-3,20-dione ll-trifluoxoacetate _ To a so]ution o~ 9a-~luoro-21-chloro-16~-methyL-1,4-pregnadlene-].1~,17~-diol-3J20-dione (1 gm.) in pyridine (5 ml.) add trifluoroacetic anhydride (1 ml.) and stir the reaction mixture at -20C.for 30 minutes. Pour the mixture into dilute hydrochloric acid and fllter o~f and dry the resultlng preclpitate oomprising 9~-~luoro-21-chloro-16a-methyl~ pregnadiene-11~,17~-diol-3,~0~dione ll-trirluoro-aoet~te whlch may be us~d without further puri~lcat:lon in E~ample 8B.
B. ~ luoro-~l-chloro-l6~-me~ Jl~-pre~nadiene-11~,17a-diol-~J~0-dione ll-~rifluoroacetate 17-retlnoate ~ool a so]ut-lon o~ 9a-rluoro-21-chloro-16a-methyl-1 J 4-pregnadiene-'1~17a.~iol~3,20-dione ll-trirluoroacet~te (S~ m~., 1 mmole) in ~enzene (~0 ml.) and tri~luoroacetic anhydride (o~6 ml.) to 0C.under an atmosphere Or nitrogen ...... ,.. . , . ., . .. ... _ ~ Decem~r 1 OJ 1r~75 1064~905 JB/l a and ln the darl~, and add retinolc aci~ (300 mg., 1 mmole) and p-toluenesulfonic acid (50 mg.). Skir the reaction mixture while allowing it tG ~arm to room temperatureG
Stir it at room temperature for an additiona]. 1/2 hour, then pour it into water and extract with et,her. Wash the comhined ether extracts several tirQes with aqueous sodium bicarbonate, then with water, dry over magneslum sulrate and evaporate in vacuo to a residue comprising 9~ ~luoro-21-chloro-16~-methyl-1,4-pregnadiene-11~ J 17a-diol-~,20-dione ll-trifluoroacetate 17-retinoate which is purified by chromatography on sillca gel GF thick layer plates.
C. 9a-Fluoro-21-chloro-16a-meth 11~,17a-diol-~,20-dione 17-retinoate . Dissolv~ the 9a-~luoro-21~chloro-16a methyl-1,4-pregnadiene-ll~J17a-diol-3,20-dione ll-tri~luoroacetate 17-retinoate prepared in Example 8B in methanol (25 ml.) J
then add sodium benzoate (~.5 gms~) and stir ~or 1/2 hour at room temperat-lre under an atlno~phe~ o~ nitx-ogen~ Eva-porate the solvent in vacuo and partition the resulting : 20 residue betwe~n ether and water~ Wash the ether layer with watQr, dry it over mQgnesium ~ul~ateJ evaporate the ether in vaouo and ohromatogrAph the re~ulting residue on __ _ silica gel GF thick layer plates, developing with ethyl acetate/chloroform (1:2). Remov~ the skeroidal retinoate band ~rom the thick layer plates, extract it with ethyl aceta~e and evapor~te in v~cuo to ~ res~dlle c~mprisin~
9a_rluoro_21_chloro_16a m~thyl-1,4-pregnadiene~ ,17a-_ 44 ~
Dece~n~er 10, 1.975 :~o~36-FTE- 1~5 10649~5 JB/lE~
d iol-7~ ?O~-di.one 17~ .rloa~
Example 9 Procedur_ ror preparin~l deso~7-retinoate~:
f~om ~l-h~ b Ao 9a-Fluoro~16a-meth~ ,4- re nadiene~ ,17c~
riol-~,20-dione 17-retino~te 21-methanesul~onate Cool a solution Or 9a-rluoro-16a-met;llyl~ -preg-nadiene~ ,17a,21-triol-3J20-dione 17-retinoate (674 mgO, 1 mmole) in pyridlne (10 ml. ), to -20C.uncler ~ atmosphere Or nitrngen and in th~ dark, add methanesulronyl chlori~l~
(redlstllled) (o.6 ml.), and allow the reaction mixture to stand at -20C.overnight. Pour the reaction mixture into dilute hydrochloric acid~ ~ilter orf' the re~ultin~
precipitate, wash i.t wlth water and dry it. Puri~y it b~ recr~stallization .~rom ether to obtaln 9a-rluoro-16a-me~hyl-1~4~pre~nadiene-11~17al21-trlol~ 0-dione 17-r~-tinoate 21-m~tha~ulfonate, B. ~-Fluoro-?1-chloro-16a-me h,yl l.ll ~r ~Aa~ le:~e l~-,7~ O-dione ~-retinoat.e q`o a solution o~ 9a-~luoro-16a-methyl-1,4-preg-nadiene~ ,17a,21-triol ~,20-dione 17-1letlnoate 21-metha nesulforlate (75.~ mg., 0~1 mmole) ln dimeth~l~orrnam:;de (3 ml,) under an atmosphere o~ ni~ro~,en ~nd ln the ~ark add lithium chlo~i.de ~4~ mæ. J 1 mss~ol..e) an~ stir the reaction December 10, i37~
20~6-~TE-45 1064905 JB/la mixture at 5ooc~ror 5 hours~ Pour the reaction mixture into water and extract with ether. Wash the combined ether extracts wi~h water, dr~ them over magnesium sul~`ate and evaporate them in vacuo to a residue comprising 9~-~luoro-~l-ehloro-16a-methyl-1~4-pregnadiene-11~317a-diol-3~20-divne 17-retinoate.
C~ 9a-Fluoro-16~-methyl-1,4- ~ e-ll~, 17~-diol-~,20-dione 17-retinoate -To a solution o~ 9a~rluoro-16a-methyl-174-pre~na-diene-llp,17a,21-trlol-3~0-dione 17~retlrloate 21-m~than~
sul~onate (~00 mg,) ~n dimethylformamide (5 ml.) ~mder an atmosphere o~ nitro~en and in the dark add acetic ac:!d (5 ml.) containlng sodium iodide (300 mg.). Heat the reac~
tion mixture on a water bath for 1/2 hour, then cool and dilute with ether. Wash the ethereal solution sequentially with water, a~ueous sodium bicarbonate and as2in with wat,er~
Evaporat.e the ether solutlon in v~ouo and ohromatograph the resultlng r~sldue on silioa ~el aF thlc,k la~er plat~
~eveloping with ethyl ~c~tat0/ohloroform (1:2~ Remove the steraidal retinoate band from the thick lay~r pl~tes, extract it, wlth ethy~ acetate and evaporate ln vacuo to a residue comprlsln~ 9a-fluoro-16a-methyl-].,~pre~nadiene-11~,17~-dlol~ 0-dione 17~retino~te~
_ 46 -:
December 10~ 197 2086~FT~-47 lV~4905 JB~la Example 10 9a,11~ 21-Trihalo-16~-methy]-1,4-pre~nadiene-_ _ ______ 17a-ol-3,20-dione 17-ret noates A . 2~ _D~ o~l~b~=LlE~r~-l5~-meth-y~ 4-pregna d ~ c~20-dione 17-retinoate Cool a solution of 9a921-dichloro..ll~-fluoro-16a~
ethyl-1~4-pregnadiene-17~-ol-3l20-dione (428 mgO, 1 mmole) in benzene (10 ml.) and trifluoroacetic anh~dride (o.6 ml.
~o 0C.under an atmosphere o~ ni~rogen and in the dark~
and add retinolc acid (300 mg., 1 mmole) and ~-toluenesul-~onic ~cid (50 mg.j. Stir the reaction mixture ~or an additiorlal 1/2 hour while allo~ing it to warm to wa~m tem-perature. Pour ~he reaotion mixture into water, extract with ether, and wash the combined ether extracts several times with aqueous sodium bicarbonat~ and then with water.
Dry the ethereal phase over magne~ium sul~te and evaporate in ~aCU07 and chromatograph the resultlng produat on silica g~l GF thick layer plates, developin~ with ~thyl aoe~ate/
I chloro~orm (1:2). Removc the st~roi~al retlnoa~e band ; 20 from the thick layer plates, e~tract it with ethyl acetate and evaporate ln vacuo to a residue comprising 9~,21-dichloro-~ luoro 16~-methyl-1,4~pr~gnadiene-17a-ol-3,20-dione ~ 17-retinoate.
.
.
Dece~ber 10, 1975 2086-~`TE- ~8 ' 1 ~ 6 49 0 5 J~/la B. 9a,11L Dichloro~21-~1u ro- et.hyl 1~4-pregna-diene-17~-ol-3,20-dione 17-retinoate _ _ To a solution o~ 9a,11~-dichloro-~1-fluoro-16a-m~thyl-1,4-pregnadiene-17a-ol-~20-dione (855 mg., 2 mmoles) in pyridine (10 ~nl.) under an atr.iosphere of` nitrogen and in ths dark add re~inoyl chloride (1.272 gm., 4 mmoles) ~nd 4 dimethylamino-pyridlne (50 mg.). Stir the reaction mix-ture~ ov~rnight at 50 C.under an atmosphere of nitrogen and in the dark, ~hen pour it into dilute hydrochloric acid and extract wlth ether. Wash the combined ether extracts with water, dry them over magneslum sulrate, evaporat~ them in vaouo and chromatograph the resultant residue on a silioa ~el column eluting first wikh petroleum ether~ then wlt.h petroleum ether/ether solv~nt m.i.xtures containin~ incre~sln~
15 amounts o~ ether and finally with ether. Combine like steroidal retinoate ~ractlons (as determ~ned by thin layer ¢hromatography) and evaporate them in vaouo to a residue comprlsing 9a911~-diohloro-21-rluo.ro-16a-methyl l,~-preg-nadi.~lle-17a-ol-~,20-~ione 17-retinoate~
Exa~ple 11 Preparati.on o~ 9aJ11~ ihalo-21-desoxy-1,4 nadiene-17a-ol-3 20-dione 17-retinoates Treat each of the ~ollowing 9a~ ~dihal~
desoxy-1~4 pregnadiene-17~ 1-3,~0-di~nes eitiler with retino'c acid~ trlfluoroacetic. anhydride and p-toluenesul-ronio a~id in benzene substarltia~.ly a~ described in -~ 4~ -December 10, 1975 2036-FTE-I~9 1064905 J3~/la Example lOA or with retinoyl chloride and 4-dimethylamino-py~id~ne in p~ridine substantially ~s described in Example lOB:
(1) 9a~ dichloro-lJ4-pre~nadiene-17a-ol ~,20-dione, (~) 9a-chloro~ -fluoro-1,4--pregnadiene-17~-ol-3,20-dioneg (3) 9u"11~-dichloro-1,4,6-pre~natriene-17a~ol ~,20-dione, (4) 9a chloro-ll~-rluoro-l, 4, 6 pregna~ri~ne-17a-ol-~,20- ~;
dione, (5) 9aJll~-dichloro-21~I`luoro-1,4-pre~nacliene-17a-ol-3, 20-dioneJ
(6) ga-¢hloro-ll~2l-difluoro-~,4-pregnadiene-l7a ~,~0-dione,
(7) 9a,11~-dichloro-21-~luoro-1,4,6-pregnatriene-17a_ ol-~,20-dione, .~ (8) 9a_ohloro-li~,21-di~luoro-1,4J6-pre6n~triene-17~-ol-~,20-dlone, (~) 9a~ t,riohloro 1~4NPre~nad1en~-17~-O1-~J2 dloIle~
( 10 ~ 906, 21~dichloro-ll,B-f~luoro-l ,, ll -pre~nad iene-17a-ol-3,20-dlone~
(11) 9~ ,21-t~ichloro-1,4,6-p egnatriene-17~ol-3,20-dione, (12) 9a~21-dichloro-11~ oro-1,4,6-pregna~riene_17a_ ol-~20-diorle, (1~) 9a,111~3-dichloro-16a-methyl-1,4-pregnadiene-17c~.-ol-3,20-dione~
. ~g _ Decem~er 10, 1975 ~()85-FTE- 50 ~0649~ JF.~/la ~ ) 9a ehloro-lJ.~-fluoro-16a ~e~hyl~ pregnadi~ne-17a-ol-3~20-dione, (15) 9o.,11~-~ichloro-16~-methyl--lJ4~-pregna~r~ene-17~-ol-3,20-d~one, (16) 9a-ehloro~ -fluoro-16~~methyl-1,496-pregn2.triene-17a-ol-3~0-dioneJ
~17j 9~,11~-dichloro-21-fluoro-1~-me~hyl-lJ4-pr~gnadietle_ 17a-ol-3~20-dl Ol1eJ
(18) 9a_chloro-ll~ -di~luoro-164-m~thyl-1s4-preg~adiene- ;
17~-ol-3,20~dior~e, (19) 9a,11~-dichloro-21-~luoro-16a methyl 1,4~ 6-pregna-trien~-17~-ol-3~20-dione, (20) 9a-chloro-11~,21 dlfluoro-16a-methyl-19 4~6-preg-natriene-17c~-ol-3g20~dione~
(21) 9a,~ ,21-trlchloro-16a-methyl-lJ4-pregnadiene_17~-ol-3,20-dione, (22) 9~21-dichloro-11~-~luoro 16~-methyrl -1 J 4-pregnadi~n~-17a~ol-3,20-dione, (23 ) 9a, 11~"~ triohloro-16a-m~thyl-1,4~6-prQgn~trlerl~-~7~-ol-3,20-di~
(Z4) 9a,,21_di.chloro-11,~-~luoro-16c~-m~th~rl 1,, 4, 6-pre~;na-trien~-17a-.ol-3J2~-dione, (25) ~a~ dlchl.oro-16~-methyl-1,4-pre~nadiene-17~-ol~
3,20-dione, (26) g~ chloro-11~-fluoro-16~-methyl 1,4-pregllad~eIle-17~-ol-3,20-dione, (273 9a,11~-cli.chloro_16~_me'chyl-1 J 4~6_pregrlatriene-17a-ol 3,20-dione, , ~
~ 5C) ~
Deoemr.~r lG, 1975 2a~;6-~r~ s J~
~L064905 (28) 9-chloro~ 3-f`lu.oro 16~3~met~hyl--1,4,6-pregrl~l;riene-17a-ol-3,20-dione, (29) 9a, 11 ~-dichloro-21-flu~o-16~-methyl-1~4-pre,gna~i~7ne~
17a-ol-3~20-dione, (~0~ ~-ohloro-~ 21-.~ifluoro-16~-methyl-1,4-preg~adiene~
17a-ol 3~20-dione, (~13 9a~ dichlvro-21-fluoro-16~-methyl l~ -pregna--triene-17~-ol-3,20-dione, (32) ga-ohloro-~ -difluoro-ls~-m2th~l 1,4~6-pregna- ~:
~rlene-17a ol 3,20-dioneJ
(3~) 9~"11~21-Griohloro 16~~methyl-1,4-pre~7nadiene-17c~-ol-3,20-dlone, ~4) 9a~"21-dichloro~ luoro-16,B-methyl-1,4-pr~gn~dlen~-17a-ol-~,20-dione, (35) 9a,11~ richloro-16~-methyl-1,4,6-pregrlatrien~-17a-ol-~,20-dlone, (36) 9~,21-dichloro-11~-fluoro-16~-me~hyl~1,4,~-p~ ,rla-triene_17a-ol-~, ~O dione, (37 ) 6a_~1uoro-9a, 11,B-dichloro~ pregna~ n~-17a ol-~, 20-~diorleJ
(38) 6-rluoro-9clJ ll,B-dichloro-~ , 6-pregna~r~ene-17a-~1-;3, 20-di one, (~9) 6a~ 9a, ll,~l;richloro-16a--methyl-1, 4-p~egnadiene-17~-ol-~, 20-dione, .
(4) 6-~luoro-9a,~ diQhloro-l~a-m~t~yl-154~6 pregna-tr1ene-l.7a~ol-~20 dlone, (41) 6~-~luoro-9~ dichloro-16~ met,hyl-~ pregnadie~e 17~-ol 3,20-dlon~
r ~ 51 ~
Deceinber lof 1975 ~o86-FTE~ ~2 lOG4905 J~3/1~
4~) 6-~luoro-9a, 11,~. dichloro-l6~B-metihy~ , 6-pre~na-triene-17a-ol-~,20-dione J
(43) 6a-fLu~ro-g~ ,2l-~richloro-l~4-pregnadiene~l7 O1-3J 20-d1One~
(443 6~1uoro-9~ ,21 trichloro~ 5-preg-natriene-17a-ol-~,20-dione, (45) 6~9a~ g~l~tetrachloro~16a-rnethyl-~4-pregnadiene-17a-ol-3,20-dione, (46) ~-~luoro-9a,11~321-trichloro~16~-ma~lyl~,6 preg-natrlene-17a-ol-3,~0-dione, (47) 6a-fluorcl-9a,11~,21-trichloro-16~-methyl~ -preg-nadiene-1.7a-ol-3,20-dlon~, (48) 6 fluoro-9a,11~,21-trichloro-16~-met~lyl-1,4J6-preg-, natriene i7a-ol-3J20-dione, (49) 6~2l-dLfluoro-ga~ dichl~ro-lJ4-pregn~dlene-l7a ol-3,20-dione~
(50) 6,21-difluoro-9a,11~-dichl.oro-1,4,6-pregna~rlelle-17awol-3,20-dior~e) ( 51 ) 6c~ 9a, llp -l;ricllloro-2~ uor~)w 16c~-m~thy~ 1, 4~pre~g-. 20 nadiene--17a-ol-3,20-dlone, (52) 6J21-di~luoro 9aJ 11~ -dlchloro-16a-methyl-1,4,6-pre~-natri~ne -17a-ol-3,','0-dlone, (53 ) 6a, 21-difluoro-9~ -dichloro~16~-methyl-1,4-preg-nadiene-17a-ol~ 0-dione~
(54) 6921-difluoro-~aJll~-dlchloro-16~me~hyl-1,4,6-pregna~rlene-1'7c~-31.~,20-dione, (5~) 6~9a,11~-trichloro-.21-rllloru 16~-me~h~1-1,1.,6 preg-~ natri.ene~l7a-ol-~,~0-dione~ and :.
52 ~
Deeamber 10, 1975 208~--Frri3-s ~;
l.~[)f64905 Js/la (56) 6J9a~ ~tri~hloro~ luoro-16a-rnethyl-1~4,6-preg-natriene-17a,-ol-~20-dione~
Isolate and puri~y each o~ the resulting products in a manner similar to tha~ described in Example lOA or lOB to obtain the corresponding 17-retinoate ester of ea~h o~ the starting compounds listed hereinabove.
Example l?
_ ~p ____on of other 21~desox,y~ll-prclgnene~ L~
diol_~,?O~dlone 17-retlno es and l-dehydro~ ~-de-_~dr____d 1 -~ e ~ o derlvatives thereof _.
: A. 21-Desox~-4-pre~nene~ 17a-diol-3,?0-dione 11-trif`luoroacetatas .~
In a manner simllar to that d~scri~ed ln Exampi.
8A~ tr~at ~a~h of' the ~ollowing 21 desox~ 4~.pr~gnene-11 17a~diol-3J20-di.o~e~ ln pyridln~ ~rlth trlf`luoro~e~c anh~dride:
(1) 9a ~luoro-lJl~~pre~nadie.ne-ll~J17a-diol 3J20~dione, (2) 1,4-pregnadie~e~ 1.7a-diol-~,20-dione, (3) 9a,21_dl~'1uoro-1,4-pregnadiene~11~,17a-dlol-3,20-~0 dione, luoro~194-pregnadiene-'].~sl7a-d:L41-~,20 di.one~
(5) 9a-~luoro-21-chloro-lJ4-pregnadie]le-11~,17a-diol-3J 20-dione) ~ .
~ _ 5~ _ Deoelnber 10, 1~75 208t~~F~E-s4 Jl~,/la ~6) 21-chloro 1~4~pregrladiçrle-11.~,17a-diol-3,~0-dlone, (7) 16a-methyl-l~LI--pregnadiene~ 3,17a-diol-3~20-dione,
( 10 ~ 906, 21~dichloro-ll,B-f~luoro-l ,, ll -pre~nad iene-17a-ol-3,20-dlone~
(11) 9~ ,21-t~ichloro-1,4,6-p egnatriene-17~ol-3,20-dione, (12) 9a~21-dichloro-11~ oro-1,4,6-pregna~riene_17a_ ol-~20-diorle, (1~) 9a,111~3-dichloro-16a-methyl-1,4-pregnadiene-17c~.-ol-3,20-dione~
. ~g _ Decem~er 10, 1975 ~()85-FTE- 50 ~0649~ JF.~/la ~ ) 9a ehloro-lJ.~-fluoro-16a ~e~hyl~ pregnadi~ne-17a-ol-3~20-dione, (15) 9o.,11~-~ichloro-16~-methyl--lJ4~-pregna~r~ene-17~-ol-3,20-d~one, (16) 9a-ehloro~ -fluoro-16~~methyl-1,496-pregn2.triene-17a-ol-3~0-dioneJ
~17j 9~,11~-dichloro-21-fluoro-1~-me~hyl-lJ4-pr~gnadietle_ 17a-ol-3~20-dl Ol1eJ
(18) 9a_chloro-ll~ -di~luoro-164-m~thyl-1s4-preg~adiene- ;
17~-ol-3,20~dior~e, (19) 9a,11~-dichloro-21-~luoro-16a methyl 1,4~ 6-pregna-trien~-17~-ol-3~20-dione, (20) 9a-chloro-11~,21 dlfluoro-16a-methyl-19 4~6-preg-natriene-17c~-ol-3g20~dione~
(21) 9a,~ ,21-trlchloro-16a-methyl-lJ4-pregnadiene_17~-ol-3,20-dione, (22) 9~21-dichloro-11~-~luoro 16~-methyrl -1 J 4-pregnadi~n~-17a~ol-3,20-dione, (23 ) 9a, 11~"~ triohloro-16a-m~thyl-1,4~6-prQgn~trlerl~-~7~-ol-3,20-di~
(Z4) 9a,,21_di.chloro-11,~-~luoro-16c~-m~th~rl 1,, 4, 6-pre~;na-trien~-17a-.ol-3J2~-dione, (25) ~a~ dlchl.oro-16~-methyl-1,4-pre~nadiene-17~-ol~
3,20-dione, (26) g~ chloro-11~-fluoro-16~-methyl 1,4-pregllad~eIle-17~-ol-3,20-dione, (273 9a,11~-cli.chloro_16~_me'chyl-1 J 4~6_pregrlatriene-17a-ol 3,20-dione, , ~
~ 5C) ~
Deoemr.~r lG, 1975 2a~;6-~r~ s J~
~L064905 (28) 9-chloro~ 3-f`lu.oro 16~3~met~hyl--1,4,6-pregrl~l;riene-17a-ol-3,20-dione, (29) 9a, 11 ~-dichloro-21-flu~o-16~-methyl-1~4-pre,gna~i~7ne~
17a-ol-3~20-dione, (~0~ ~-ohloro-~ 21-.~ifluoro-16~-methyl-1,4-preg~adiene~
17a-ol 3~20-dione, (~13 9a~ dichlvro-21-fluoro-16~-methyl l~ -pregna--triene-17~-ol-3,20-dione, (32) ga-ohloro-~ -difluoro-ls~-m2th~l 1,4~6-pregna- ~:
~rlene-17a ol 3,20-dioneJ
(3~) 9~"11~21-Griohloro 16~~methyl-1,4-pre~7nadiene-17c~-ol-3,20-dlone, ~4) 9a~"21-dichloro~ luoro-16,B-methyl-1,4-pr~gn~dlen~-17a-ol-~,20-dione, (35) 9a,11~ richloro-16~-methyl-1,4,6-pregrlatrien~-17a-ol-~,20-dlone, (36) 9~,21-dichloro-11~-fluoro-16~-me~hyl~1,4,~-p~ ,rla-triene_17a-ol-~, ~O dione, (37 ) 6a_~1uoro-9a, 11,B-dichloro~ pregna~ n~-17a ol-~, 20-~diorleJ
(38) 6-rluoro-9clJ ll,B-dichloro-~ , 6-pregna~r~ene-17a-~1-;3, 20-di one, (~9) 6a~ 9a, ll,~l;richloro-16a--methyl-1, 4-p~egnadiene-17~-ol-~, 20-dione, .
(4) 6-~luoro-9a,~ diQhloro-l~a-m~t~yl-154~6 pregna-tr1ene-l.7a~ol-~20 dlone, (41) 6~-~luoro-9~ dichloro-16~ met,hyl-~ pregnadie~e 17~-ol 3,20-dlon~
r ~ 51 ~
Deceinber lof 1975 ~o86-FTE~ ~2 lOG4905 J~3/1~
4~) 6-~luoro-9a, 11,~. dichloro-l6~B-metihy~ , 6-pre~na-triene-17a-ol-~,20-dione J
(43) 6a-fLu~ro-g~ ,2l-~richloro-l~4-pregnadiene~l7 O1-3J 20-d1One~
(443 6~1uoro-9~ ,21 trichloro~ 5-preg-natriene-17a-ol-~,20-dione, (45) 6~9a~ g~l~tetrachloro~16a-rnethyl-~4-pregnadiene-17a-ol-3,20-dione, (46) ~-~luoro-9a,11~321-trichloro~16~-ma~lyl~,6 preg-natrlene-17a-ol-3,~0-dione, (47) 6a-fluorcl-9a,11~,21-trichloro-16~-methyl~ -preg-nadiene-1.7a-ol-3,20-dlon~, (48) 6 fluoro-9a,11~,21-trichloro-16~-met~lyl-1,4J6-preg-, natriene i7a-ol-3J20-dione, (49) 6~2l-dLfluoro-ga~ dichl~ro-lJ4-pregn~dlene-l7a ol-3,20-dione~
(50) 6,21-difluoro-9a,11~-dichl.oro-1,4,6-pregna~rlelle-17awol-3,20-dior~e) ( 51 ) 6c~ 9a, llp -l;ricllloro-2~ uor~)w 16c~-m~thy~ 1, 4~pre~g-. 20 nadiene--17a-ol-3,20-dlone, (52) 6J21-di~luoro 9aJ 11~ -dlchloro-16a-methyl-1,4,6-pre~-natri~ne -17a-ol-3,','0-dlone, (53 ) 6a, 21-difluoro-9~ -dichloro~16~-methyl-1,4-preg-nadiene-17a-ol~ 0-dione~
(54) 6921-difluoro-~aJll~-dlchloro-16~me~hyl-1,4,6-pregna~rlene-1'7c~-31.~,20-dione, (5~) 6~9a,11~-trichloro-.21-rllloru 16~-me~h~1-1,1.,6 preg-~ natri.ene~l7a-ol-~,~0-dione~ and :.
52 ~
Deeamber 10, 1975 208~--Frri3-s ~;
l.~[)f64905 Js/la (56) 6J9a~ ~tri~hloro~ luoro-16a-rnethyl-1~4,6-preg-natriene-17a,-ol-~20-dione~
Isolate and puri~y each o~ the resulting products in a manner similar to tha~ described in Example lOA or lOB to obtain the corresponding 17-retinoate ester of ea~h o~ the starting compounds listed hereinabove.
Example l?
_ ~p ____on of other 21~desox,y~ll-prclgnene~ L~
diol_~,?O~dlone 17-retlno es and l-dehydro~ ~-de-_~dr____d 1 -~ e ~ o derlvatives thereof _.
: A. 21-Desox~-4-pre~nene~ 17a-diol-3,?0-dione 11-trif`luoroacetatas .~
In a manner simllar to that d~scri~ed ln Exampi.
8A~ tr~at ~a~h of' the ~ollowing 21 desox~ 4~.pr~gnene-11 17a~diol-3J20-di.o~e~ ln pyridln~ ~rlth trlf`luoro~e~c anh~dride:
(1) 9a ~luoro-lJl~~pre~nadie.ne-ll~J17a-diol 3J20~dione, (2) 1,4-pregnadie~e~ 1.7a-diol-~,20-dione, (3) 9a,21_dl~'1uoro-1,4-pregnadiene~11~,17a-dlol-3,20-~0 dione, luoro~194-pregnadiene-'].~sl7a-d:L41-~,20 di.one~
(5) 9a-~luoro-21-chloro-lJ4-pregnadie]le-11~,17a-diol-3J 20-dione) ~ .
~ _ 5~ _ Deoelnber 10, 1~75 208t~~F~E-s4 Jl~,/la ~6) 21-chloro 1~4~pregrladiçrle-11.~,17a-diol-3,~0-dlone, (7) 16a-methyl-l~LI--pregnadiene~ 3,17a-diol-3~20-dione,
(8) 9a-~luoro~16a-me~hyl 1,J~-pregnadlenc-11.~17-diol-3~20-dione, (93 16~-me~hy3.-1,4-pregnadiene~ ,17~-diol-~20-dione, (10) 9a-fluoro~ methyl-134-preg~adiene~ 917a-diol-3,20-dlone, (11) 16-methylene 1J4-pregnadiane-1L~,17a diol-3,20-dion~, (12) 9a-fluoro-16-m~thylene-1,4-pxegn~diene-l~yl7~-diol- ;
3,20-dionef (1~) 16~-methyl~ luoro-1,4-pregnad~ene-11~,17~-cliol-~,20-dione, (14) 16c~-m~th~].-21-chloro-1>4-pregnadiene~ ,17a-diol-3~20-dlone, (15) 9a,21-difllloro-16a-methyl-1,4-pre~nadiene-11~,17a-diol-i ~,20-dionel .
(16) 16~-me~hyl-21 ~luoro-1,4-pregn~dîene-llp,17~-cl~ol-3,~0 dione, (1'7) 16~-m~t~yl~ hloro l,~-pre~nadiene-ll~ cllol-3~20-dio~e, (18) 9~J21-difluoro-16~-m~thyl-1~4-~reKnadiene~ J17a-dlol-3,20 dlone, (19) 16-methyler~ l-fluoro-1,4-pregnadiene 11~,17a-diol-0-dione~
~5 (~0~ 1~-methylene-21-chloro 1,~-p.regnadi.ene-11~,17a~d.iol--~,. 20-dionel (21) 9a,21-~i~luo o--16-methyl.en0-1~4-pregnadiene~ Jl7a-dlol-~,, 20-dior.e, : - 5 Deeember ~09 197~
1064905 og6-FriE- 55 22) 6~ uoro-l6a-methyl-lJ4-ple~na(~iene-~ 7a-diol-3, 20-dloneJ
(2~) 6a,9a-di~luoro 16~ me~hyl 1,4-pregnadiene~ ,17~-diol-3,20-dione, ~24) 6a,21-difluoro-16a-methyl-lJ4-pregnadiene-11~,17a-diol-~,20-dione~
~25) 6~-fluoro-16~-rhethyl-1,4~pre~nadiene-11~,17a-diol-~,20-dione, f (26) 6a, 9a-dlfluoro-16~3-methyl-1,4-pregnadiene~ ,17a-diol-3,20-dione, (~7) 6a,21-dlrluoro-16~-methyl~ r-pregnadiene~ ,1'7a-d~ol-3,~0-dion~, (28) 6~-fluor-o-16-rnethylene-1,4-pre~nadlene~ ,17a ~iol-~,20-dione, (2g) 6a,~-di~luoro-16 methylene-1,4-pregnadiene~lL~17a diol-~,20-dione, ~30) 6a~21-difluoro-1~-methylene-1,4-pregnadielle~ ,17a_ diol-3,20-dioneJ
(31) 6-~luoro 16~-me~hyl-1~4,6-pre~natriene-lla,17a-diol-3,20-dioneJ
(32) 6J 9a-dlrluoro-16a~methyl~ J 6-pregnatriene-11~,17a-diol~3,20-dion~J
(33) 6,~ difluox-o-16a-methyl-1,~.,6-pregnatriene-11~,17a-dlol-3,20-dlone, ~34) 6-.~luoro--15~-methyl~ ,5 ~re~ t.rlene-11~9 17a-diol-3~Z0-dione~
(35) 6,9a-dif'luoro-16~-.met~lyl 1~4~6-pregnatriene-11~17a-diol--3~20-dione~
Decernber 10, 1~75 1064905 J~/la (36) 6,2'1~di~1uoro-16p methyl-1,4,6--pregnatriene~llfl, 17a-d~ol-3,20-dione~
(37) 6-~luor~-16_methylene--lJ4,6-pregnatriene~ 17a_ diol-~20~dlsne, (~8~ 6~9a-difluoro-16-methylene-154~6-pregnatriene-ll~p 17a-dj.ol 3~20-dione, (39) 6,~1-di.fluoro--16-methylene-1~ 4, 6-pregna~riene-11~, 17a-cliol-~20-d~one, (40) ~I ph~nyl~ ,17a-di~droxy-16a-met~yl-20-keto-1~,6-pr~gnadieno ~J 2-c]pyrazole, ~41) 2'--phenyl-9~-fluoro-].l~J17a-dihydroxy-].6~-methyl-20-keto-~J6-pregnadieno~,'2-c]pyrazole, (42) 2' phenyl-9a-rluoro~21--chloro~ ,17~-dlhydroxy~
methyl-4,~ preg~adieno[~,2-c]p~razole, (4~ ) 2'-phenyl-11~17a-dihydroxy-16~-methyl 20-keto~4,6-~regnadieno~3J2.-c~pyrazole, (44) 2'-phenyl-9a~fluoro-1'1~17a-dihydro~ 16~-m~thyl-'20 keto-4,6 pre~nadi~no[~,2-a]p~I-aæol~
(45~ 2'-~phenyl~9a ~luoro--21~hloro~11P,17~-cllhy~roxy--16~ methyl--20 ~eto-4~6-pregnadieno~3,2-c¦pyrazole~
(46) 2'-ph~nyl~ ,17a-dlhydroxy 16-methylene-20-keto-~6-pre~n~dL~no~3,2~o]pyraæole/
(4r~) 2'-phenyl-9a-~luoro~11~,17a-dihydroxy-16-methylene-20-keto~4~6-pregnadienot3~2~c~pyra~ol~5 (48) 2'... phenyl-Sa~ oro-21-~hloro-ll~J17a~dihydroxy-16-nle~hylen~-20-keto-4,6~pre~nad'~eno~3l2_c~p~raæole~ and (49) ~'-phe~ 6~16a.-di~,ethyl-~t~-~'L~Ioro-11~917~-dihydroxy-` 20-keto-4,6-pregnadieno{3,2-c]pyra;~oleO
; - 56 -ber lO, 1975 ~o~6-~T~-57 1~64905 JB/la Isolate and purify eaC}l 0~ the resultillg produots in a marmer similar to that desoribed i.n Example 8A to obtain the ll-trlfluoroacetate ester of each o~ the above listed ll~hy~roxy starting compounds.
Bo 21-Desox ~ pregnene-11~,17~-di - ?0-dione 11-tri~luoroacetate 17-retinoates __ ___ In ~ manner simil~r to that described in E;xample 8B, treat each o~ the 49 ll-tri~luoroacetate esters PL e-pared in Examplel2~ in benzene and trifl-ioroac~ti~ an-hydrlde ak 0C.under an akmosphere o~ n$.tro~en and in the dar~ wi'ch ret,lnolc a¢id and p-toluellesul~oni~ aci~
Isolate and purify each o~ the resulting products ln ~
manner simllar to that desoribed in Example ~ to obtain the co~responding ll-trirluoroacetate 17-re'cinoate esters of the 49 11~17a-dihydroxy starting compounds listed in Ex~mple 12A.
C'. ~l-Deso~ ~rl~-llP 17c~-d:Lol-3,~0-dlone 1'~, retinoate3 I~ a mar~er similar to that described in Example ~C,~ ~r~t ~ach ~.~' th~ -trifluoroaoetate 17~^-retinoate esters prepared in EY~a~nple 12B in methanol wi.th sodium .~ b~nzoa~e at roorn temperature under an atmosphere o~ nitro-.
~en. Isolate and puri.~r each OI' the resultin3 produ~ts in a manner ~imilar to tha',, des~ribed in Example 8C to obtain th~ 17-retinoate est;ers o~ each o~ the ~9 4~.preg-: -- 57 ~ec~mber 10, 19l5 ~o86-FTE-~;$
~L06490~5 J:i3/la nene~ 17a-diol~ 0-dione startin~ ~on1pounc~s listed ln above Ex~mple 12A.
Example 13 Preparation of 21-retinoates, 17a-retinoates, and 17a,21-diretinoates of 4-pre~nene 3~20-dione~ and _ e ~ 1,~-bisdehydro derivatjves thereof -Pre~n~ne-21-ol-~20 dione 21-retinoate~ and 1 dehydro$ 6-deh~dro arld 1,6-bisdehydr-o derivatives thereor _s___ ~ __ In a manner slmilar to ~hat desori.bed in Example lA ~I) treat each of the ~ollowing l~-pregnen~-21--ol~3,~0-diones in dry tetrahydro~uran under an atmosphere o~ nitro gen in the dark ~lith N-retinoylimidazole and sodium me~;ho-xide and then ~.solat~ and pu.rif~ the r~sultln~ produc~s t,o obl;ain the corre~ponding 21.-r~tlnoate e~ c-s of tha ~olluwln~ 21-~hydrox~ ~3t~roids:
(1) 9c3-fluoro-1,4-pregnac~i~ne-11~,17c~21-triol-~,20-dion~, (~) 9a-chloro-lJ4-pregnadiene-11~, 17~J 21-triol-3,20-dlone, (3) 9~-fluoro-4-pr~nene-11~,17a,21--triol-~,20-dione, (4) ~a-chloro-4-pregnene~ J17~21_trlol-3J20~diolleg (5) 16a-me.hyl~1~4-pregnadlene-11~17a~21-triol-~20-dione~
December 10~ 1975 1~6490s JB/la (~) 9a-ChJ~OrO-1t~ thY1-1J~1-Pr~e~;I1ad:Len~ J17(X~21-triol-3,20-dlone, ~7) 16~-methyl-~1,4-pregnadien~ J 17aJ 21-triol-~,20-dione~
(8) 9a-chloro-16~-me~hyl-13 ~-pregnadisne-11,~517a~21-triol-3,20-~ione9 (g) 16~nethylene-1,4-pregnadiene-11.~,17a~ riol '3J 20-dione, (10 ) 16-meth;Y1ene-9a-Ch1OrO-iJ 4-Pregnadiene-11~B9 17aJ 21- ~
trlol-3,20-dlone,~
(1.1) 9~-f'luo~v-1~-methylene 1J 4-pregnadiene-ll~J17a~21-trlol-~J 20-dione (12) 16~-methyl-4-pregnene-11~17a,21-triol-~J20-dione J
(1~) 9a-:~luoro-16a~me!;hyl-4-pregnene-11,~,17a,21-t,rlol-3~20~dioneJ
(14) 9a-chloro-16a-methyl-4-pregnene~ 17a~21-triol 3'J ~!O ~dloneJ
. (15) 16~-m~hyl-4-pr~gnene~ ,17a,21-~riol-3,~0-dione, (16) ~u-~luoro_16~math~1_4~pre~nene-11~,17a,~1_tr.Lol_ 3~20-d.~one, (17) 9a Ch1OrO-16,B-me~ChY1-~4-Pre~I1ene~ Bg17~J 21~trlol 3,20 dloneJ
(18) 16-~m~thylene-4~pregnene~ ,,17a"21-triol ~,,20-dion~J
(19) 9a~l.uoro-16-methylene-4-pregnen~ J].7aJ21-triol-~,20 d~one, (20) 9a-~hloro-16 nie~hylene-4-pre~n~ne~ ,17aJ21 triol-3J20--dioneJ
: (21) 6a~ oro-1~4-~re~n~tdien~ J17a,21-triol-3~20-dione~
':
~ 5 -~b~-r 10, ~o~6 ~r~ 60 J~
~649~al5 ('~2) 6a~9a-dLfluoro-1,4-p~e~n~dien~pl7~"21-triol~
: 3,~0-dloneJ
(2~) 6a-fluoro-9~-chloro-1,4-pregrladiene-ll~.L7a,21.-triol-3,20-dioneg f24) 2-chloro-6u-fluoro-1,4-pregnadien~ 17~,21-triol~
3J20-dione, (25) ~-chloro-6a~9a-difluoro-1~4 pregnadiene-11~,17~, 21-triol-3,20-dione~
~26) 2~9~-dichloro 6a fluoro-1,4-pregnadiene~ 17a, ~0 21~triol-3,20-dione, (27) 6a-~luoro-l~-pregnene-llp,17a~ tr101-3,20-dlone~
(~8) 6a,9a-difluoro-4-pregIlene-llp,17a,21-~r:lol-~J20 dlon~
(29) 6a-~luoro-9a-chloro~ regnen~ ,17~21-triol-3,20-dloneS
(30~ 6a-~luor3-16a-meth~rl-134-pregnadiene~ /17~,21-triol-3~0-dione, (31) 6a,~ di.~luoro-16~-methyl-lJ~ e~rladi~n~ ,1'7a~ ;
21~tri~ ,2~-dlone~
.~, (3~) 6~J9~-dl~hlor~o-16a~m~pr~nadlen~_llp~l7a, 21-trlol~ 0-dione, (~3) 6~-~1uoro-16~-m~th~ 4-~re~n~di.ene-11~,17a~
~ri.ol..~,20-.~ne, (34) 6~y9a-di~luoro-16~-m~thyl-1~l~-pre~nad-ene~-llpJ17a, Xl-~riol ~,20-dione~
(35) ~ luoro~a-chloro-16~-me~hyl-1 J ~r -pre~r,~diene l:Lp~1'7aJ21-tr'.ol-3,20-~lo~ie~
D~cemher :I.0~ 1975 ~086-Fl~- 61 JB/la ~649~5 (36) 6a-f:Luor~ 6-rnethyleno-l~4-ple~lladierle ~ 7aJ~l-triol-3,20-dione, (37 ) 6a, 9a-dirluoro_l6_methylene_l, 4~pregnadiene-ll,B, 17a, 21-triol-3,20-dione, ~38) 6a L luoro-9a-chloro-16-methylene-1, 4-pregnadiene-11~,17a,21-triol-3~20-dione) (39) 16~-methyl-4,6-pregnadien~ ,17~,~1-triol-3/20 dioneJ
~40) 9a-fluoro-16a-methyl-4,6-pregn&di.ene-11~,17a,21 triol-~,~0-diorle, (41) 9~-ohloro-16a-m~thyl-4~6-pre~nadl~ne~ ,17a,~1-trlol-3,20-dione, (42) 16~-mekhyl-4 7 6-pre~nadiene~ ,17a,21 ~riol-3,20-~lor~e, (4~) 9a-fluoro-16~-methyl-~,6-pregnadiene-l.l~J17aJ~l-trlol..3,20-dlone, (44) 9a-chloro-16~-methyl-4,6-pregnadiene 11~,17a~21-trlol-~J 20 -dioile, (1~5) 16~ ethyle~e-4J6-pre~nadlene-llp,17al~1-trlol-3~20-dloneJ
(46) 9a-~luoro-16-methylene-4,6-pre$nadiene-11~,17a~21-tr.iol-3,20-dione, (47) g~-ohloro.~l6-m~tllylene-4~6-pre~lladiene~ 7aJ2 triol-~J20-dione, (48) 6-flll~ro-1,4,6-pregnatriene-11~,~7a9~1-triol-3J20-dlone 9 ~49) 6,9~-di~luoro-1,4,6-pregl~trien~ J17~,21-triol-~5 ~ 20-d ione r Decem~er 10, 1975 2086-FTi~-62 1064!~05 ~3/la (50 ) 6-f luoro-9a-cllloro-l, 4 ~ 6-pre&~r:l~trierle-ll,B, 17aJ 21-trlol-3,20-dione, (51) 6-ch].oro-1,4,6-pregnatriene~ 17a, 21-triol-~20-dione~
(52) 6~chloro 9a-~luoro-1,4~6-pregn~trlene~ ,17a~21--triol-~7~0-dione~
~53) 6,9a-dlchloro-1,4,~ pregnatriene-11~,17a,21-triol~
3J20-dione, (54) 6-methyl-1,4,6-pregnatriene-11~, 17a, '~l~tr~ol-3, 20-dion~, ~55) 6-methyl-9a-fluoro-1,~ -pregnatrierle-ll,B,17a,21-triol-3,20-dione J
(56) 6-methyl-ga-chloro 1,4,6-pre~natrie~e-11~,1'7a~21-triol-3~0~dione, (57) 6-azido-1,4,6-pregn~triene-11,~,17a,21 triol-~,20-`: dione, (58) 6-azido-9~-fluoro-1,4,6-pregnatrl~ne~11~17a,21-~riol-3,20-dione, (59) 6-azldo-9a ¢hloro-lJ4,6-pre3n~trlenQ-.ll~17~21 triol~,20-dione, (60) 6-fltloro-~,6-pregnadien~ ,17a,21-tli.ol ~,20-dion~, (61) 6~9a-clifluoro-4,6~pr~nadielle-ll,B,17~,21~trlol~3,20-dlone, (62) 6~fluoro--ga-chloro-4~6~~regnadien~-l]~l7a~2 triol~3,20~dlone, (63) 6-chloro-4,6-pregnadiene-11~,~17a,21~trio'-3~20-dlone, (64) 6-chloro-9a--~luoro-4,6~pre~nadlene~11B,17a,2].-triol~
, .
- 62 ~
D~ce.~r 10, 1975 2086-F'I'E-63 lOG490S JBJl~
3,20--dione, (65) 6,9~-dichloro-4,6-pregnadiene~ /17~21-triol-3~20-dione, (~6) 6-methyl-4,6-pregnadiene-11~,17a,21~r-tol-3g20-dione~
(67) 6-methyl-9~-fluoro-4,6-pregnadiene-11~,17a~21-~riol ~,20-dione, (68) 6-methyl--9a~chloro-4,6-pregnadiene-11~,17a,21-triol--3,20-dione, (69) 6 az~ do-l~5 6-pre~nadlene-11~,17921-triol-3~20-di3ne, (70) 6-azido-9a-~ oro-4,6-pre~nadiene-11~,17a/21-triol-[ 3,20-dionP, (71~ 6-az~do 9~-chloro-4,6-pregn~diene-llp,17~,21~~rioJ.-'I ~;J 20-diolle, (72) 6-fluoro-16~-m2thyl-1~4~6-preæna~riene-11~.17~,21-triol ~,20-dione9 ~73) 6,9a-di~luoro-16~-methyl-1, 4J 6-pre~natrien~-l.L~,17a, 21-triol-3,~0-dlone J
(71~) 6~rllloro-9a-ohloro-l~a~methyl-1,4J6-pre~natriene-11 7a~ triol~3~()-dlone~
~0 (75) 6 rluoro-16~-methyl-1,4,G pre~natrlene 11~]7 21-triol-3,'20-dione, ~76) 6,9~-di~).uoro-lG~-methyl-lJ4,~-pregnatriene~ ,17~, 2~ trlol-3,20 dlone, (7'7~ 6-~iuoro--9a-chloro~-16~-m~hyl-1,4,6-pregna~riene-~5 11~,17a~21-trlol-~5~0-di.one, (78) 5~fi.uoro-16~m~t~lyl~ne-.l r 4 ~ 6-pre~natrlene-1~, 17a 21-triol.-~20-dione, : - 6;j _ ~ece~e:r 107 1975 -~'.r.'L~.-64 1064905 JB/la (79) 6,9a-dichloro-16-methylene-1, 4J 6-pregnatriene~
17a~21-trlol~3J20-dlone, (80) 6-fluoro-9a-chloro-16-rnethylene~ ,5-pre~natrlene-11~,17a,21-trlol-~,20-dione, (81) 6-azldo-16a-methyl-1,4,6-pregn~trlene-11~17ag~1-triol-3,20-dione, (82) 6-azido-9a-fluoro-16a methyl-1~4,5-pregnatriene-,17a~21-triol-3~20-dione, (83) 6-azido-9a chloro-l6a-me'chyl--1,4,6-pre~natriene--11~17a,21~trlol-3,20-dione, ~84) 6-azido-16~-methyl-19 ~ J 5-pregnatriene~ ,17~,21-~riol-3J20-dione, (85) 6-azido-9a-~luoro-16~-methyl-1,1~,6-pregnatric~ne-11~,17a,21.-triol-3,~0-dlorle, (86) 6-azido-9a-chloro~16~-me~hyl--lJ~,6-pr:egnatriene-17a,21-triol-3~0-dione, (87) 6-azido~ met;hylene-1~4,6-pre~na~rlene-}1~,17a, 21-triol-3J20-dione, (88) 6-azido-9a-~luoro-16 methyl~ne 1,1~J6-pre~natrlene-. ~0 11~,17a,21-tr:i.ol 3,~0-cliono, (89) 6-azido-9a-cllloro-16-methylene-1,4~6-pr~snatiriene-11~,17aJ21-trlol~3~20_dione~
(90) 6-~luoro-1.6a-methyl~ ,6-pr~gnadien~ ,17a,21-trlol-~3,20-dione, (~1) 6,9a difluoro-16a~meth~J~4,6-pregnadi~ne~ ,17a, 21-triol-3,20-dione (g2) 6-~luoro~ chloro-16a-methyl-4,6-pregnadierle~
17,21 tr-iol-3,20-dione., - 6~ -. . .
DeCemher 1OJ 1~75 ~0/ -~TE-65 (93) 6-~luoro 16~-methyl-4,6-pregnadiene~ ,17a,21 triol-~,20-dione, (94) 6,9a-di~luoro-16~-methyl-4,6-pregnadiene-11~, 17aJ
21-triol-3~20-dlone, (95) 6-rluoro~9a-chloro-16~-methyl-4~6~pregnadiene-11~, 17~/21-triol- ~9 20-diona, (96) 6-~luoro-16-methylene-~J6-pregnadiene-11~,17a~21-triol-3,20-dioneJ
(97) 6,9a-di~luoro-16-methylene-4,6-pregnadiene~ ,17~, ` 10 21-triol-~,20-dione, ; (98) 6-~luoro-9a-~hloro 16-meth~lene-l~,6-pregrladiene-11~717a,21-triol-3,20-dlone, (99) 6-azido-16a~methyl-4~pregnadiene-11~,17a,21-~riol-, 3,20-dione, (100) 6-azido-9~-fluoro 16a-methyl-4,6-pregnadiene-11~,17aJ
~ 21-tr_ol-~,20-dione, j (101) 6-azido-ga-chloro-l6a-methyl-4J6~pregnadiene^ll~Jl7a~
:
21-~riol-~,20-dione, ; (102) 6-aældo-l6~-me~hyl~4,6-pregnadlene~ ,17a,21-triol-3~0-dlonel (103) 6-aæido-9a-fluoro-16~-meth~yl-l~6-pregnadiene-11~, 17~,21-triol-~,20-dion~, (104) 6-azldo-9~-chloro-16~-lneth~1-4,6~pregnadi.ene~
17a,~1-triol 3J23-d.ione, (iO5) 6~a~ido-16~meth~Jlene-4,6-pregnadiene~ ,17a,21-'criol-~,20~clione, (106) 6-azido-9~-~luoro-16-methylene-4,6-pregn~diene-11 17a,21-triol~3J20--dione, `
G5 ~.
Dece~ber ].0, 1~75 2086-FTE_66 106~ S J~3/la (107) 6-azido-9~,-chloro-16-meth~Jlene-4,6-pregnadi.ene-11~917~21-triol-3,20-diolle, (108) 9~-flu3ro-lg4-pre~nadiene-J(a,21-diol~ 20-trione, ~109) 9a-~luoro-4-pregnene-17~,21.~diol-3911,20-trlone, (L10) 16a-methyl-1~4-pregnadiene-17a,21-diol-3~11,20-tri.one, (111) 16~-methyl-1,4-pregnadiene-17~,21-diol~3,11~20-; - trione, ~:~
(112) 16-methylene-1,4-preænad~ene-17a,21-d~ol-3,11J20 trlone~
(113) 16a-methyl-4-pregnene-17a,21-diol-3,11,20-trione, (114) 9a-~luoro~16~-~ethyl-4-pregnene-17a,21-diol-3,11, 20-trione, (115) 16~-methyl-4-pregnene-17c~,21-diol-~,11,20-trione, (116) 9a-fluoro-16~-methyl-4-pre~nene-17a,21-diol-~,11, 20-trione, ~117) 16-methyl~ne-4-pre~nene-1 7aJ 21- CI iol-~,11,20-tric)ne~
(118) 9a6_i~1uoro_16_methylene_4_~re~Ilene_1'7~, 21_cl~ol_ ;J
~0 ll~0-trione~
(119) 6a-fluoro-1,4-pregnadien~ 17a,21-diol-3,11,20-trion~, (120) 6a~9~-difluoro-1~4-pre~nadiene-17a~21-diol-3,11, 20-krion~, tl21~ 6~-~luoro-4-pregnene-17a,21-diol-3,11~20-trione~
(122) 6aJ9~-dl~luoro~4-pregnene-17a,~1-diol-~311,20-trione9 ' - 6~ -December 10~ 1975 2086-~TE-67 106gL905 Js/la (123) 6a-fluoro~-16a-methyl-1,4-pregnadlene-17a"~ diol-3,11, ~o trioneJ
( 124 ) 6a, 9a-dillv.oro-16a-methyl-1,4-pregnadiene-17a,21-diol-3,11,20-trione, (125) 6~fluoro~16~-methyl-1,4-pre~nadiene~17a12].-diol-20-trione, ( 1~6 ) 6a, 9a~d~fluoro-16~-methyl-1,4-pregnadiene-17~.x/21 dlol-~11,20-trione~
( 127 ) 6a ~luoro-16-methylene-134-pregIladiene-17~,21-diol-~,11,20-trione, (128) 6a~9a-di~luoro-16-methylene-1,4-pregn~diene-].7~,21-diol-3,11,20-trione, (129) 1,4,6-pregnatrlene-17aJ21-diol-3J11,20-trione, (130) 9a-rluoro-lJ4,6-pregnatriene_17a,21_diol_~,11,20_ trione, (131) 4,6-pregnadiene-17aJ21-diol-3,11,20-triorle, (13~) 9a-fluoro-4,6-pre~rladlene~l7~2l-d~iol-3~ll,2()-~rione~
(133) 16a-me~h~1-1,4 J 6-pregnatriene 17~,21-dlol-3~ 0-trlone, ~ (13~) 9~ 1UOrO-16a-me~hY1-1~ 6-Pre~ atriet1e-1~ 21-diO1 3~ 2O-triOr1 (135) 16~B-m~!thY1 1J 1I~ 6-Pr~:~g11atr:lene-17a~21-diO1~ ~j9 11J2 trlone~ ~
(136) 9a-fluoro-16,~-me~hyl~-1,4,6-pregnatriene-17a,21-dio~-3J 11~ 20-trlone, (1~7) lG-methylene-:L,4J6-pregnatriene~1.7c~,21-dlol-3,11., 20-trlone, - 67 _ ~ecem~er 10, 1975 106490S JB/la (138) 9a-flluoro-l6~mekhylene~ J 6 pregnatriene-17~,21-diol-~,11,20-trione, (139) 6-~luoro-1,4,~-pregnatrle~le-17a~21-di.ol-3,11~20-tr ioneJ
(140) 6,9a-difluoro-1,1~,6-pregnatriene-17~,21-dlol-3,11, 20 trione7 (141) 6-chloro-1~4f6-pregnatriene-17~,21-diol-3~ 20-trlona, ~142) 6-chloro-9a-~luoro-1,4J6-pregnatriene-17a,~1-diol 35}1,20-trione, (143) 6-methyl-lJ4,6~pregnatriene-17a,~1-diol-3,11,20-trlone J
(144) 6-methyl-9a-~luoro-1,4,6-pregnatriene-17a~21-diol-- 3,11,20-trione, ~145~ 6-azido-1,l~,6-pregnatriene-17a,21-diol-3~ 0-trione~
(146) 6-azi~o-9a-fluoro-1,4,6--pregnatriene-17~,21-diol-3,11,20-trione, (14'7) 6-f'luoro-16a-nlethyl-1,4,6-pre~na~riene-17a,21-diol-~11,20 trioneJ
~ 8) 6,9a di~luorc-16a-methyl-1,l~,6-pregnatriene-17a,21-d~ol-3,1},~0-trlone, (149) 6-flu~ro-16~-methyl 1~4.,6-pregnatriene-17a,21-dlol 3,11.~20-~rione~
~5 ~150~ 6,9~-di.~luoro--16~-methyl~1,4,6--pregnatriene-17a,21-diol--3,11,20~trioneJ
(151) 6-~luoro-16-mel;hylene-194,6~pregnatriene-17a,21-diol-3,11,~0-trione, Decem~er 10~ 1~7 - 20~6~FTE-69 J~
(152) 6,9~-di~luoro-16-m~thylene-1,4,6-pregnatriene-17a,21-dioi-~,11,20-trione, (153) 6-azido-16a-methyl-1/4,6-pregnatriene-17a,21-diol-. 3,11J 20-trione, (154) 6-azido-9a-Lluoro-16a-methyl-1,4,6-pregnatriene-17a32'~i.ol-~,11,20~trione, ¦ ~155) 6-azido-16B-methyl-1,4,6-pregnatriene-17~,21^diol-3,11,20-trione, (156) 6-azido-9a-fluoro-16~-methyl-lJ4,6-pregnatrlene-17~,21-diol~ O trione, ~157) 6-azido-16-methylene-1,4~6-pregrla~riene-17a,21_ diol-3, 11J 20-trione, (158) 6-azido-9a-~luoro-16-methylene-1,1~,6-pregnatriene-. 17~1-diol-~,11,20-trione, !, 1$ (159) 9a,11~-dichloro-1,4 pregnadiene-17a,21-diol-~,20 dione, : (160) 9a~chloro~ luo~o lJ4~-pre~nadlene--17aJ21--dlol-3J20-dione~
t161) ~a,ll~-dlchloro-1,4,6-p~eglla~rlene-17a~21-diol-. ~0 3J20-dione~
(162) 9a-chloro~ -fluoro 1~4J6-pregnatrlene-17aJ21-diol-3~20-dione, (16~) ga511~ dlchloro-l~-pregnene 17a,~1-diol 3,20-dione, ~ (164) 9a-chloro~ -f`luoro--4-pregnene_17aJ21-diol-3,20-~5 dione, ~165) 9~ -di¢llloro~4,6~pregnadi~ne-17~21~diol-~,20-dione, December 10~ 1975 2086-F'~E- 70 1~6490S JB/la (166) 9a-chlolo llp-rluoro-496-pregnfldi.ene-17a,21-diol-3,20-dione, (167) 9a,11~-dich].oro-16~-methyl~ pregnacliene-17a,21-diol-3,20 dlone, (168~ g~-chloro-ll~-fluoro-l6~-methy~ 4-pregnadiene 17a,21-dlol--3,20-dione, (169) 9a,11~-diohloro-16a methyl~l,4,5-pregn2triene 17a, ; 21-dlol-3,20~dione~
(170) 9~-chloro~ luoro-16a~methyl-1,496~pregnatriene-17a,21-diol-~,20~dione, (171) 9~ -dichloro-16~-methyl-1,4--pregnadiene-17a,21-diol-3,20-d-lone, (172) 9~-~chloro-11~-~].uoro-16~-methyl-lJ4-pre~nadiene-17~,21-diol-3,20-dioneJ
(173) 9a,11~-dichloro-16~-methyl-1,4,6-pregnatriene-17~, 21-diol-3~20~dione, (174) 9a chloro-11~-~luoro-16~-me~hyl-1,4,6-pregnatr~ene 17~,21~dlol-~,20-dione~
~175) 9~J ll~-dlohloro 16-m~th~leno-~1,4-pregnadiene-17a~21-diol-3,20-dioneJ
(176) 9a-ohloro-ll~-~luoro-l~-methylene-194-pregnadiene-1'7a,21-dlol-~,20-dione~
(177) 9a,11~-dichloro-16-methylene-1~4,6-pregnatriene-17a,21-dlol-3,20-dione, ~178) 9a-chloro~ -fluoro-16-methylens-1,4,6-pregnatriene-17a,21-diol-3,20-dione, ~179) 6~-fluoro-9a,11~-dlchloro~ 4~pregnadiene-17a,21-dlol-~,20-dione, ecember 10, 19~5 2086~-l?TE-71 4g 0 5 JB/la .
(1~0) 6u-fluoro-9~ dichloro~ pre~nene--17a,21-diol-3,20-dione, (181) 6-fluoro~9a,11~-di.ehloro-16~-methyl-1,1~-pregna~
diene-17a,?l-diol 3,20-dione, (182) 9~ -diohloro-6a-fluoro-16~-methyl-1,4-pre~na-diene-17~,21-diol~3,20-dione, (183 3 9aJll~-dichloro-6a-~luoro-1~-me~hylene-1,4-pregna-diene-17~.,21-diol--3J20-dione, (184) 6a~1uoro-9u,11~-dichloro-16a-me~hyl-4-pregnsne-10 17a,~1-diol-~,20-dione, (185) 6a-rluoro-9~ -d:Lchloro-16~-methyl-4-pregnene-17a~21-diol-3J20-dioneJ
(186) 6~-~luoro-9a.,11~-dichloro-16-methylene-4-pregnene-17~,21-diol--3,20-dione, (187) lJ4-pregnadiene-11~,21-diol-~J~0-dioneJ
(188) 9~-fluoro-1,4-pregnadiene~ ,21-diol 3J20-dioneJ
(189) 4-pre~nene-11~,~1-diol-3J20-dione, (190) 9a-~luoro-4-pregnene~ ,21-diol-3,20-dione, (191) 16~-nlethyl-1,4-pregn~dlene-11~,21-dlol-~20-dione, (19~) 9~-~luoro-16a~methyl-1,4-pregna~iene-11~,21-dlol-3,20-dione, (193) 16,~-methyl-1,4-pre~nadlene-ll,B,21-dlol-3,20-dione, (194) 9~--f`1uoro-16~-rnethyl-].Jl~pregnadiene-11~,21-diol-3,20-d~one, (195) 16--methylene-1~4-pregnadiene~ ,21-di.ol-3,20-dione~
(196) 9~-rluo~o-16-rne~hylene-},4-preglladierle-ll,B,21.~diol-3~20-dione~
December 10~ 1975 2086-FTE-7~
1~64905 J~a (197) 16~-methyl~ pregnene 11~ diol~3,20-dione, ~198) 9~-fluoro-16-~-methyl-4-pregnene-11~,21 diol-3,20- q dioneJ
(199) 16,R-methyl-4-pregnene-ll,B,21 divl-3"2()-dioneJ
(200) 9a-fluoro~16~~methyl-4-pregnene-11~,21-diol.~,~20-d~one, : (201) 16-methylene-4-pregnene~ J21-~1Ol~3,20-dione, .
(202) 9a~fluoro-16-methylene-4-pregnene~ ,21-d~ol-3J20-dione, (2G~) 6f~-~luoro-16a-met,hyl-1,4-preg~adiene-ll~J21-diol-3,20-dione, (204) 6a,9a-dlf~luoro-16-~ m-thyl-1,4-pregnadiene~ll~l^.diol-~,~0-dione, (205) 6a-fluoro-16~~n,ethyl-lJ4-pregnadiene-11~21-d:lol-~ 15 ~J20-dione, ; (206) 6~1~a~diiPluoro-16~-methyl-1,4-pregnadielle-diol-~,20-dione, (~07) 6a~f'1uoro-16~m~thylene-1,4-pregnadiene 11~,21-~iol-3, 20-dioneJ
(208) ~9-~-diPluoro-16-meth~le.n-t-1,l~-pregrlac~iene-11~, 21--dio].-~,20-dione, (209) 6r~-rluoro-l6~-methy~ 4-pregnadien~ 2l-dioL
3J20-dione, ~210) 6Jgfa-di~luoro~ -methyl-lJ4-pre~nadiene-llpJ2 diol-~20-dione~
(211) 1,4-pregnadiene-'ll.,B,16c~,J17ag2'1-tetrol-~,20--dioneJ
~12) ~ luoro-1,4-pregnadiene~ ,16ayl7aJ21-tetrol~
~, 2C-clloneJ
.
. _ 7~ ~ .
December L0) 1.9 ~6-~'L'E~7 ~ o~;~9 ~ 5 2~1a (213) 4--pregnene-11~16~,17~21-~etrol-~J20-diorleJ
(214) ~a~fluoro-4-pregnene~11~16a,17c~,21-tetrol--3,20-dione, (~15~ 1~4-pregnadiene~11~,16a,17a,21~t,etrol~~ J 20-d~.orle 16-ace~ate,-~216) 9a~~1uoro~1,4~pregnadlene-ll~J16~17a,21-tetrol-0-dlone l~-acetate, (217) 16~,17a-isopropylidenedioxy-1,4~pregnadiene~ /21-diol-~,20~dlon~, (218) ~c~-~luoro-16~,17a-isopropylidenedioxy~l,l~--pregna~
diene~ 21 diol-3,20-dlone, (219) 6a-fluoro-lJ4-pregnadiene-11~, 16~J 1.7a,21-tetrol-3,20--d~ons, (220) 6~,9a-difll;,oro-1,4-pregnadiene-11~,16u,17a,~1-tetrol~
3,20-dione, (~21 ) 6cl-riuoro-l 1 4-pregnadien~ ,16a,17a,21-tetrol-O-d Lone 16-a~etate (X2~) 6a,g~-d~ uoro~ pre~adien~ 16 tetrol-3l~`0-cllon~ 16-acetat~
Z0 (~23) 6c~.flu~ro-]6~,17a-isopropylldelledioxy-1,4-pre~na-diene-11~3~ diol.-~0-~ione, (2~1~) 6a,~~di~1uor-o-~1ha,17a-lsop.ropylidenedloxy-1,4-: pre~nadiene~ l-diol.-~,20-dione, ~225) 6~-~luoro-1,4--pregnadiene-11~17a,21-triol~3,20-dlone~
~226) 6~9a-di.fluoro-ly4-pre~nadiene--11~,17a,21-t;riol-3,20-dion~:, ~ 7;~
DeCember 1OJ 19 1 ~ 6 49 ~ S JB/la ~2~7) 6~--fluoro--16M-methyl-1"4-pregnadiene~ ,17~,21-tri.ol-~,20-dione, (22~,) 6~,9~dl~1uoro-].6~~methyl-1,4-pregnadiene-11~,17a, 21-triol-~,23-dione, (229) 6~-~luoro~ methyl-1,4-pregnadiene~ ,17~J21-~riol-3,20-dione, (230) 6~,9~-dlfluor~-16~-methyl~ -pregna~iene~ ,17a, 21-triol-~,20-dione~
(231) ~-rluoro-16-methylene-1,4-pregnadiene-11~,17-~
21-triol-3,20-dione, (232j 6~,9~-di.,luoro-16-methylerle-1,4-pregnadiene-ll~J17~, 21-triol--~,20-dioneJ
(Z33) 2 7 -phenyl-11~,17~,21-trihydroxy-20-keto--4,6-pre~-~ nadieno[3~2-c~pyrazole, ; 15 (2~4) 2'-phenyl-6-azido-11~,17a,21-trihydroxy-20-k~o-4,6-pregnadieno~3,2-o]pyrazole, (235) 2'-phenyl-6-methyl.-11~.,17~21-l,ri.hydroxy-20-k~to-4J6-pregnadieno~,2-o]pyrazolc, (~36 ) ~ ' -ph~ny~ ~ G- rluoro ~ rj'~J 21~t~1hydr~xy~20-k~to-; . 20 4~6-pregnadieno~,2-c]pyrazole, ~2~7) 2'-phenyl~ ,17~,21-tr~}lydroxy-16~--methyl-~0-keto--4,6-pregnadienol3,~~c]py~razol~ ~
(2~8) ~'-phenyl-6-azido-11~,17~,,21-trihydroxy-16a-methyl 20-keto-4,S-pregnadieno[3,2-c]pyrazole, (2~9) 2'~phenyl-6 methyl~ J17~,~1-trihydroxy-16a-tnethyl-~0 keto-4J6-pre~nadieno E3, 2-c Ipyraz~leJ
(~40) 2'-phenyl-6-fiuor~-llp,1'7a,21-trlhydroxy-16a..me~hyl-20-~eto-4J6-pregnadieno~,2-c]pyrazole, .
7 1~ .
Det~mber 1OJ 1975 ~o86-FT~-75 1064905 JB/la (241) 2' phenyl~ L7~,21~rlhyrlroxlJ-16~~rllethyl-20-keto-4,6-pregnadieno~3J2-c]pyrazole, (242~ 2'-phenyl~6-azido-11~9 17J 2~-trlhydroxy-16~-rnethyl-20-keto--~,6-pregnadieno~,2-c~pyrazole, (24~ phenyl-6-methyl 11~17a,21-trihydroxy-16~,-methyl-20-ketcJ-4,6-pregnadieno[3,2 c]pyrazole, (244) 2'-phenyl-6-fluoro-118,17~21-trlhydroxy-16~-metllyl-20-keto-4,6-pregnadieno~3~2-c~pyrazole, (24~) 6-~luoro~16c~-methyl-1,4~6 ~regnatr~ne-llB,21-dto].-~SJ 20~ ioneJ
(246) 6a-fluoro-g~-chloro-16~-methyl~ -pregn~diene-11 ~l-diol-3~20-d.l.one, (~47) 6~ uoro-g~ -dichloro-l6~l7~ sopropyl.id~e . , dioxy-1,4-pregnadiene-21.-ol-3,20-dione, (~48) 6,16-dimethyl-1,4,6,15-pregnatetraene-11~17~121-j:
triol-3~20-dione, ~249) 1~ me'ch~l-1,4J8-pregnatriene~ ,17u,21-triol-3,20-dione 17-propionate~
(250) 9a ~luor~ ,21-dihydro~-3,11-tlikeko~ pre~-: 20 ~ladLe~otl7aJ16~_d]oxaæol~ne, (251~ -ol~loroethoxy)-6-fo~my~1-9~ oro-16~,17~-lso-propylidenedioxy-~,5.-pre~llclt~iene-11~,21-diol-20-one~
(25~) 2a-methyl-6-f}uoro~-4J6-pregnadiene-11~,16~,17~J~1 tetrol-3,20~dione, (25~) 2a-methyl-6,9~-dj.fluoro 4~6--pregnadiene~ 16a, 17a.,21~tetrol-~20-di~e, ~25~ 1'7a--chloro~ t-pregnadier~ 21-diol 3,20-dion~g .~ece~her 10, 1975 20~6-~TE_76 10649~5 JB/la (255) 6~methy'l-4-pragnene~ ,17a,21-triol-3~20-dione J
(256) 6a-me~hyl--1,4-pregn~diene~ ,17a,21-triol-~,20-dioneJ
~257~ 6a,16~-dlmethyl-4-pregnene~ 917aJ21-trlol-3~20-dione, (258) 6a~16~-dlmethyl-4-pregnene~ 31'7a,21-triol-~920-dlone$
(259) 6u~16a-dimethyl-lJ4-pregnadiene-11~17~.,21-trlol ~i, 20-dione,, (260) 6a516~-dlmethyl-1,4-pregnadie~e~ 7C~J 21-triol-3~20-dione, (~61) 6a-methyl~9a-~luoro.. 4.. ple~llene~ ,17a~21_t~iol_~,20_ dioneJ
(262) 6~--meth~1-9a fluoro-1,4--pregrad.~ene-11~,17c~,21-triol-3,20-dione, (263) 6a,16~ dlmeth~rl~9~ rluoro-~-pregnene-11~,17a,21--trlol 3,20-dion~, (264) 6CY, 16~-dimethyl-~ oro-4-pr~gn~ne-11~,1'7a~21-' triol~ O~dlon~J
'~ 20 (265) 6aJ16~-~lm~thyl~9a-r'luoro-1,4--pregnad.i.ene-11~,17aJ
21-triol-3,20-dione, and (~66) 6~,16~-dilllethyl 9a-f`luoro-1,4-pregnadiene-11~,17a, 21 triol-3~20~-dione.
' Dec~mbe~ ~0, 1~75 ~ 086~TE-77 B. l~-Pregnene~17a,2J-dio ~J20 dione 17-r-~tinoates In a manner ~imilar to that described in Rxample 5A treat each o~ the 4-pregnene-17~,21-diol-~,2Q-dione 21-retinoates prepared in Example 13A (i.e. the 21-re~i-noates o~ starting compo~nds 1-186, 211-216~ 219-222~
; 225_244, 248 and 255-266~ with cuprous iodide and methyl lithium in dry tetrahydrofuran~ and isolate and purify the resulting product substantially as described to obtain the 17-retinoates o~ the ~-pregnene-17~,21-diol 3,20-diones numbered 1-186, ~ 216, 219-222~ 225-244, 248 and 255-266.
C. 4-Pregnene-17a~21-dlol-~,20-di n~ 9 In a manner similar to that described in Example 6A~
treat each of the 4-pregnene-17a,21-diol-3~20-dione 17-retlnoates prepared as desorlbed in Example 13B w~kh N--retinoylimidazole and .soclium methoxide under a~ atmosphere o~ nitrogen in the dar~. Isolate and puri~y each of' the resulting products subs~an~ially as described to obtain the 17,21~-diretinoat~ of the ~-pregn~ne-17~,21-dioJ.-3,20-diones numbered 1-186~ 211-216, 219-222, 225-244 248 and 255-266.
~ecember 10~ 1975 2086~F'r~_78 1~69L9~i5 ~f/la Example 1 4-Pregnene~ ,17a~21-triol-3,20-dione 21-9910 cis-re~inoate and the 1 dehydro analo~ the~eof In a manner similar to that described in ~xample lA (I~ treat each o~ 4-pregnene 11~17~"21-triol~ 0-dione and 3.,4~pregnadiene-11~,17a,21-triol~~,20-dione in dry tetrahydro~uran under nitrogen and in the dark ~i~h N ~9,10-cis-retinoyljlmidazole and sodium me~hoxlda.
Isolate and puri~y the resulting p~oducts in a manner similar to that descl~ibed in .ExampJ.e lA (I) to obtain 4-pregnene~ ,17~,21-triol-3,20-dlone 21-~,10 c,i.s-reti noat~ and l,4-pregnadiene-11~,17a~ triol-3,20-dione 21-9,10-cls-retinoate, respectivelyO
. - 7~ -l~ece~e-r 1~ 75 ~086-r`i`~-7~
~OG49~$ J~/la Example 15 .' ~ .
21-Desox~-21-chloro-prednisolone 17-retlr,oate A. 21-Desoxy-~l-chloro-prednlsolo.le ll-nitra~e __ .
21-Desoxy-21-chloro-prednisolc,ne (2 ~0) 7~/as added to a st rred) ice-cold solution o~ acetyl nj~tra1;e prepared lrorn acet1c acid (20 ml.)~ acatic anhydride (16 ml.) and fuming nitric aci.d (4 ml~) at 0C. Arter two hours at 0C" ~he solution was poured onto ice/water, and the pale yellow solid was ril1;ered orf' arld puri~i~d by chromatography on activated magneslum silica~e (~'lo-f~ ~
risil" ) .
B. 21-Desoxy-?l-chloro-predni.solone ll-nitrate 17-retinoate Thls compound was prepared by reactlon o~ the compound o~ step A wlth retl.noic acid~ trirluoroaoetic anhyflride and ~-~olu~nesul~nic acid in benzelle by kh~
method o~7 F~ample 8 B.
C. 21 ~ l-chloro-prednisolone 17-reti.noate A solution o~ 21-de~oxy-21~chloro-prednisolone nitrate 17-retinoate (0.5 g.) in glaclal acetic ~cid (40 ml.) was stirred wi~h zlnc dust ~4 gv) ror 5 minutes at rooln temperatllre. The %inc dust was t~lerl liltered or~/ ancl the f7iltrate was conoentrated aJ rOOm temperature and reduced pressure to a smal1 volume ~nd ~radQ~r ~
December 10~ 197 ~ o86-FTE-80 diluted with water. The ~itle cornpourld was extracted with ether and, arter evaporati.on to dryness, was puri-fied by chromatography on silica gel GF thick layer plates.
Exampls 16 Trlamcinolone 17-reti~oate 21-acetate .. . .. . _ A. Triamcinolone 21-acetate 11~,16a-bis-t~
lether h solution of triamcinolone 21-acetate (1 ~,) in pyridine (4 ml.) was treated wlth trimethylsilyl chlo-ride (1 g~; 100~ excess) at room temperature overnight~
The reaction mixture was then diluted with methylene chlo-rlde and washed with copper nitrate solution. ~vaporation of the methylene chloride yields the desired 1-~,16~-di-etherJ which can be used in part B withou~ furt~ler puri~
fication.
B. Triamcinolone 17-retinoate 21- _ etate 11~16~-bis-t ~
This compound was prepared by reaction of the compound of step A with retinoic acid, trifluoroacetic anhydride and p-tolu~nesulfonic acid in benzene by the mekhod of ExampJ.e 8 ~.
. ~0 -DeCember 1OJ 1975 1 ~ ~ 4905 JB/la C. Triamcinolone 17-re~inoate 21.-acetate A solution of triamcinolone 17-retinoate 21-ace-tate~ ,16a-bis trimethylsilyl ether (~.5 gO) in methanol (25 mlO) and 2N aqueous HCl (5 ml.) was.le~t to stand ~or one hour. The s~lvent was then removed in vacuo and ~he residue was taken up in ether. The etherea7 solution was washed with water, dried and evaporated. The product was puri~ied by chromatography on silica gel GF thick layer plates~ elution there~rom and recrystallisation, ` .
~ _ 81 -Docernber 10, lg75 ;~o86~ TE~82 ~ a FO~MULATION EXAMPLE ~
______ TOPICAL COSMETIC COMPOSITIONS OF
STh~OIDAL RETINOATES
A. Creams (1) Hydrocortisone 21-retinoate (Ool~) (4-Pregnene~ ,17a321-triol-~,20-dione 21-retlnoate) mg/g Hydrocortisone 21-retinoate 1~0 l~hite Petrolatum, USP 150~0 Mineral O11J USP 60.0 .Cetostearyl Alcohol r~.o ' Cetomacrogol 1000~ 22.5 4-Chloro-m-cresol 1.0 Puri~ied Water USP to make 1.0 g : ~ (2) Dexamethasone 21-retinoate (0.?5~) ~ o-16a-me~hyl-1,4-pre~nadlene~ J17a,21-triol-~,20-dione 21-retinoate~
m~
Dexamethasone 21-retinoate 2.5 Stearyl Alcohol USP 90.0 White P~trolatum USP 10.0 Propylene Glycol U.SP 50.0 Sodium Lauryl Sul~ate USP 10.0 4-Chloro-m-oresol 1.0 Puri~ied Water USP to make 1.0 g ' ~r~ k , :
December 10, 1975 (3) Betamethasone 17-valerate ~l-retinoate (0~5~) (9a-Fluoro-16~-methyl-1,4-pregnad1ene~ , a 21-t O1-~J 20-dione_17-valerate 21-retinoate) mg/g Betamethasone 17~valerate 21-retinoate 5.0 Sorbitan Monostearate 20.0 Polysorbata 60 15.0 Spermaceti USP 3Q.O
Cetostearyl A].cohol 100.0 2-Octyl-dodecanol 100.0 Benzyl Alcohol 10.0 Puri~ied Water USP to make 1.0 g ~ ." ' ' .
B. Ointments : (1) Hydrocortisone 21-retinoate (0.25~) ; mg/g Hydrocortisone 21-retinoate 2~5 Mineral 011 USP . 50l0 Propylene Glyool USP 50.0 : Petrolaturll USP to make 1.0 g (2) Hydrocortlsone ~l-retinoate (0.0?5~1 m~/g Hydrocortisone 21-retinoate 0.25 . 20 Polyethylene Glycol 400 USP 50.0 Polyethylena Glycol 4000 USP to make 1.0 ~ 83 December lO, 1975 2 o8 6 ~r~E~ ~ 8 1 1~6490S JB/la (~) Betametha.sone 21-retinoate (0.25~) (9~-Fluoro-16~-methyl-1,4-pregnadiene-11~,17a 21-triol-3,20-dione ~l-retinoate) _,_ Betamethasone 21-retinoate 2.5 Hydrogenated Lanolin 100.0 Mineral Oil USP 100.0 Propylene Glycol USP 50.0 Petrolatum USP to make 1.0 g C. Solutions (1) Hydro¢ort-lsone 21-retinoate (0.1~) mg/ml Hydrocortisone 21_retinoate 1.0 Alcohol USP 50.0 Propylene Glycol USP to make 1.0 ~ .
(2) Dexamethasone 21-retinoate t.5~1 Dexamethasone 21-retinoate 5.0 Polyethylene Glycol 400, USP to make 1.0 g (3) Predni olone 21-retinoate (0.25%) (I,4-Pregnadiene~ ,17a,21-triol-3 20-dione ?1-ret,inoate) mg/ml Prednlsolone 21-re-tlnoate 2.5 ; Isopropyl Alcohol NF 700.0 Puri~ied Water VSP to make 1.0 ml ... 81~ _ December 10, 1975 ~lO649C)$ 2086-FTE-85 D. Loti.ons (1) Hydrocortisone 21-retinoate (0~
mg/g Hydrocortisone 21-retinoate l.Q
Isopropyl Alcohol NF 500.0 Carbopol 934 3-Sodium Hydroxide USP q~s.
Puri~ied Water to make 1.0 g E. Gels (1) Betamethasone 1'7-valerate 21-retinoate (0.25%) ,~ m~/~
¦ 10 Betamethasone 17-valerate 21-retinoate 2.5 Alcohol USP 600.0 Ca~bopol 940 1.0 Monoisopropanolamine 0.1 iurified Water USP to make 1.0 (?) H~dro¢ortisone 21-retinoate (0.0~5~) ..
mg,~
Hydrocortisone 21-retinoate 0.25 Aloohol USP 150cO
Carbopol 940 ~ ~0.0 Propylene Glycol USP 150.0 Diisopropanolamine suf~iclent Purifled Water USP to make 1.0 g ' .
December lQJ 1975 2086-FTE-~6 1~36490~ JB/la FORMULATION EXAMPLE II
INTRALESIONAL COSr~ETIC COMPOSITIONS OF
STEROIDAL RETINOATES
A. Hydrocortisone 21-retinoate (0.1% to 0.5~) (1) mg/ml Hydrocortisone 21-retinoate 1.0-5.0 (sterile precip~tated) Monobasic Sodium Phosphate 6.o Dibasic Sodiurn Phosphate Anhydrous 0.5 Polysorbate 80, USP 0.1 Benzyl Alcohol, R 9,o Sodium Chlorlde, USP 2.5 Methyl p-hydroxybenzoate, USP 1,3 Propyl p-hydroxybenzoate, USP 0.2 Sodium Carboxymethylcellulose, USP 3.0 Disodium Edetate, USP 0.1 Water for In~ectlon, USP q.s. ad 1.0 ml .
(2) ~
Hydrocortisone 21-retinoate 1.0-5.0 (sterile precipitated) Polysorbate 80 USP 1.0 ~enz~l Alcohol, R ~ 9.0 Triethanolamine 98~ USP 7~6 Sorbitol 70% USP d.5 ml Hydrochloric Acid ~7~ 0~0035 ml Water ~or In~ection q.s. ad 1.0 ml December 10, 1975 2086-~TE- 87 S JB/la B. Prednisolone ~l~retinoate (0.1% to 0 5~) .
mg/ml Prednisolone 21-retinoate 1.0-5.0 (sterile precipitated) Mono~asic Sodium Phosphate 6.o Dibasic Sodium Phosphate Anhydrous 0.5 Polysorbate 80, USP ~ 0.1 Benzyl Alcohol, R . 9.0 Sodium Chloride, USP 2.5 Methyl p-hydroxybenzoate, USP l.~
Propyl p-hydroxybenzoate J USP O ~ 2 Sodium Carboxymethylcellulose, USP 3.0 Disodlum Edetate, USP 0.1 Water ~or In~ectionJ USP q.sO ad l.0 ml C. Dexamethasone 21-retinoate (0 .25~ to O . 5~) . m~/ml Dexamethason~ 21-retinoate 2~5-5.0 (sterile preaipikated) Monobaslc Sodium Phosph~te 6.o Dlbasic Sodlum Phosphate Anhydrous 0.5 Polysorbate 80, USP 0.5 Benzyl Alcohol, R 9,0 Methyl p-hydroxyben~oate, USP l.~
Propyl p-hydr-oxybenzoateJ USP 0.2 Sodium Chloride, USP 2.5 Sodium Carboxymethylcellulose, USP. ~.0 Disodium Ede~ate, USP 0.1 Water rOr Injection~ USP q.s. ad lrO Inl ~' ~
December 10, 1975 ~OG4905 JB/la D. Betamethasone 17-valerate 21-retinoate (0.25 to 0.5%) Betamethasone 17-valerate 21-retinoate 2.5-5.0 (~terile precipitated) Monobasic Sodium Phosphate 6.o Dibasic Sodium Phosphate Anhydrous 0.5 Polysorbate 80, USP 0.1 Benzyl Alcohol, R 9.0 Sodium Chloride, USP 2~5 Methyl p hydroxybenzoate, USP 1.3 Propyl ~-hydroxybenzoate, USP 0.2 Sodium Carboxymethyloellulose, USP 3.0 Disodium Edetate, USP 0.1 Water for In~ection, USP q.s. ad 1.0 ml ~ 88 -
3,20-dionef (1~) 16~-methyl~ luoro-1,4-pregnad~ene-11~,17~-cliol-~,20-dione, (14) 16c~-m~th~].-21-chloro-1>4-pregnadiene~ ,17a-diol-3~20-dlone, (15) 9a,21-difllloro-16a-methyl-1,4-pre~nadiene-11~,17a-diol-i ~,20-dionel .
(16) 16~-me~hyl-21 ~luoro-1,4-pregn~dîene-llp,17~-cl~ol-3,~0 dione, (1'7) 16~-m~t~yl~ hloro l,~-pre~nadiene-ll~ cllol-3~20-dio~e, (18) 9~J21-difluoro-16~-m~thyl-1~4-~reKnadiene~ J17a-dlol-3,20 dlone, (19) 16-methyler~ l-fluoro-1,4-pregnadiene 11~,17a-diol-0-dione~
~5 (~0~ 1~-methylene-21-chloro 1,~-p.regnadi.ene-11~,17a~d.iol--~,. 20-dionel (21) 9a,21-~i~luo o--16-methyl.en0-1~4-pregnadiene~ Jl7a-dlol-~,, 20-dior.e, : - 5 Deeember ~09 197~
1064905 og6-FriE- 55 22) 6~ uoro-l6a-methyl-lJ4-ple~na(~iene-~ 7a-diol-3, 20-dloneJ
(2~) 6a,9a-di~luoro 16~ me~hyl 1,4-pregnadiene~ ,17~-diol-3,20-dione, ~24) 6a,21-difluoro-16a-methyl-lJ4-pregnadiene-11~,17a-diol-~,20-dione~
~25) 6~-fluoro-16~-rhethyl-1,4~pre~nadiene-11~,17a-diol-~,20-dione, f (26) 6a, 9a-dlfluoro-16~3-methyl-1,4-pregnadiene~ ,17a-diol-3,20-dione, (~7) 6a,21-dlrluoro-16~-methyl~ r-pregnadiene~ ,1'7a-d~ol-3,~0-dion~, (28) 6~-fluor-o-16-rnethylene-1,4-pre~nadlene~ ,17a ~iol-~,20-dione, (2g) 6a,~-di~luoro-16 methylene-1,4-pregnadiene~lL~17a diol-~,20-dione, ~30) 6a~21-difluoro-1~-methylene-1,4-pregnadielle~ ,17a_ diol-3,20-dioneJ
(31) 6-~luoro 16~-me~hyl-1~4,6-pre~natriene-lla,17a-diol-3,20-dioneJ
(32) 6J 9a-dlrluoro-16a~methyl~ J 6-pregnatriene-11~,17a-diol~3,20-dion~J
(33) 6,~ difluox-o-16a-methyl-1,~.,6-pregnatriene-11~,17a-dlol-3,20-dlone, ~34) 6-.~luoro--15~-methyl~ ,5 ~re~ t.rlene-11~9 17a-diol-3~Z0-dione~
(35) 6,9a-dif'luoro-16~-.met~lyl 1~4~6-pregnatriene-11~17a-diol--3~20-dione~
Decernber 10, 1~75 1064905 J~/la (36) 6,2'1~di~1uoro-16p methyl-1,4,6--pregnatriene~llfl, 17a-d~ol-3,20-dione~
(37) 6-~luor~-16_methylene--lJ4,6-pregnatriene~ 17a_ diol-~20~dlsne, (~8~ 6~9a-difluoro-16-methylene-154~6-pregnatriene-ll~p 17a-dj.ol 3~20-dione, (39) 6,~1-di.fluoro--16-methylene-1~ 4, 6-pregna~riene-11~, 17a-cliol-~20-d~one, (40) ~I ph~nyl~ ,17a-di~droxy-16a-met~yl-20-keto-1~,6-pr~gnadieno ~J 2-c]pyrazole, ~41) 2'--phenyl-9~-fluoro-].l~J17a-dihydroxy-].6~-methyl-20-keto-~J6-pregnadieno~,'2-c]pyrazole, (42) 2' phenyl-9a-rluoro~21--chloro~ ,17~-dlhydroxy~
methyl-4,~ preg~adieno[~,2-c]p~razole, (4~ ) 2'-phenyl-11~17a-dihydroxy-16~-methyl 20-keto~4,6-~regnadieno~3J2.-c~pyrazole, (44) 2'-phenyl-9a~fluoro-1'1~17a-dihydro~ 16~-m~thyl-'20 keto-4,6 pre~nadi~no[~,2-a]p~I-aæol~
(45~ 2'-~phenyl~9a ~luoro--21~hloro~11P,17~-cllhy~roxy--16~ methyl--20 ~eto-4~6-pregnadieno~3,2-c¦pyrazole~
(46) 2'-ph~nyl~ ,17a-dlhydroxy 16-methylene-20-keto-~6-pre~n~dL~no~3,2~o]pyraæole/
(4r~) 2'-phenyl-9a-~luoro~11~,17a-dihydroxy-16-methylene-20-keto~4~6-pregnadienot3~2~c~pyra~ol~5 (48) 2'... phenyl-Sa~ oro-21-~hloro-ll~J17a~dihydroxy-16-nle~hylen~-20-keto-4,6~pre~nad'~eno~3l2_c~p~raæole~ and (49) ~'-phe~ 6~16a.-di~,ethyl-~t~-~'L~Ioro-11~917~-dihydroxy-` 20-keto-4,6-pregnadieno{3,2-c]pyra;~oleO
; - 56 -ber lO, 1975 ~o~6-~T~-57 1~64905 JB/la Isolate and purify eaC}l 0~ the resultillg produots in a marmer similar to that desoribed i.n Example 8A to obtain the ll-trlfluoroacetate ester of each o~ the above listed ll~hy~roxy starting compounds.
Bo 21-Desox ~ pregnene-11~,17~-di - ?0-dione 11-tri~luoroacetate 17-retinoates __ ___ In ~ manner simil~r to that described in E;xample 8B, treat each o~ the 49 ll-tri~luoroacetate esters PL e-pared in Examplel2~ in benzene and trifl-ioroac~ti~ an-hydrlde ak 0C.under an akmosphere o~ n$.tro~en and in the dar~ wi'ch ret,lnolc a¢id and p-toluellesul~oni~ aci~
Isolate and purify each o~ the resulting products ln ~
manner simllar to that desoribed in Example ~ to obtain the co~responding ll-trirluoroacetate 17-re'cinoate esters of the 49 11~17a-dihydroxy starting compounds listed in Ex~mple 12A.
C'. ~l-Deso~ ~rl~-llP 17c~-d:Lol-3,~0-dlone 1'~, retinoate3 I~ a mar~er similar to that described in Example ~C,~ ~r~t ~ach ~.~' th~ -trifluoroaoetate 17~^-retinoate esters prepared in EY~a~nple 12B in methanol wi.th sodium .~ b~nzoa~e at roorn temperature under an atmosphere o~ nitro-.
~en. Isolate and puri.~r each OI' the resultin3 produ~ts in a manner ~imilar to tha',, des~ribed in Example 8C to obtain th~ 17-retinoate est;ers o~ each o~ the ~9 4~.preg-: -- 57 ~ec~mber 10, 19l5 ~o86-FTE-~;$
~L06490~5 J:i3/la nene~ 17a-diol~ 0-dione startin~ ~on1pounc~s listed ln above Ex~mple 12A.
Example 13 Preparation of 21-retinoates, 17a-retinoates, and 17a,21-diretinoates of 4-pre~nene 3~20-dione~ and _ e ~ 1,~-bisdehydro derivatjves thereof -Pre~n~ne-21-ol-~20 dione 21-retinoate~ and 1 dehydro$ 6-deh~dro arld 1,6-bisdehydr-o derivatives thereor _s___ ~ __ In a manner slmilar to ~hat desori.bed in Example lA ~I) treat each of the ~ollowing l~-pregnen~-21--ol~3,~0-diones in dry tetrahydro~uran under an atmosphere o~ nitro gen in the dark ~lith N-retinoylimidazole and sodium me~;ho-xide and then ~.solat~ and pu.rif~ the r~sultln~ produc~s t,o obl;ain the corre~ponding 21.-r~tlnoate e~ c-s of tha ~olluwln~ 21-~hydrox~ ~3t~roids:
(1) 9c3-fluoro-1,4-pregnac~i~ne-11~,17c~21-triol-~,20-dion~, (~) 9a-chloro-lJ4-pregnadiene-11~, 17~J 21-triol-3,20-dlone, (3) 9~-fluoro-4-pr~nene-11~,17a,21--triol-~,20-dione, (4) ~a-chloro-4-pregnene~ J17~21_trlol-3J20~diolleg (5) 16a-me.hyl~1~4-pregnadlene-11~17a~21-triol-~20-dione~
December 10~ 1975 1~6490s JB/la (~) 9a-ChJ~OrO-1t~ thY1-1J~1-Pr~e~;I1ad:Len~ J17(X~21-triol-3,20-dlone, ~7) 16~-methyl-~1,4-pregnadien~ J 17aJ 21-triol-~,20-dione~
(8) 9a-chloro-16~-me~hyl-13 ~-pregnadisne-11,~517a~21-triol-3,20-~ione9 (g) 16~nethylene-1,4-pregnadiene-11.~,17a~ riol '3J 20-dione, (10 ) 16-meth;Y1ene-9a-Ch1OrO-iJ 4-Pregnadiene-11~B9 17aJ 21- ~
trlol-3,20-dlone,~
(1.1) 9~-f'luo~v-1~-methylene 1J 4-pregnadiene-ll~J17a~21-trlol-~J 20-dione (12) 16~-methyl-4-pregnene-11~17a,21-triol-~J20-dione J
(1~) 9a-:~luoro-16a~me!;hyl-4-pregnene-11,~,17a,21-t,rlol-3~20~dioneJ
(14) 9a-chloro-16a-methyl-4-pregnene~ 17a~21-triol 3'J ~!O ~dloneJ
. (15) 16~-m~hyl-4-pr~gnene~ ,17a,21-~riol-3,~0-dione, (16) ~u-~luoro_16~math~1_4~pre~nene-11~,17a,~1_tr.Lol_ 3~20-d.~one, (17) 9a Ch1OrO-16,B-me~ChY1-~4-Pre~I1ene~ Bg17~J 21~trlol 3,20 dloneJ
(18) 16-~m~thylene-4~pregnene~ ,,17a"21-triol ~,,20-dion~J
(19) 9a~l.uoro-16-methylene-4-pregnen~ J].7aJ21-triol-~,20 d~one, (20) 9a-~hloro-16 nie~hylene-4-pre~n~ne~ ,17aJ21 triol-3J20--dioneJ
: (21) 6a~ oro-1~4-~re~n~tdien~ J17a,21-triol-3~20-dione~
':
~ 5 -~b~-r 10, ~o~6 ~r~ 60 J~
~649~al5 ('~2) 6a~9a-dLfluoro-1,4-p~e~n~dien~pl7~"21-triol~
: 3,~0-dloneJ
(2~) 6a-fluoro-9~-chloro-1,4-pregrladiene-ll~.L7a,21.-triol-3,20-dioneg f24) 2-chloro-6u-fluoro-1,4-pregnadien~ 17~,21-triol~
3J20-dione, (25) ~-chloro-6a~9a-difluoro-1~4 pregnadiene-11~,17~, 21-triol-3,20-dione~
~26) 2~9~-dichloro 6a fluoro-1,4-pregnadiene~ 17a, ~0 21~triol-3,20-dione, (27) 6a-~luoro-l~-pregnene-llp,17a~ tr101-3,20-dlone~
(~8) 6a,9a-difluoro-4-pregIlene-llp,17a,21-~r:lol-~J20 dlon~
(29) 6a-~luoro-9a-chloro~ regnen~ ,17~21-triol-3,20-dloneS
(30~ 6a-~luor3-16a-meth~rl-134-pregnadiene~ /17~,21-triol-3~0-dione, (31) 6a,~ di.~luoro-16~-methyl-lJ~ e~rladi~n~ ,1'7a~ ;
21~tri~ ,2~-dlone~
.~, (3~) 6~J9~-dl~hlor~o-16a~m~pr~nadlen~_llp~l7a, 21-trlol~ 0-dione, (~3) 6~-~1uoro-16~-m~th~ 4-~re~n~di.ene-11~,17a~
~ri.ol..~,20-.~ne, (34) 6~y9a-di~luoro-16~-m~thyl-1~l~-pre~nad-ene~-llpJ17a, Xl-~riol ~,20-dione~
(35) ~ luoro~a-chloro-16~-me~hyl-1 J ~r -pre~r,~diene l:Lp~1'7aJ21-tr'.ol-3,20-~lo~ie~
D~cemher :I.0~ 1975 ~086-Fl~- 61 JB/la ~649~5 (36) 6a-f:Luor~ 6-rnethyleno-l~4-ple~lladierle ~ 7aJ~l-triol-3,20-dione, (37 ) 6a, 9a-dirluoro_l6_methylene_l, 4~pregnadiene-ll,B, 17a, 21-triol-3,20-dione, ~38) 6a L luoro-9a-chloro-16-methylene-1, 4-pregnadiene-11~,17a,21-triol-3~20-dione) (39) 16~-methyl-4,6-pregnadien~ ,17~,~1-triol-3/20 dioneJ
~40) 9a-fluoro-16a-methyl-4,6-pregn&di.ene-11~,17a,21 triol-~,~0-diorle, (41) 9~-ohloro-16a-m~thyl-4~6-pre~nadl~ne~ ,17a,~1-trlol-3,20-dione, (42) 16~-mekhyl-4 7 6-pre~nadiene~ ,17a,21 ~riol-3,20-~lor~e, (4~) 9a-fluoro-16~-methyl-~,6-pregnadiene-l.l~J17aJ~l-trlol..3,20-dlone, (44) 9a-chloro-16~-methyl-4,6-pregnadiene 11~,17a~21-trlol-~J 20 -dioile, (1~5) 16~ ethyle~e-4J6-pre~nadlene-llp,17al~1-trlol-3~20-dloneJ
(46) 9a-~luoro-16-methylene-4,6-pre$nadiene-11~,17a~21-tr.iol-3,20-dione, (47) g~-ohloro.~l6-m~tllylene-4~6-pre~lladiene~ 7aJ2 triol-~J20-dione, (48) 6-flll~ro-1,4,6-pregnatriene-11~,~7a9~1-triol-3J20-dlone 9 ~49) 6,9~-di~luoro-1,4,6-pregl~trien~ J17~,21-triol-~5 ~ 20-d ione r Decem~er 10, 1975 2086-FTi~-62 1064!~05 ~3/la (50 ) 6-f luoro-9a-cllloro-l, 4 ~ 6-pre&~r:l~trierle-ll,B, 17aJ 21-trlol-3,20-dione, (51) 6-ch].oro-1,4,6-pregnatriene~ 17a, 21-triol-~20-dione~
(52) 6~chloro 9a-~luoro-1,4~6-pregn~trlene~ ,17a~21--triol-~7~0-dione~
~53) 6,9a-dlchloro-1,4,~ pregnatriene-11~,17a,21-triol~
3J20-dione, (54) 6-methyl-1,4,6-pregnatriene-11~, 17a, '~l~tr~ol-3, 20-dion~, ~55) 6-methyl-9a-fluoro-1,~ -pregnatrierle-ll,B,17a,21-triol-3,20-dione J
(56) 6-methyl-ga-chloro 1,4,6-pre~natrie~e-11~,1'7a~21-triol-3~0~dione, (57) 6-azido-1,4,6-pregn~triene-11,~,17a,21 triol-~,20-`: dione, (58) 6-azido-9~-fluoro-1,4,6-pregnatrl~ne~11~17a,21-~riol-3,20-dione, (59) 6-azldo-9a ¢hloro-lJ4,6-pre3n~trlenQ-.ll~17~21 triol~,20-dione, (60) 6-fltloro-~,6-pregnadien~ ,17a,21-tli.ol ~,20-dion~, (61) 6~9a-clifluoro-4,6~pr~nadielle-ll,B,17~,21~trlol~3,20-dlone, (62) 6~fluoro--ga-chloro-4~6~~regnadien~-l]~l7a~2 triol~3,20~dlone, (63) 6-chloro-4,6-pregnadiene-11~,~17a,21~trio'-3~20-dlone, (64) 6-chloro-9a--~luoro-4,6~pre~nadlene~11B,17a,2].-triol~
, .
- 62 ~
D~ce.~r 10, 1975 2086-F'I'E-63 lOG490S JBJl~
3,20--dione, (65) 6,9~-dichloro-4,6-pregnadiene~ /17~21-triol-3~20-dione, (~6) 6-methyl-4,6-pregnadiene-11~,17a,21~r-tol-3g20-dione~
(67) 6-methyl-9~-fluoro-4,6-pregnadiene-11~,17a~21-~riol ~,20-dione, (68) 6-methyl--9a~chloro-4,6-pregnadiene-11~,17a,21-triol--3,20-dione, (69) 6 az~ do-l~5 6-pre~nadlene-11~,17921-triol-3~20-di3ne, (70) 6-azido-9a-~ oro-4,6-pre~nadiene-11~,17a/21-triol-[ 3,20-dionP, (71~ 6-az~do 9~-chloro-4,6-pregn~diene-llp,17~,21~~rioJ.-'I ~;J 20-diolle, (72) 6-fluoro-16~-m2thyl-1~4~6-preæna~riene-11~.17~,21-triol ~,20-dione9 ~73) 6,9a-di~luoro-16~-methyl-1, 4J 6-pre~natrien~-l.L~,17a, 21-triol-3,~0-dlone J
(71~) 6~rllloro-9a-ohloro-l~a~methyl-1,4J6-pre~natriene-11 7a~ triol~3~()-dlone~
~0 (75) 6 rluoro-16~-methyl-1,4,G pre~natrlene 11~]7 21-triol-3,'20-dione, ~76) 6,9~-di~).uoro-lG~-methyl-lJ4,~-pregnatriene~ ,17~, 2~ trlol-3,20 dlone, (7'7~ 6-~iuoro--9a-chloro~-16~-m~hyl-1,4,6-pregna~riene-~5 11~,17a~21-trlol-~5~0-di.one, (78) 5~fi.uoro-16~m~t~lyl~ne-.l r 4 ~ 6-pre~natrlene-1~, 17a 21-triol.-~20-dione, : - 6;j _ ~ece~e:r 107 1975 -~'.r.'L~.-64 1064905 JB/la (79) 6,9a-dichloro-16-methylene-1, 4J 6-pregnatriene~
17a~21-trlol~3J20-dlone, (80) 6-fluoro-9a-chloro-16-rnethylene~ ,5-pre~natrlene-11~,17a,21-trlol-~,20-dione, (81) 6-azldo-16a-methyl-1,4,6-pregn~trlene-11~17ag~1-triol-3,20-dione, (82) 6-azido-9a-fluoro-16a methyl-1~4,5-pregnatriene-,17a~21-triol-3~20-dione, (83) 6-azido-9a chloro-l6a-me'chyl--1,4,6-pre~natriene--11~17a,21~trlol-3,20-dione, ~84) 6-azido-16~-methyl-19 ~ J 5-pregnatriene~ ,17~,21-~riol-3J20-dione, (85) 6-azido-9a-~luoro-16~-methyl-1,1~,6-pregnatric~ne-11~,17a,21.-triol-3,~0-dlorle, (86) 6-azido-9a-chloro~16~-me~hyl--lJ~,6-pr:egnatriene-17a,21-triol-3~0-dione, (87) 6-azido~ met;hylene-1~4,6-pre~na~rlene-}1~,17a, 21-triol-3J20-dione, (88) 6-azido-9a-~luoro-16 methyl~ne 1,1~J6-pre~natrlene-. ~0 11~,17a,21-tr:i.ol 3,~0-cliono, (89) 6-azido-9a-cllloro-16-methylene-1,4~6-pr~snatiriene-11~,17aJ21-trlol~3~20_dione~
(90) 6-~luoro-1.6a-methyl~ ,6-pr~gnadien~ ,17a,21-trlol-~3,20-dione, (~1) 6,9a difluoro-16a~meth~J~4,6-pregnadi~ne~ ,17a, 21-triol-3,20-dione (g2) 6-~luoro~ chloro-16a-methyl-4,6-pregnadierle~
17,21 tr-iol-3,20-dione., - 6~ -. . .
DeCemher 1OJ 1~75 ~0/ -~TE-65 (93) 6-~luoro 16~-methyl-4,6-pregnadiene~ ,17a,21 triol-~,20-dione, (94) 6,9a-di~luoro-16~-methyl-4,6-pregnadiene-11~, 17aJ
21-triol-3~20-dlone, (95) 6-rluoro~9a-chloro-16~-methyl-4~6~pregnadiene-11~, 17~/21-triol- ~9 20-diona, (96) 6-~luoro-16-methylene-~J6-pregnadiene-11~,17a~21-triol-3,20-dioneJ
(97) 6,9a-di~luoro-16-methylene-4,6-pregnadiene~ ,17~, ` 10 21-triol-~,20-dione, ; (98) 6-~luoro-9a-~hloro 16-meth~lene-l~,6-pregrladiene-11~717a,21-triol-3,20-dlone, (99) 6-azido-16a~methyl-4~pregnadiene-11~,17a,21-~riol-, 3,20-dione, (100) 6-azido-9~-fluoro 16a-methyl-4,6-pregnadiene-11~,17aJ
~ 21-tr_ol-~,20-dione, j (101) 6-azido-ga-chloro-l6a-methyl-4J6~pregnadiene^ll~Jl7a~
:
21-~riol-~,20-dione, ; (102) 6-aældo-l6~-me~hyl~4,6-pregnadlene~ ,17a,21-triol-3~0-dlonel (103) 6-aæido-9a-fluoro-16~-meth~yl-l~6-pregnadiene-11~, 17~,21-triol-~,20-dion~, (104) 6-azldo-9~-chloro-16~-lneth~1-4,6~pregnadi.ene~
17a,~1-triol 3J23-d.ione, (iO5) 6~a~ido-16~meth~Jlene-4,6-pregnadiene~ ,17a,21-'criol-~,20~clione, (106) 6-azido-9~-~luoro-16-methylene-4,6-pregn~diene-11 17a,21-triol~3J20--dione, `
G5 ~.
Dece~ber ].0, 1~75 2086-FTE_66 106~ S J~3/la (107) 6-azido-9~,-chloro-16-meth~Jlene-4,6-pregnadi.ene-11~917~21-triol-3,20-diolle, (108) 9~-flu3ro-lg4-pre~nadiene-J(a,21-diol~ 20-trione, ~109) 9a-~luoro-4-pregnene-17~,21.~diol-3911,20-trlone, (L10) 16a-methyl-1~4-pregnadiene-17a,21-diol-3~11,20-tri.one, (111) 16~-methyl-1,4-pregnadiene-17~,21-diol~3,11~20-; - trione, ~:~
(112) 16-methylene-1,4-preænad~ene-17a,21-d~ol-3,11J20 trlone~
(113) 16a-methyl-4-pregnene-17a,21-diol-3,11,20-trione, (114) 9a-~luoro~16~-~ethyl-4-pregnene-17a,21-diol-3,11, 20-trione, (115) 16~-methyl-4-pregnene-17c~,21-diol-~,11,20-trione, (116) 9a-fluoro-16~-methyl-4-pre~nene-17a,21-diol-~,11, 20-trione, ~117) 16-methyl~ne-4-pre~nene-1 7aJ 21- CI iol-~,11,20-tric)ne~
(118) 9a6_i~1uoro_16_methylene_4_~re~Ilene_1'7~, 21_cl~ol_ ;J
~0 ll~0-trione~
(119) 6a-fluoro-1,4-pregnadien~ 17a,21-diol-3,11,20-trion~, (120) 6a~9~-difluoro-1~4-pre~nadiene-17a~21-diol-3,11, 20-krion~, tl21~ 6~-~luoro-4-pregnene-17a,21-diol-3,11~20-trione~
(122) 6aJ9~-dl~luoro~4-pregnene-17a,~1-diol-~311,20-trione9 ' - 6~ -December 10~ 1975 2086-~TE-67 106gL905 Js/la (123) 6a-fluoro~-16a-methyl-1,4-pregnadlene-17a"~ diol-3,11, ~o trioneJ
( 124 ) 6a, 9a-dillv.oro-16a-methyl-1,4-pregnadiene-17a,21-diol-3,11,20-trione, (125) 6~fluoro~16~-methyl-1,4-pre~nadiene~17a12].-diol-20-trione, ( 1~6 ) 6a, 9a~d~fluoro-16~-methyl-1,4-pregnadiene-17~.x/21 dlol-~11,20-trione~
( 127 ) 6a ~luoro-16-methylene-134-pregIladiene-17~,21-diol-~,11,20-trione, (128) 6a~9a-di~luoro-16-methylene-1,4-pregn~diene-].7~,21-diol-3,11,20-trione, (129) 1,4,6-pregnatrlene-17aJ21-diol-3J11,20-trione, (130) 9a-rluoro-lJ4,6-pregnatriene_17a,21_diol_~,11,20_ trione, (131) 4,6-pregnadiene-17aJ21-diol-3,11,20-triorle, (13~) 9a-fluoro-4,6-pre~rladlene~l7~2l-d~iol-3~ll,2()-~rione~
(133) 16a-me~h~1-1,4 J 6-pregnatriene 17~,21-dlol-3~ 0-trlone, ~ (13~) 9~ 1UOrO-16a-me~hY1-1~ 6-Pre~ atriet1e-1~ 21-diO1 3~ 2O-triOr1 (135) 16~B-m~!thY1 1J 1I~ 6-Pr~:~g11atr:lene-17a~21-diO1~ ~j9 11J2 trlone~ ~
(136) 9a-fluoro-16,~-me~hyl~-1,4,6-pregnatriene-17a,21-dio~-3J 11~ 20-trlone, (1~7) lG-methylene-:L,4J6-pregnatriene~1.7c~,21-dlol-3,11., 20-trlone, - 67 _ ~ecem~er 10, 1975 106490S JB/la (138) 9a-flluoro-l6~mekhylene~ J 6 pregnatriene-17~,21-diol-~,11,20-trione, (139) 6-~luoro-1,4,~-pregnatrle~le-17a~21-di.ol-3,11~20-tr ioneJ
(140) 6,9a-difluoro-1,1~,6-pregnatriene-17~,21-dlol-3,11, 20 trione7 (141) 6-chloro-1~4f6-pregnatriene-17~,21-diol-3~ 20-trlona, ~142) 6-chloro-9a-~luoro-1,4J6-pregnatriene-17a,~1-diol 35}1,20-trione, (143) 6-methyl-lJ4,6~pregnatriene-17a,~1-diol-3,11,20-trlone J
(144) 6-methyl-9a-~luoro-1,4,6-pregnatriene-17a~21-diol-- 3,11,20-trione, ~145~ 6-azido-1,l~,6-pregnatriene-17a,21-diol-3~ 0-trione~
(146) 6-azi~o-9a-fluoro-1,4,6--pregnatriene-17~,21-diol-3,11,20-trione, (14'7) 6-f'luoro-16a-nlethyl-1,4,6-pre~na~riene-17a,21-diol-~11,20 trioneJ
~ 8) 6,9a di~luorc-16a-methyl-1,l~,6-pregnatriene-17a,21-d~ol-3,1},~0-trlone, (149) 6-flu~ro-16~-methyl 1~4.,6-pregnatriene-17a,21-dlol 3,11.~20-~rione~
~5 ~150~ 6,9~-di.~luoro--16~-methyl~1,4,6--pregnatriene-17a,21-diol--3,11,20~trioneJ
(151) 6-~luoro-16-mel;hylene-194,6~pregnatriene-17a,21-diol-3,11,~0-trione, Decem~er 10~ 1~7 - 20~6~FTE-69 J~
(152) 6,9~-di~luoro-16-m~thylene-1,4,6-pregnatriene-17a,21-dioi-~,11,20-trione, (153) 6-azido-16a-methyl-1/4,6-pregnatriene-17a,21-diol-. 3,11J 20-trione, (154) 6-azido-9a-Lluoro-16a-methyl-1,4,6-pregnatriene-17a32'~i.ol-~,11,20~trione, ¦ ~155) 6-azido-16B-methyl-1,4,6-pregnatriene-17~,21^diol-3,11,20-trione, (156) 6-azido-9a-fluoro-16~-methyl-lJ4,6-pregnatrlene-17~,21-diol~ O trione, ~157) 6-azido-16-methylene-1,4~6-pregrla~riene-17a,21_ diol-3, 11J 20-trione, (158) 6-azido-9a-~luoro-16-methylene-1,1~,6-pregnatriene-. 17~1-diol-~,11,20-trione, !, 1$ (159) 9a,11~-dichloro-1,4 pregnadiene-17a,21-diol-~,20 dione, : (160) 9a~chloro~ luo~o lJ4~-pre~nadlene--17aJ21--dlol-3J20-dione~
t161) ~a,ll~-dlchloro-1,4,6-p~eglla~rlene-17a~21-diol-. ~0 3J20-dione~
(162) 9a-chloro~ -fluoro 1~4J6-pregnatrlene-17aJ21-diol-3~20-dione, (16~) ga511~ dlchloro-l~-pregnene 17a,~1-diol 3,20-dione, ~ (164) 9a-chloro~ -f`luoro--4-pregnene_17aJ21-diol-3,20-~5 dione, ~165) 9~ -di¢llloro~4,6~pregnadi~ne-17~21~diol-~,20-dione, December 10~ 1975 2086-F'~E- 70 1~6490S JB/la (166) 9a-chlolo llp-rluoro-496-pregnfldi.ene-17a,21-diol-3,20-dione, (167) 9a,11~-dich].oro-16~-methyl~ pregnacliene-17a,21-diol-3,20 dlone, (168~ g~-chloro-ll~-fluoro-l6~-methy~ 4-pregnadiene 17a,21-dlol--3,20-dione, (169) 9a,11~-diohloro-16a methyl~l,4,5-pregn2triene 17a, ; 21-dlol-3,20~dione~
(170) 9~-chloro~ luoro-16a~methyl-1,496~pregnatriene-17a,21-diol-~,20~dione, (171) 9~ -dichloro-16~-methyl-1,4--pregnadiene-17a,21-diol-3,20-d-lone, (172) 9~-~chloro-11~-~].uoro-16~-methyl-lJ4-pre~nadiene-17~,21-diol-3,20-dioneJ
(173) 9a,11~-dichloro-16~-methyl-1,4,6-pregnatriene-17~, 21-diol-3~20~dione, (174) 9a chloro-11~-~luoro-16~-me~hyl-1,4,6-pregnatr~ene 17~,21~dlol-~,20-dione~
~175) 9~J ll~-dlohloro 16-m~th~leno-~1,4-pregnadiene-17a~21-diol-3,20-dioneJ
(176) 9a-ohloro-ll~-~luoro-l~-methylene-194-pregnadiene-1'7a,21-dlol-~,20-dione~
(177) 9a,11~-dichloro-16-methylene-1~4,6-pregnatriene-17a,21-dlol-3,20-dione, ~178) 9a-chloro~ -fluoro-16-methylens-1,4,6-pregnatriene-17a,21-diol-3,20-dione, ~179) 6~-fluoro-9a,11~-dlchloro~ 4~pregnadiene-17a,21-dlol-~,20-dione, ecember 10, 19~5 2086~-l?TE-71 4g 0 5 JB/la .
(1~0) 6u-fluoro-9~ dichloro~ pre~nene--17a,21-diol-3,20-dione, (181) 6-fluoro~9a,11~-di.ehloro-16~-methyl-1,1~-pregna~
diene-17a,?l-diol 3,20-dione, (182) 9~ -diohloro-6a-fluoro-16~-methyl-1,4-pre~na-diene-17~,21-diol~3,20-dione, (183 3 9aJll~-dichloro-6a-~luoro-1~-me~hylene-1,4-pregna-diene-17~.,21-diol--3J20-dione, (184) 6a~1uoro-9u,11~-dichloro-16a-me~hyl-4-pregnsne-10 17a,~1-diol-~,20-dione, (185) 6a-rluoro-9~ -d:Lchloro-16~-methyl-4-pregnene-17a~21-diol-3J20-dioneJ
(186) 6~-~luoro-9a.,11~-dichloro-16-methylene-4-pregnene-17~,21-diol--3,20-dione, (187) lJ4-pregnadiene-11~,21-diol-~J~0-dioneJ
(188) 9~-fluoro-1,4-pregnadiene~ ,21-diol 3J20-dioneJ
(189) 4-pre~nene-11~,~1-diol-3J20-dione, (190) 9a-~luoro-4-pregnene~ ,21-diol-3,20-dione, (191) 16~-nlethyl-1,4-pregn~dlene-11~,21-dlol-~20-dione, (19~) 9~-~luoro-16a~methyl-1,4-pregna~iene-11~,21-dlol-3,20-dione, (193) 16,~-methyl-1,4-pre~nadlene-ll,B,21-dlol-3,20-dione, (194) 9~--f`1uoro-16~-rnethyl-].Jl~pregnadiene-11~,21-diol-3,20-d~one, (195) 16--methylene-1~4-pregnadiene~ ,21-di.ol-3,20-dione~
(196) 9~-rluo~o-16-rne~hylene-},4-preglladierle-ll,B,21.~diol-3~20-dione~
December 10~ 1975 2086-FTE-7~
1~64905 J~a (197) 16~-methyl~ pregnene 11~ diol~3,20-dione, ~198) 9~-fluoro-16-~-methyl-4-pregnene-11~,21 diol-3,20- q dioneJ
(199) 16,R-methyl-4-pregnene-ll,B,21 divl-3"2()-dioneJ
(200) 9a-fluoro~16~~methyl-4-pregnene-11~,21-diol.~,~20-d~one, : (201) 16-methylene-4-pregnene~ J21-~1Ol~3,20-dione, .
(202) 9a~fluoro-16-methylene-4-pregnene~ ,21-d~ol-3J20-dione, (2G~) 6f~-~luoro-16a-met,hyl-1,4-preg~adiene-ll~J21-diol-3,20-dione, (204) 6a,9a-dlf~luoro-16-~ m-thyl-1,4-pregnadiene~ll~l^.diol-~,~0-dione, (205) 6a-fluoro-16~~n,ethyl-lJ4-pregnadiene-11~21-d:lol-~ 15 ~J20-dione, ; (206) 6~1~a~diiPluoro-16~-methyl-1,4-pregnadielle-diol-~,20-dione, (~07) 6a~f'1uoro-16~m~thylene-1,4-pregnadiene 11~,21-~iol-3, 20-dioneJ
(208) ~9-~-diPluoro-16-meth~le.n-t-1,l~-pregrlac~iene-11~, 21--dio].-~,20-dione, (209) 6r~-rluoro-l6~-methy~ 4-pregnadien~ 2l-dioL
3J20-dione, ~210) 6Jgfa-di~luoro~ -methyl-lJ4-pre~nadiene-llpJ2 diol-~20-dione~
(211) 1,4-pregnadiene-'ll.,B,16c~,J17ag2'1-tetrol-~,20--dioneJ
~12) ~ luoro-1,4-pregnadiene~ ,16ayl7aJ21-tetrol~
~, 2C-clloneJ
.
. _ 7~ ~ .
December L0) 1.9 ~6-~'L'E~7 ~ o~;~9 ~ 5 2~1a (213) 4--pregnene-11~16~,17~21-~etrol-~J20-diorleJ
(214) ~a~fluoro-4-pregnene~11~16a,17c~,21-tetrol--3,20-dione, (~15~ 1~4-pregnadiene~11~,16a,17a,21~t,etrol~~ J 20-d~.orle 16-ace~ate,-~216) 9a~~1uoro~1,4~pregnadlene-ll~J16~17a,21-tetrol-0-dlone l~-acetate, (217) 16~,17a-isopropylidenedioxy-1,4~pregnadiene~ /21-diol-~,20~dlon~, (218) ~c~-~luoro-16~,17a-isopropylidenedioxy~l,l~--pregna~
diene~ 21 diol-3,20-dlone, (219) 6a-fluoro-lJ4-pregnadiene-11~, 16~J 1.7a,21-tetrol-3,20--d~ons, (220) 6~,9a-difll;,oro-1,4-pregnadiene-11~,16u,17a,~1-tetrol~
3,20-dione, (~21 ) 6cl-riuoro-l 1 4-pregnadien~ ,16a,17a,21-tetrol-O-d Lone 16-a~etate (X2~) 6a,g~-d~ uoro~ pre~adien~ 16 tetrol-3l~`0-cllon~ 16-acetat~
Z0 (~23) 6c~.flu~ro-]6~,17a-isopropylldelledioxy-1,4-pre~na-diene-11~3~ diol.-~0-~ione, (2~1~) 6a,~~di~1uor-o-~1ha,17a-lsop.ropylidenedloxy-1,4-: pre~nadiene~ l-diol.-~,20-dione, ~225) 6~-~luoro-1,4--pregnadiene-11~17a,21-triol~3,20-dlone~
~226) 6~9a-di.fluoro-ly4-pre~nadiene--11~,17a,21-t;riol-3,20-dion~:, ~ 7;~
DeCember 1OJ 19 1 ~ 6 49 ~ S JB/la ~2~7) 6~--fluoro--16M-methyl-1"4-pregnadiene~ ,17~,21-tri.ol-~,20-dione, (22~,) 6~,9~dl~1uoro-].6~~methyl-1,4-pregnadiene-11~,17a, 21-triol-~,23-dione, (229) 6~-~luoro~ methyl-1,4-pregnadiene~ ,17~J21-~riol-3,20-dione, (230) 6~,9~-dlfluor~-16~-methyl~ -pregna~iene~ ,17a, 21-triol-~,20-dione~
(231) ~-rluoro-16-methylene-1,4-pregnadiene-11~,17-~
21-triol-3,20-dione, (232j 6~,9~-di.,luoro-16-methylerle-1,4-pregnadiene-ll~J17~, 21-triol--~,20-dioneJ
(Z33) 2 7 -phenyl-11~,17~,21-trihydroxy-20-keto--4,6-pre~-~ nadieno[3~2-c~pyrazole, ; 15 (2~4) 2'-phenyl-6-azido-11~,17a,21-trihydroxy-20-k~o-4,6-pregnadieno~3,2-o]pyrazole, (235) 2'-phenyl-6-methyl.-11~.,17~21-l,ri.hydroxy-20-k~to-4J6-pregnadieno~,2-o]pyrazolc, (~36 ) ~ ' -ph~ny~ ~ G- rluoro ~ rj'~J 21~t~1hydr~xy~20-k~to-; . 20 4~6-pregnadieno~,2-c]pyrazole, ~2~7) 2'-phenyl~ ,17~,21-tr~}lydroxy-16~--methyl-~0-keto--4,6-pregnadienol3,~~c]py~razol~ ~
(2~8) ~'-phenyl-6-azido-11~,17~,,21-trihydroxy-16a-methyl 20-keto-4,S-pregnadieno[3,2-c]pyrazole, (2~9) 2'~phenyl-6 methyl~ J17~,~1-trihydroxy-16a-tnethyl-~0 keto-4J6-pre~nadieno E3, 2-c Ipyraz~leJ
(~40) 2'-phenyl-6-fiuor~-llp,1'7a,21-trlhydroxy-16a..me~hyl-20-~eto-4J6-pregnadieno~,2-c]pyrazole, .
7 1~ .
Det~mber 1OJ 1975 ~o86-FT~-75 1064905 JB/la (241) 2' phenyl~ L7~,21~rlhyrlroxlJ-16~~rllethyl-20-keto-4,6-pregnadieno~3J2-c]pyrazole, (242~ 2'-phenyl~6-azido-11~9 17J 2~-trlhydroxy-16~-rnethyl-20-keto--~,6-pregnadieno~,2-c~pyrazole, (24~ phenyl-6-methyl 11~17a,21-trihydroxy-16~,-methyl-20-ketcJ-4,6-pregnadieno[3,2 c]pyrazole, (244) 2'-phenyl-6-fluoro-118,17~21-trlhydroxy-16~-metllyl-20-keto-4,6-pregnadieno~3~2-c~pyrazole, (24~) 6-~luoro~16c~-methyl-1,4~6 ~regnatr~ne-llB,21-dto].-~SJ 20~ ioneJ
(246) 6a-fluoro-g~-chloro-16~-methyl~ -pregn~diene-11 ~l-diol-3~20-d.l.one, (~47) 6~ uoro-g~ -dichloro-l6~l7~ sopropyl.id~e . , dioxy-1,4-pregnadiene-21.-ol-3,20-dione, (~48) 6,16-dimethyl-1,4,6,15-pregnatetraene-11~17~121-j:
triol-3~20-dione, ~249) 1~ me'ch~l-1,4J8-pregnatriene~ ,17u,21-triol-3,20-dione 17-propionate~
(250) 9a ~luor~ ,21-dihydro~-3,11-tlikeko~ pre~-: 20 ~ladLe~otl7aJ16~_d]oxaæol~ne, (251~ -ol~loroethoxy)-6-fo~my~1-9~ oro-16~,17~-lso-propylidenedioxy-~,5.-pre~llclt~iene-11~,21-diol-20-one~
(25~) 2a-methyl-6-f}uoro~-4J6-pregnadiene-11~,16~,17~J~1 tetrol-3,20~dione, (25~) 2a-methyl-6,9~-dj.fluoro 4~6--pregnadiene~ 16a, 17a.,21~tetrol-~20-di~e, ~25~ 1'7a--chloro~ t-pregnadier~ 21-diol 3,20-dion~g .~ece~her 10, 1975 20~6-~TE_76 10649~5 JB/la (255) 6~methy'l-4-pragnene~ ,17a,21-triol-3~20-dione J
(256) 6a-me~hyl--1,4-pregn~diene~ ,17a,21-triol-~,20-dioneJ
~257~ 6a,16~-dlmethyl-4-pregnene~ 917aJ21-trlol-3~20-dione, (258) 6a~16~-dlmethyl-4-pregnene~ 31'7a,21-triol-~920-dlone$
(259) 6u~16a-dimethyl-lJ4-pregnadiene-11~17~.,21-trlol ~i, 20-dione,, (260) 6a516~-dlmethyl-1,4-pregnadie~e~ 7C~J 21-triol-3~20-dione, (~61) 6a-methyl~9a-~luoro.. 4.. ple~llene~ ,17a~21_t~iol_~,20_ dioneJ
(262) 6~--meth~1-9a fluoro-1,4--pregrad.~ene-11~,17c~,21-triol-3,20-dione, (263) 6a,16~ dlmeth~rl~9~ rluoro-~-pregnene-11~,17a,21--trlol 3,20-dion~, (264) 6CY, 16~-dimethyl-~ oro-4-pr~gn~ne-11~,1'7a~21-' triol~ O~dlon~J
'~ 20 (265) 6aJ16~-~lm~thyl~9a-r'luoro-1,4--pregnad.i.ene-11~,17aJ
21-triol-3,20-dione, and (~66) 6~,16~-dilllethyl 9a-f`luoro-1,4-pregnadiene-11~,17a, 21 triol-3~20~-dione.
' Dec~mbe~ ~0, 1~75 ~ 086~TE-77 B. l~-Pregnene~17a,2J-dio ~J20 dione 17-r-~tinoates In a manner ~imilar to that described in Rxample 5A treat each o~ the 4-pregnene-17~,21-diol-~,2Q-dione 21-retinoates prepared in Example 13A (i.e. the 21-re~i-noates o~ starting compo~nds 1-186, 211-216~ 219-222~
; 225_244, 248 and 255-266~ with cuprous iodide and methyl lithium in dry tetrahydrofuran~ and isolate and purify the resulting product substantially as described to obtain the 17-retinoates o~ the ~-pregnene-17~,21-diol 3,20-diones numbered 1-186, ~ 216, 219-222~ 225-244, 248 and 255-266.
C. 4-Pregnene-17a~21-dlol-~,20-di n~ 9 In a manner similar to that described in Example 6A~
treat each of the 4-pregnene-17a,21-diol-3~20-dione 17-retlnoates prepared as desorlbed in Example 13B w~kh N--retinoylimidazole and .soclium methoxide under a~ atmosphere o~ nitrogen in the dar~. Isolate and puri~y each of' the resulting products subs~an~ially as described to obtain the 17,21~-diretinoat~ of the ~-pregn~ne-17~,21-dioJ.-3,20-diones numbered 1-186~ 211-216, 219-222, 225-244 248 and 255-266.
~ecember 10~ 1975 2086~F'r~_78 1~69L9~i5 ~f/la Example 1 4-Pregnene~ ,17a~21-triol-3,20-dione 21-9910 cis-re~inoate and the 1 dehydro analo~ the~eof In a manner similar to that described in ~xample lA (I~ treat each o~ 4-pregnene 11~17~"21-triol~ 0-dione and 3.,4~pregnadiene-11~,17a,21-triol~~,20-dione in dry tetrahydro~uran under nitrogen and in the dark ~i~h N ~9,10-cis-retinoyljlmidazole and sodium me~hoxlda.
Isolate and puri~y the resulting p~oducts in a manner similar to that descl~ibed in .ExampJ.e lA (I) to obtain 4-pregnene~ ,17~,21-triol-3,20-dlone 21-~,10 c,i.s-reti noat~ and l,4-pregnadiene-11~,17a~ triol-3,20-dione 21-9,10-cls-retinoate, respectivelyO
. - 7~ -l~ece~e-r 1~ 75 ~086-r`i`~-7~
~OG49~$ J~/la Example 15 .' ~ .
21-Desox~-21-chloro-prednisolone 17-retlr,oate A. 21-Desoxy-~l-chloro-prednlsolo.le ll-nitra~e __ .
21-Desoxy-21-chloro-prednisolc,ne (2 ~0) 7~/as added to a st rred) ice-cold solution o~ acetyl nj~tra1;e prepared lrorn acet1c acid (20 ml.)~ acatic anhydride (16 ml.) and fuming nitric aci.d (4 ml~) at 0C. Arter two hours at 0C" ~he solution was poured onto ice/water, and the pale yellow solid was ril1;ered orf' arld puri~i~d by chromatography on activated magneslum silica~e (~'lo-f~ ~
risil" ) .
B. 21-Desoxy-?l-chloro-predni.solone ll-nitrate 17-retinoate Thls compound was prepared by reactlon o~ the compound o~ step A wlth retl.noic acid~ trirluoroaoetic anhyflride and ~-~olu~nesul~nic acid in benzelle by kh~
method o~7 F~ample 8 B.
C. 21 ~ l-chloro-prednisolone 17-reti.noate A solution o~ 21-de~oxy-21~chloro-prednisolone nitrate 17-retinoate (0.5 g.) in glaclal acetic ~cid (40 ml.) was stirred wi~h zlnc dust ~4 gv) ror 5 minutes at rooln temperatllre. The %inc dust was t~lerl liltered or~/ ancl the f7iltrate was conoentrated aJ rOOm temperature and reduced pressure to a smal1 volume ~nd ~radQ~r ~
December 10~ 197 ~ o86-FTE-80 diluted with water. The ~itle cornpourld was extracted with ether and, arter evaporati.on to dryness, was puri-fied by chromatography on silica gel GF thick layer plates.
Exampls 16 Trlamcinolone 17-reti~oate 21-acetate .. . .. . _ A. Triamcinolone 21-acetate 11~,16a-bis-t~
lether h solution of triamcinolone 21-acetate (1 ~,) in pyridine (4 ml.) was treated wlth trimethylsilyl chlo-ride (1 g~; 100~ excess) at room temperature overnight~
The reaction mixture was then diluted with methylene chlo-rlde and washed with copper nitrate solution. ~vaporation of the methylene chloride yields the desired 1-~,16~-di-etherJ which can be used in part B withou~ furt~ler puri~
fication.
B. Triamcinolone 17-retinoate 21- _ etate 11~16~-bis-t ~
This compound was prepared by reaction of the compound of step A with retinoic acid, trifluoroacetic anhydride and p-tolu~nesulfonic acid in benzene by the mekhod of ExampJ.e 8 ~.
. ~0 -DeCember 1OJ 1975 1 ~ ~ 4905 JB/la C. Triamcinolone 17-re~inoate 21.-acetate A solution of triamcinolone 17-retinoate 21-ace-tate~ ,16a-bis trimethylsilyl ether (~.5 gO) in methanol (25 mlO) and 2N aqueous HCl (5 ml.) was.le~t to stand ~or one hour. The s~lvent was then removed in vacuo and ~he residue was taken up in ether. The etherea7 solution was washed with water, dried and evaporated. The product was puri~ied by chromatography on silica gel GF thick layer plates~ elution there~rom and recrystallisation, ` .
~ _ 81 -Docernber 10, lg75 ;~o86~ TE~82 ~ a FO~MULATION EXAMPLE ~
______ TOPICAL COSMETIC COMPOSITIONS OF
STh~OIDAL RETINOATES
A. Creams (1) Hydrocortisone 21-retinoate (Ool~) (4-Pregnene~ ,17a321-triol-~,20-dione 21-retlnoate) mg/g Hydrocortisone 21-retinoate 1~0 l~hite Petrolatum, USP 150~0 Mineral O11J USP 60.0 .Cetostearyl Alcohol r~.o ' Cetomacrogol 1000~ 22.5 4-Chloro-m-cresol 1.0 Puri~ied Water USP to make 1.0 g : ~ (2) Dexamethasone 21-retinoate (0.?5~) ~ o-16a-me~hyl-1,4-pre~nadlene~ J17a,21-triol-~,20-dione 21-retinoate~
m~
Dexamethasone 21-retinoate 2.5 Stearyl Alcohol USP 90.0 White P~trolatum USP 10.0 Propylene Glycol U.SP 50.0 Sodium Lauryl Sul~ate USP 10.0 4-Chloro-m-oresol 1.0 Puri~ied Water USP to make 1.0 g ' ~r~ k , :
December 10, 1975 (3) Betamethasone 17-valerate ~l-retinoate (0~5~) (9a-Fluoro-16~-methyl-1,4-pregnad1ene~ , a 21-t O1-~J 20-dione_17-valerate 21-retinoate) mg/g Betamethasone 17~valerate 21-retinoate 5.0 Sorbitan Monostearate 20.0 Polysorbata 60 15.0 Spermaceti USP 3Q.O
Cetostearyl A].cohol 100.0 2-Octyl-dodecanol 100.0 Benzyl Alcohol 10.0 Puri~ied Water USP to make 1.0 g ~ ." ' ' .
B. Ointments : (1) Hydrocortisone 21-retinoate (0.25~) ; mg/g Hydrocortisone 21-retinoate 2~5 Mineral 011 USP . 50l0 Propylene Glyool USP 50.0 : Petrolaturll USP to make 1.0 g (2) Hydrocortlsone ~l-retinoate (0.0?5~1 m~/g Hydrocortisone 21-retinoate 0.25 . 20 Polyethylene Glycol 400 USP 50.0 Polyethylena Glycol 4000 USP to make 1.0 ~ 83 December lO, 1975 2 o8 6 ~r~E~ ~ 8 1 1~6490S JB/la (~) Betametha.sone 21-retinoate (0.25~) (9~-Fluoro-16~-methyl-1,4-pregnadiene-11~,17a 21-triol-3,20-dione ~l-retinoate) _,_ Betamethasone 21-retinoate 2.5 Hydrogenated Lanolin 100.0 Mineral Oil USP 100.0 Propylene Glycol USP 50.0 Petrolatum USP to make 1.0 g C. Solutions (1) Hydro¢ort-lsone 21-retinoate (0.1~) mg/ml Hydrocortisone 21_retinoate 1.0 Alcohol USP 50.0 Propylene Glycol USP to make 1.0 ~ .
(2) Dexamethasone 21-retinoate t.5~1 Dexamethasone 21-retinoate 5.0 Polyethylene Glycol 400, USP to make 1.0 g (3) Predni olone 21-retinoate (0.25%) (I,4-Pregnadiene~ ,17a,21-triol-3 20-dione ?1-ret,inoate) mg/ml Prednlsolone 21-re-tlnoate 2.5 ; Isopropyl Alcohol NF 700.0 Puri~ied Water VSP to make 1.0 ml ... 81~ _ December 10, 1975 ~lO649C)$ 2086-FTE-85 D. Loti.ons (1) Hydrocortisone 21-retinoate (0~
mg/g Hydrocortisone 21-retinoate l.Q
Isopropyl Alcohol NF 500.0 Carbopol 934 3-Sodium Hydroxide USP q~s.
Puri~ied Water to make 1.0 g E. Gels (1) Betamethasone 1'7-valerate 21-retinoate (0.25%) ,~ m~/~
¦ 10 Betamethasone 17-valerate 21-retinoate 2.5 Alcohol USP 600.0 Ca~bopol 940 1.0 Monoisopropanolamine 0.1 iurified Water USP to make 1.0 (?) H~dro¢ortisone 21-retinoate (0.0~5~) ..
mg,~
Hydrocortisone 21-retinoate 0.25 Aloohol USP 150cO
Carbopol 940 ~ ~0.0 Propylene Glycol USP 150.0 Diisopropanolamine suf~iclent Purifled Water USP to make 1.0 g ' .
December lQJ 1975 2086-FTE-~6 1~36490~ JB/la FORMULATION EXAMPLE II
INTRALESIONAL COSr~ETIC COMPOSITIONS OF
STEROIDAL RETINOATES
A. Hydrocortisone 21-retinoate (0.1% to 0.5~) (1) mg/ml Hydrocortisone 21-retinoate 1.0-5.0 (sterile precip~tated) Monobasic Sodium Phosphate 6.o Dibasic Sodiurn Phosphate Anhydrous 0.5 Polysorbate 80, USP 0.1 Benzyl Alcohol, R 9,o Sodium Chlorlde, USP 2.5 Methyl p-hydroxybenzoate, USP 1,3 Propyl p-hydroxybenzoate, USP 0.2 Sodium Carboxymethylcellulose, USP 3.0 Disodium Edetate, USP 0.1 Water for In~ectlon, USP q.s. ad 1.0 ml .
(2) ~
Hydrocortisone 21-retinoate 1.0-5.0 (sterile precipitated) Polysorbate 80 USP 1.0 ~enz~l Alcohol, R ~ 9.0 Triethanolamine 98~ USP 7~6 Sorbitol 70% USP d.5 ml Hydrochloric Acid ~7~ 0~0035 ml Water ~or In~ection q.s. ad 1.0 ml December 10, 1975 2086-~TE- 87 S JB/la B. Prednisolone ~l~retinoate (0.1% to 0 5~) .
mg/ml Prednisolone 21-retinoate 1.0-5.0 (sterile precipitated) Mono~asic Sodium Phosphate 6.o Dibasic Sodium Phosphate Anhydrous 0.5 Polysorbate 80, USP ~ 0.1 Benzyl Alcohol, R . 9.0 Sodium Chloride, USP 2.5 Methyl p-hydroxybenzoate, USP l.~
Propyl p-hydroxybenzoate J USP O ~ 2 Sodium Carboxymethylcellulose, USP 3.0 Disodlum Edetate, USP 0.1 Water ~or In~ectionJ USP q.sO ad l.0 ml C. Dexamethasone 21-retinoate (0 .25~ to O . 5~) . m~/ml Dexamethason~ 21-retinoate 2~5-5.0 (sterile preaipikated) Monobaslc Sodium Phosph~te 6.o Dlbasic Sodlum Phosphate Anhydrous 0.5 Polysorbate 80, USP 0.5 Benzyl Alcohol, R 9,0 Methyl p-hydroxyben~oate, USP l.~
Propyl p-hydr-oxybenzoateJ USP 0.2 Sodium Chloride, USP 2.5 Sodium Carboxymethylcellulose, USP. ~.0 Disodium Ede~ate, USP 0.1 Water rOr Injection~ USP q.s. ad lrO Inl ~' ~
December 10, 1975 ~OG4905 JB/la D. Betamethasone 17-valerate 21-retinoate (0.25 to 0.5%) Betamethasone 17-valerate 21-retinoate 2.5-5.0 (~terile precipitated) Monobasic Sodium Phosphate 6.o Dibasic Sodium Phosphate Anhydrous 0.5 Polysorbate 80, USP 0.1 Benzyl Alcohol, R 9.0 Sodium Chloride, USP 2~5 Methyl p hydroxybenzoate, USP 1.3 Propyl ~-hydroxybenzoate, USP 0.2 Sodium Carboxymethyloellulose, USP 3.0 Disodium Edetate, USP 0.1 Water for In~ection, USP q.s. ad 1.0 ml ~ 88 -
Claims (24)
1. A process for the preparation of a retinoate ester of an anti-inflammatory steroid of the pregnane series having a retinoyloxy group at at least one of the 16.alpha.-17.alpha.- and 21-positions, which comprises the step of esterify-ing a corresponding anti-inflammatory steroid of the preg-nane series having a hydroxyl group at at least one of the 16.alpha.-, 17.alpha.- and 21-positions with retinoic acid in the presence of a dehydrating or esterifying agent or with a reactive derivative of retinoic acid.
2. A process as claimed in claim 1 for the preparation of a retinoate ester of a steroid of the pregnane series, said retinoate ester being a 3,20-diketo-4-dehydro-pregnane or a 3-enol ether thereof or a 3-desoxy[3,2-c]pyrazole derivative thereof, and having a hydroxyl group or a hydro-lysable derivative thereof at at least one of the 17.alpha.- and 21-positions when said retinoate is a 16.alpha.-retinoate, which comprises the step of esterifying a corresponding steroid of the pregnane series being a 3,20-diketo-4-dehydro-pregnane or a 3-enol ether thereof or a 3-desoxy[3,2-c]pyrazole derivative thereof with retinoic acid in the presence of a dehydrating or esterifying agent or with a reactive deri-vative of retinoic acid.
3. A process as claimed in claim 2 for the preparation of a retinoate ester of the formula I
wherein X is hydrogen or halogen having an atomic weight of less than 100;
Y is (H,.beta.-OH) or oxygen, or, provided that X is halogen, (H,.beta.-halogen);
A is hydrogen, .alpha.-methyl, .alpha.-azido, .alpha.-bromo, .alpha.-chloro, .alpha.-fluoro, .beta.-fluoro or .alpha.-fluoromethyl;
B is hydrogen or, provided that Y is (H,.beta.-OH), B is also methyl, fluorine, chlorine or bromine;
W is H2, (H, lower alkyl), (H,.alpha.-Cl), (H,.alpha.-OH), (H,a-re-tinoyloxy), (H,.alpha.-OR1), wherein R1 is an acyl radical of a hydrocarbon carboxylic acid having up to 12 carbon atoms, or =CHT wherein T is hydrogen, lower alkyl, fluorine or chlorine;
Q is hydroxy, retinoyloxy, OR wherein R is an acyl radical of a hydrocarbon carboxylic acid having up to 12 carbon atoms, or, provided that W is hydrogen or (H, lower alkyl), Q is also hydrogen or chlorine, or Q taken together with W is a 16.alpha.,17.alpha.-lower alkylidenedioxy group; and Z is hydroxy or retinoyloxy or, provided that Q is hydroxy or retinoyloxy, or that Q is OR and W is retinoyloxy, Z
is also hydrogen, chlorine, fluorine or OR2 wherein R2 is an acyl radical of a hydrocarbon carboxylic acid having up to 12 carbon atoms;
or a 1-dehydro, 6-dehydro, or 1,6-bis-dehydro derivative thereof;
or, when B is hydrogen, a 3-desoxy[3,2-c]pyrazole deri-vative thereof or its 6-dehydro derivative;
or, when A is hydrogen, a 6,6-difluoro derivative there-of, or its 1-dehydro derivative;
with the proviso that at least one of the following condi-tions applies: (i) Q is a retinoyloxy group; (ii) Z is a retinoyloxy group; (iii) W is the group (H, .alpha.-retinoyloxy);
which comprises the step of esterifying a corresponding steroidal alcohol having the formula I wherein A, B; Q, W, X, Y and Z are as derined above, except that at least one of the following conditions applies:
(i) Q is a hydroxy group; (ii) Z is a hydroxy group;
(iii) W is a group (H,.alpha.-OH);
or a 1-dehydro, 6-dehydro, or 1,6-bis-dehydro derivative thereof;
or, when B is hydrogen, a 3-desoxy[3,2-c]pyrazole deri-vative thereof or its 6-dehydro derivative;
or, when A is hydrogen, a 6,6-difluoro derivative there-of, or its 1-dehydro derivative;
with retinoic acid in the presence of a dehydrating or esterifying agent or with a reactive derivative of re-tinoic acid.
wherein X is hydrogen or halogen having an atomic weight of less than 100;
Y is (H,.beta.-OH) or oxygen, or, provided that X is halogen, (H,.beta.-halogen);
A is hydrogen, .alpha.-methyl, .alpha.-azido, .alpha.-bromo, .alpha.-chloro, .alpha.-fluoro, .beta.-fluoro or .alpha.-fluoromethyl;
B is hydrogen or, provided that Y is (H,.beta.-OH), B is also methyl, fluorine, chlorine or bromine;
W is H2, (H, lower alkyl), (H,.alpha.-Cl), (H,.alpha.-OH), (H,a-re-tinoyloxy), (H,.alpha.-OR1), wherein R1 is an acyl radical of a hydrocarbon carboxylic acid having up to 12 carbon atoms, or =CHT wherein T is hydrogen, lower alkyl, fluorine or chlorine;
Q is hydroxy, retinoyloxy, OR wherein R is an acyl radical of a hydrocarbon carboxylic acid having up to 12 carbon atoms, or, provided that W is hydrogen or (H, lower alkyl), Q is also hydrogen or chlorine, or Q taken together with W is a 16.alpha.,17.alpha.-lower alkylidenedioxy group; and Z is hydroxy or retinoyloxy or, provided that Q is hydroxy or retinoyloxy, or that Q is OR and W is retinoyloxy, Z
is also hydrogen, chlorine, fluorine or OR2 wherein R2 is an acyl radical of a hydrocarbon carboxylic acid having up to 12 carbon atoms;
or a 1-dehydro, 6-dehydro, or 1,6-bis-dehydro derivative thereof;
or, when B is hydrogen, a 3-desoxy[3,2-c]pyrazole deri-vative thereof or its 6-dehydro derivative;
or, when A is hydrogen, a 6,6-difluoro derivative there-of, or its 1-dehydro derivative;
with the proviso that at least one of the following condi-tions applies: (i) Q is a retinoyloxy group; (ii) Z is a retinoyloxy group; (iii) W is the group (H, .alpha.-retinoyloxy);
which comprises the step of esterifying a corresponding steroidal alcohol having the formula I wherein A, B; Q, W, X, Y and Z are as derined above, except that at least one of the following conditions applies:
(i) Q is a hydroxy group; (ii) Z is a hydroxy group;
(iii) W is a group (H,.alpha.-OH);
or a 1-dehydro, 6-dehydro, or 1,6-bis-dehydro derivative thereof;
or, when B is hydrogen, a 3-desoxy[3,2-c]pyrazole deri-vative thereof or its 6-dehydro derivative;
or, when A is hydrogen, a 6,6-difluoro derivative there-of, or its 1-dehydro derivative;
with retinoic acid in the presence of a dehydrating or esterifying agent or with a reactive derivative of re-tinoic acid.
4. A process as claimed in claim 3 wherein the retinoic acid or reactive derivative thereof is all-trans-retinoic acid or reactive derivative thereof and the resulting retinoate ester is an all-trans-retinoate.
5. A process as claimed in claim 3 wherein the step of esterification with retinoic acid is followed by at least one of the following optional finishing steps:
(a) Migration of an esterifying retinoyl group from one hydroxy substituent in the steroid nucleus to an-other;
(b) Selective hydrolysis of an ester group at the 21-position in a 16.alpha.- or 17.alpha.-retinoate or at the 16.alpha.-position in a 17.alpha.-retinoate;
(c) Removal of a protecting ether or ester group from an 11.beta.-hydroxy, 16.alpha.-hydroxy and/or 21-hydroxy group;
(d) Elimination of a 21-hydroxy group through sulfo-nation, exchange of the sulfonate group for iodide, and reduction of the iodide;
(e) Transformation of a 21-hydroxy group into a 21-chlo-rine or fluorine atom through sulfonation and exchange of the sulfonate group for chloride or fluoride;
(f) Acylation of a free 16.alpha.-, 17.alpha.- or 21-hydroxy group.
(a) Migration of an esterifying retinoyl group from one hydroxy substituent in the steroid nucleus to an-other;
(b) Selective hydrolysis of an ester group at the 21-position in a 16.alpha.- or 17.alpha.-retinoate or at the 16.alpha.-position in a 17.alpha.-retinoate;
(c) Removal of a protecting ether or ester group from an 11.beta.-hydroxy, 16.alpha.-hydroxy and/or 21-hydroxy group;
(d) Elimination of a 21-hydroxy group through sulfo-nation, exchange of the sulfonate group for iodide, and reduction of the iodide;
(e) Transformation of a 21-hydroxy group into a 21-chlo-rine or fluorine atom through sulfonation and exchange of the sulfonate group for chloride or fluoride;
(f) Acylation of a free 16.alpha.-, 17.alpha.- or 21-hydroxy group.
6. A process as claimed in claim 3 wherein a 16.alpha.- or 21-monoretinoate or a 16.alpha.,21-diretinoate is prepared by reaction of the corresponding 16.alpha.- or 21-ol or 16.alpha.,21-diol with retinoic acid in the presence of an inert solvent and a carbodiimide, an .alpha.-alkynylamine, an alkoxyacetylene or boron trifluoride, or by reaction of the corresponding 16.alpha.- or 21-ol or 16.alpha.,21-diol with retinoyl chloride in the presence of a base, with N-retinoylimidazole in the presence of a base, or with a retinoate of an N-hydroxyimide of a dicarboxylic acid.
7. A process as claimed in claim 6 wherein a 16.alpha.- or 21-monoretinoate or 16.alpha.,21-diretinoate is prepared from the corresponding 16.alpha.- or 21-ol or 16,21-diol by reaction with retinoic acid in the presence of an inert solvent and dicyclohexylcarbodiimide or 1-cyclohexyl-3-(2-morpholino-ethyl) carbodiimide metho-p-toluenesulfonate or ethoxy-acetylene or boron trifluoride etherate, or by reaction with retinoyl chloride in pyridine, with N-retinoylimidazole in the presence of an inert solvent and of sodium methoxide, sodamide or imidazolylsodium, or with N-hydroxy-phthalimide retinoate or N-hydroxysuccinimide retinoate in the presence of an inert organic solvent.
8. A process for the preparation of a 21-all-trans-re-tinoate having the formula II
wherein A is hydrogen, methyl or fluorine;
X is hydrogen or fluorine;
W is H2, (H,.alpha.-methyl) or (H,.beta.-methyl);
or a 1-dehydro derivative thereof;
which comprises reacting a steroid alcohol of the formula or a 1-dehydro derivative thereof;
wherein A, X and W are as defined above, with all-trans-retinoic acid in the presence of an inert solvent and a carbodiimide, an .alpha.-alkynylamine, an alkoxyacetylene or boron trifluoride, or with all-trans-retinoyl chloride in the presence of a base, with N-all-trans-retinoylimidazole in the presence of a base, or with an all-trans-retinoate of an N-hydroxyimide of a dicarboxylic acid.
wherein A is hydrogen, methyl or fluorine;
X is hydrogen or fluorine;
W is H2, (H,.alpha.-methyl) or (H,.beta.-methyl);
or a 1-dehydro derivative thereof;
which comprises reacting a steroid alcohol of the formula or a 1-dehydro derivative thereof;
wherein A, X and W are as defined above, with all-trans-retinoic acid in the presence of an inert solvent and a carbodiimide, an .alpha.-alkynylamine, an alkoxyacetylene or boron trifluoride, or with all-trans-retinoyl chloride in the presence of a base, with N-all-trans-retinoylimidazole in the presence of a base, or with an all-trans-retinoate of an N-hydroxyimide of a dicarboxylic acid.
9. A process as claimed in claim 8 wherein the 21-all-trans-retinoate is prepared by reaction of the steroid alcohol with all-trans-retinoic acid in the presence of an inert solvent and dicyclohexylcarbodiimide or 1-cyclohexyl--3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate or ethoxyacetylene or boron trifluoride etherate, or by reaction with all-trans-retinoyl chloride in pyridine, with N-all-trans-retinoylimidazole in the presence of an inert solvent and of sodium methoxide, sodamide or imidazolylsodium, or with N-hydroxy-phthalimide all-trans-retinoate or N-hydroxy-succinimide all-trans-retinoate in the presence of an inert organic solvent.
10. A process as claimed in claim 8 wherein 4-pregnene-11.beta.,17.alpha.,21-triol-3,20-dione 21-all-trans-retinoate or 1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 21-all-trans-retinoate is prepared by reaction of 4-pregnene-11.beta.,17.alpha.,21-triol-3,20-dione or of 1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione respectively with all-trans-retinoic acid in the presence of an inert solvent and a carbodiimide or with N-all-trans-retinoylimidazole in the presence of a base.
11. A process as claimed in claim 10 wherein 4-pregnene-11.beta.,17.alpha.,21-triol-3,20-dione 21-all-trans-retinoate or 1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 21-all-trans-retinoate is prepared by reaction of 4-pregnene-11.beta.,17.alpha.,21-triol-3,20-dione or of 1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione respectively with all-trans-retinoic acid in the presence of an inert solvent and 1-cyclohexyl-3-(2-morpho-linoethyl)carbodiimide metho-p-toluenesulfonate or with N-all-trans-retinoylimidazole in the presence of an inert solvent and of sodium methoxide.
12. A process as claimed in claim 6 wherein 9.alpha.-fluoro-16.beta.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 21-all-trans-retinoate, 9.alpha.-fluoro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 21-all-trans-retinoate, 9.alpha.-fluoro-1,4-pregnadiene-11.beta.,16.alpha.,17.alpha.,21-tetrol-3,20-dione 16-all-trans-retinoate 21-acetate or 9.alpha.-fluoro-16.beta.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 17-n-valerate 21-all-trans-retinoate is prepared by reaction of 9.alpha.-fluoro-16,.beta.-methyl-1,4-pregnadiene-11.beta.,17a,21-triol-3,20-dione, 9.alpha.-fluoro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione, 9.alpha.-fluoro-1,4-pregnadiene-11.beta.,16.alpha.,17.alpha., 21-tetrol-3,20-dione 21-acetate or 9.alpha.-fluoro-16.beta.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 17-n-valerate respectively with all-trans-retinoic acid in the presence of an inert solvent and a carbodiimide or with N-all-trans-retinoylimidazole in the presence of a base.
13. A process as claimed in claim 12 wherein 9.alpha.-fluoro-16.beta.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 21-all-trans-retinoate, 9.alpha.-fluoro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 21-all-trans-retinoate, 9.alpha.-fluoro-1,4-pregnadiene-11.beta.,16.alpha.,17.alpha.,21-tetrol-3,20-dione 16-all-trans-retinoate 21-acetate or 9.alpha.-fluoro-16.beta.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 17-n-valerate 21-all-trans-retinoate is prepared by reaction of 9.alpha.-fluoro-16.beta.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione, 9.alpha.-fluoro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione, 9.alpha.-rluoro-1,4-pregnadiene-11.beta.,16.alpha.,17.alpha.,-21-tetrol-3,20-dione 21-acetate or 9.alpha.-fluoro-16.beta.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 17-n-valerate respectively with all-trans-retinoic acid in the presence of an inert solvent and 1-cyclohexyl-3-(2-morpho-linoethyl)carbodiimide metho-p-toluenesulfonate or with N-all-trans-retinoylimidazole in the presence of an inert solvent and of sodium methoxide.
14. A process as claimed in claim 5 wherein a 17-mono-all-trans-retinoate of a 17.alpha.,21-diol is prepared by mono-esterification at the 21-position with all-trans-retinoic acid in the presence of a dehydrating or esterifying agent or with a reactive derivative of all-trans-retinoic acid, followed by treatment of the resulting 21-all-trans-retinoate with a non-hydroxylic base in an anhydrous aprotic medium and by protonation of the product whereby the 17.alpha.-mono--all-trans-retinoate is formed.
15. A process as claimed in claim 14 wherein 4-pregnene-11.beta.,17.alpha.,21-triol-3,20-dione 17-all-trans-retinoate or 9.alpha.-fluoro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 17-all-trans-retinoate is prepared by reaction of 4-pregnene-11.beta.,17.alpha.,21-triol-3,20-dione or of 9.alpha.-fluoro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione re-spectively with all-trans-retinoic acid in the presence of an inert solvent and a carbodiimide or with N-all-trans-retinoylimidazole in the presence of a base, followed by reaction of the resulting 21-all-trans-retinoate with a non-hydroxylic base in an anhydrous aprotic medium and then by protonation of the product to yield the required 17.alpha.-all-trans-retinoate.
16. A process as claimed in claim 15 wherein 4-pregnene-11.beta.,17.alpha.,21-triol-3,20-dione 17-all-trans-retinoate or 9.alpha.-fluoro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 17-all-trans-retinoate is prepared by reaction of 4-pregnene-11.beta.,17.alpha.,21-triol-3,20-dione or of 9.alpha.-fluoro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione respectively with all-trans-retinoic acid in the presence of an inert solvent and 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-p-toluenesulfonate or with N-all-trans-retinoylimidazole in the presence of an inert solvent and of sodium methoxide, followed by reaction of the resulting 21-all-trans-retinoate with lithium dimethyl cuprate in anhydrous tetrahydrofuran, 1,2-dimethoxy-ethane, dioxan or diethyl ether and then by protonation of the product to yield the required 17.alpha.-all-trans-retinoate.
17. A retinoate ester of the formula I defined in claim 3;
or a 1-dehydro, 6-dehydro, or 1,6-bis-dehydro derivative thereof;
or, when B is hydrogen, a 3-desoxy[3,2-c]pyrazole deri-vative thereof or its6-dehydro derivative;
or, when A is hydrogen, a 6,6-difluoro derivative thereof, or its 1-dehydro derivative;
whenever prepared by a process claimed in claim 3 or by an obvious chemical equivalent thereof.
or a 1-dehydro, 6-dehydro, or 1,6-bis-dehydro derivative thereof;
or, when B is hydrogen, a 3-desoxy[3,2-c]pyrazole deri-vative thereof or its6-dehydro derivative;
or, when A is hydrogen, a 6,6-difluoro derivative thereof, or its 1-dehydro derivative;
whenever prepared by a process claimed in claim 3 or by an obvious chemical equivalent thereof.
18. An all-trans-retinoate ester of the formula I de-fined in claim 3;
or a 1-dehydro3 6-dehydro, or 1,6-bis-dehydro derivative thereof;
or, when B is hydrogen, a 3-desoxy[3,2-c]pyrazole deri-vative thereof or its 6-dehydro derivative;
or, when A is hydrogen, a 6,6-difluoro derivative thereof, or its 1-dehydro derivative;
whenever prepared by a process claimed in claim 4 or by an obvious chemical equivalent thereof.
or a 1-dehydro3 6-dehydro, or 1,6-bis-dehydro derivative thereof;
or, when B is hydrogen, a 3-desoxy[3,2-c]pyrazole deri-vative thereof or its 6-dehydro derivative;
or, when A is hydrogen, a 6,6-difluoro derivative thereof, or its 1-dehydro derivative;
whenever prepared by a process claimed in claim 4 or by an obvious chemical equivalent thereof.
19. A 16.alpha.- or 21-monoretinoate or a 16.alpha.,21-diretinoate ester of the formula I defined in claim 3;
or a 1-dehydro, 6-dehydro, or 1,6-bis-dehydro derivative thereof;
or when B is hydrogen, a 3-desoxy[3,2-c]pyrazole deri-vative thereof or its 6-dehydro derivative;
or, when A is hydrogen, a 6,6-difluoro derivative thereof, or its 1-dehydro derivative;
whenever prepared by a process claimed in claim 6 or claim 7 or by an obvious chemical equivalent thereof.
or a 1-dehydro, 6-dehydro, or 1,6-bis-dehydro derivative thereof;
or when B is hydrogen, a 3-desoxy[3,2-c]pyrazole deri-vative thereof or its 6-dehydro derivative;
or, when A is hydrogen, a 6,6-difluoro derivative thereof, or its 1-dehydro derivative;
whenever prepared by a process claimed in claim 6 or claim 7 or by an obvious chemical equivalent thereof.
20. A 21-all-trans-retinoate ester of the formula II de-fined in claim 8, or a 1-dehydro derivative thereof, when-ever prepared by a process claimed in claim 8 or claim 9 or by an obvious chemical equivalent thereof.
21. 4-Pregnene-11.beta.,17.alpha.,21-triol-3,20-dione 21-all-trans-retinoate and 1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 21-all-trans-retinoate whenever prepared by a process as claimed in claim 10 or claim 11 or by an obvious chemical equivalent thereof.
22. 9.alpha.-Fluoro-16.beta.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 21-all-trâns-retinoate, 9.alpha.-fluoro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 21-all-trans-retinoate, 9.alpha.-fluoro-1,4-pregnadiene-11.beta.,16.alpha.,17.alpha.,21-tetrol-3,20-dione 16-all-trans-retinoate 21-acetate or 9.alpha.-fluoro-16.beta.-methyl-1,4-pregnadiene-11.beta.,17.alpha.,21-triol-3,20-dione 17-n-valerate 21-all-trans-retinoate whenever prepared by a process as claimed in claim 12 or claim 13 or by an obvious chemical equivalent thereof.
23. A 17-mono-all-trans-retinoate ester of the formula I
defined in claim 3;
or a 1-dehydro, 6-dehydro, or 1,6-bis-dehydro derivative thereof;
or, when B is hydrogen, a 3-desoxy[3,2-c]pyrazole deri-vative thereof or its 6-dehydro derivative;
or, when A is hydrogen, a 6,6-dirluoro derivative thereof, or its 1-dehydro derivative;
whenever prepared by a process claimed in claim 14 or by an obvious chemical equivalent thereof.
defined in claim 3;
or a 1-dehydro, 6-dehydro, or 1,6-bis-dehydro derivative thereof;
or, when B is hydrogen, a 3-desoxy[3,2-c]pyrazole deri-vative thereof or its 6-dehydro derivative;
or, when A is hydrogen, a 6,6-dirluoro derivative thereof, or its 1-dehydro derivative;
whenever prepared by a process claimed in claim 14 or by an obvious chemical equivalent thereof.
24. 4-Pregnene-11.beta.,17.alpha.,21-triol-3,20-dione 17-all-trans-retinoate or 9.alpha.-fluoro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha., 21-triol-3,20-dione 17-all-trans-retinoate whenever pre-pared by a process as claimed in claim 15 or claim 16 or by an obvious chemical equivalent thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/554,351 US3984544A (en) | 1975-02-28 | 1975-02-28 | Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1064905A true CA1064905A (en) | 1979-10-23 |
Family
ID=24213007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA246,486A Expired CA1064905A (en) | 1975-02-28 | 1976-02-24 | Terpenoid esters of steroids |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US3984544A (en) |
| JP (1) | JPS51110551A (en) |
| AR (1) | AR218851A1 (en) |
| AU (1) | AU502298B2 (en) |
| BE (1) | BE838923A (en) |
| CA (1) | CA1064905A (en) |
| CH (1) | CH629825A5 (en) |
| CS (1) | CS195722B2 (en) |
| DD (1) | DD125593A5 (en) |
| DE (1) | DE2607418A1 (en) |
| DK (1) | DK142201B (en) |
| ES (1) | ES445488A1 (en) |
| FI (1) | FI760472A (en) |
| FR (1) | FR2302099A1 (en) |
| GB (1) | GB1533614A (en) |
| GR (1) | GR59913B (en) |
| HK (1) | HK7082A (en) |
| HU (1) | HU176716B (en) |
| IE (1) | IE43452B1 (en) |
| IL (1) | IL49103A (en) |
| KE (1) | KE3189A (en) |
| LU (1) | LU74421A1 (en) |
| NL (1) | NL7601864A (en) |
| NO (1) | NO760607L (en) |
| NZ (1) | NZ180110A (en) |
| PH (1) | PH13213A (en) |
| PT (1) | PT64835B (en) |
| SE (2) | SE7602279L (en) |
| ZA (1) | ZA761128B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4843096A (en) * | 1985-06-26 | 1989-06-27 | Stiefel Laboratories, Inc. | Treatment of acne |
| US4885311A (en) * | 1987-06-29 | 1989-12-05 | Molecular Design International | Topical transretinoids for treatment of acne and skin diseases |
| FR2644459B1 (en) * | 1989-03-16 | 1994-10-28 | Oreal | RETINOIC ESTERS OF L-CLADINOSE, THEIR PREPARATION PROCESS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS |
| US5648563A (en) * | 1991-04-09 | 1997-07-15 | Sloan-Kettering Institute For Cancer Research | Retro-alpha-retinol derivative and uses of retro-alpha-retinol |
| US6506917B1 (en) * | 1991-12-18 | 2003-01-14 | The Salk Institute For Biological Studies | Compounds and compositions useful for modulation of processes mediated by RXR |
| US7056954B2 (en) * | 1991-12-18 | 2006-06-06 | The Salk Institute For Biological Studies | Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor |
| FR2761600B1 (en) * | 1998-06-19 | 2000-03-31 | Oreal | FOAMING COMPOSITION FOR THE WASHING AND TREATMENT OF HAIR AND / OR SCALP BASED ON AN ACTIVE INGREDIENT, AN ANIONIC SURFACTANT, AN AMPHOTERIC SURFACTANT AND A PROPENETANT |
| JP4699347B2 (en) * | 2003-01-17 | 2011-06-08 | ウィスコンシン・アルムニ・リサーチ・ファウンデーション | Modified retinoid compounds and uses thereof |
| CA2513586A1 (en) * | 2003-01-17 | 2004-08-05 | Wisconsin Alumni Research Foundation | Method of reducing toxicity of retinoids |
| JP2005020400A (en) * | 2003-06-26 | 2005-01-20 | Hitachi Communication Technologies Ltd | Radio base station, radio communication system, communication control method of radio base station, and construction method of radio communication network |
| US20080139518A1 (en) * | 2006-12-04 | 2008-06-12 | Concert, Llc | Topical compositions for treatment of skin conditions |
| US20090203628A1 (en) * | 2008-02-12 | 2009-08-13 | Jan Marini | Composition, Method And Kit For Treating Skin Disorders And Improving Skin Condition |
| UA111867C2 (en) | 2011-11-11 | 2016-06-24 | Аллерган, Інк. | PHARMACEUTICAL COMPOSITION AND METHOD OF APPLICATION OF 4-PROGEN-11β-17-21-TRIOL-3,20-DION DERIVATIVES |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1530972A (en) * | 1966-07-15 | 1968-06-28 | Angeli Inst Spa | Process for preparing steroid esters |
| US3780177A (en) * | 1967-06-16 | 1973-12-18 | Warner Lambert Co | 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use |
-
1975
- 1975-02-28 US US05/554,351 patent/US3984544A/en not_active Expired - Lifetime
-
1976
- 1976-02-18 CH CH206576A patent/CH629825A5/en not_active IP Right Cessation
- 1976-02-24 FI FI760472A patent/FI760472A/fi not_active Application Discontinuation
- 1976-02-24 PT PT64835A patent/PT64835B/en unknown
- 1976-02-24 PH PH18137A patent/PH13213A/en unknown
- 1976-02-24 AR AR262357A patent/AR218851A1/en active
- 1976-02-24 SE SE7602279A patent/SE7602279L/en not_active Application Discontinuation
- 1976-02-24 NO NO760607A patent/NO760607L/no unknown
- 1976-02-24 DE DE19762607418 patent/DE2607418A1/en not_active Withdrawn
- 1976-02-24 CA CA246,486A patent/CA1064905A/en not_active Expired
- 1976-02-24 FR FR7605092A patent/FR2302099A1/en active Granted
- 1976-02-24 NL NL7601864A patent/NL7601864A/en not_active Application Discontinuation
- 1976-02-24 NZ NZ180110A patent/NZ180110A/en unknown
- 1976-02-24 GB GB7261/76A patent/GB1533614A/en not_active Expired
- 1976-02-24 ES ES445488A patent/ES445488A1/en not_active Expired
- 1976-02-24 GR GR50146A patent/GR59913B/en unknown
- 1976-02-24 LU LU74421A patent/LU74421A1/xx unknown
- 1976-02-25 AU AU11420/76A patent/AU502298B2/en not_active Expired
- 1976-02-25 BE BE164627A patent/BE838923A/en unknown
- 1976-02-25 IE IE374/76A patent/IE43452B1/en unknown
- 1976-02-25 IL IL49103A patent/IL49103A/en unknown
- 1976-02-25 JP JP51019829A patent/JPS51110551A/ja active Pending
- 1976-02-25 ZA ZA761128A patent/ZA761128B/en unknown
- 1976-02-25 DK DK79976AA patent/DK142201B/en unknown
- 1976-02-26 DD DD191540A patent/DD125593A5/xx unknown
- 1976-02-26 CS CS761262A patent/CS195722B2/en unknown
- 1976-02-27 HU HU76SCHE557A patent/HU176716B/en unknown
-
1979
- 1979-02-05 SE SE7901000A patent/SE7901000L/en unknown
-
1982
- 1982-02-18 HK HK70/82A patent/HK7082A/en unknown
- 1982-02-26 KE KE3189A patent/KE3189A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU1142076A (en) | 1977-09-01 |
| AR218851A1 (en) | 1980-07-15 |
| CS195722B2 (en) | 1980-02-29 |
| GB1533614A (en) | 1978-11-29 |
| DK142201C (en) | 1981-03-02 |
| FR2302099A1 (en) | 1976-09-24 |
| GR59913B (en) | 1978-03-20 |
| HK7082A (en) | 1982-02-26 |
| BE838923A (en) | 1976-08-25 |
| NL7601864A (en) | 1976-08-31 |
| PT64835A (en) | 1976-03-01 |
| ES445488A1 (en) | 1977-11-01 |
| PT64835B (en) | 1977-06-07 |
| PH13213A (en) | 1980-02-07 |
| IE43452B1 (en) | 1981-02-25 |
| IE43452L (en) | 1976-08-28 |
| FR2302099B1 (en) | 1978-11-10 |
| CH629825A5 (en) | 1982-05-14 |
| HU176716B (en) | 1981-04-28 |
| IL49103A (en) | 1979-12-30 |
| DD125593A5 (en) | 1977-05-04 |
| DK79976A (en) | 1976-08-29 |
| US3984544A (en) | 1976-10-05 |
| SE7901000L (en) | 1979-02-05 |
| JPS51110551A (en) | 1976-09-30 |
| DE2607418A1 (en) | 1976-09-09 |
| DK142201B (en) | 1980-09-22 |
| IL49103A0 (en) | 1976-04-30 |
| SE7602279L (en) | 1976-08-30 |
| NZ180110A (en) | 1978-06-20 |
| ZA761128B (en) | 1977-02-23 |
| LU74421A1 (en) | 1977-01-07 |
| NO760607L (en) | 1976-08-31 |
| KE3189A (en) | 1982-04-02 |
| AU502298B2 (en) | 1979-07-19 |
| FI760472A (en) | 1976-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3639434A (en) | 17-acyloxysteroids and their manufacture | |
| US4124707A (en) | 7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor | |
| CA1099254A (en) | PROCESS FOR THE PREPARATION OF 7 .alpha.-HALOGENO-3-OXO-4- DEHYDRO STEROIDS AND NOVEL 7.alpha.-HALOGENO DERIVATIVES PRODUCED THEREBY | |
| CA1064905A (en) | Terpenoid esters of steroids | |
| DE1443957B1 (en) | 9 alpha-chloro or 9 alpha-fluoro-16 beta-methyl-prednisolone-17,21-diesters and a process for their preparation | |
| US2882282A (en) | Method of producing 3-keto-delta4, 6-steroid compounds from 3-keto a-ring saturated 6-dihydro steroid compounds | |
| US4226862A (en) | Steroids and process for preparing the same | |
| US4336200A (en) | 17α-Acyloxy-5β-corticoids | |
| US4567172A (en) | 6α-Methylprednisolone derivatives | |
| CA1278293C (en) | Androstane-17 beta-carboxylic acid esters | |
| US4318853A (en) | 9β,11β-Epoxy-5β-corticoids | |
| EP0072546B1 (en) | Hydrocortisone derivatives, their preparation and their utilization | |
| GB2130587A (en) | Novel 6a-methylcorticoids and their manufacture and use | |
| US4990612A (en) | 16α-methylation process | |
| CA1099255A (en) | Corticoids | |
| CA1101410A (en) | Polyhalogenated steroids | |
| US4021459A (en) | Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy 20-keto-pregnenes | |
| US4427591A (en) | Reduced A ring-Δ9(11) -corticoids | |
| US3833563A (en) | Novel pregnanoic acid derivatives | |
| US3932388A (en) | -Azido-4,6-pregnadieno(3,2-c)pyrazoles, processes for their preparation and intermediates useful therein | |
| US2744110A (en) | 3-ethylene mercaptole derivatives of progesterone | |
| US3014030A (en) | 9alpha-methylpregnenes, pregnadienes and intermediates therefor | |
| Fox et al. | 16α-Hydroxy Steroids. V. 1 11β-Esters of Triamcinolone | |
| US3947409A (en) | 16-Alkyl-1,4,9(11)-pregnatrienes and 9,11-epoxides thereof | |
| US3484436A (en) | Bicyclo(2.2.2)octane - 1 - -carboxylate esters of delta**4 - pregnene corticoid steroids |